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ABSTRACT 
 
The incidence of degenerative aortic stenosis is increasing with an ageing population. Valve 
replacement is the only proven treatment, but this carries significant procedural risk in older 
people. Current guidelines advocate intervention in symptomatic severe aortic stenosis, but 
non-cardiac symptoms and comorbidity may obscure this assessment. Clinical biomarkers 
offer the potential for objective patient assessment. My aim was to firstly assess the validity 
and reproducibility of novel blood biomarkers of disease progression in aortic stenosis. 
Secondly, in older patients considered for valve replacement, my aim was to compare 
measures of frailty with conventional surgical risk assessment. 
 
In 265 patients with asymptomatic aortic stenosis and 46 healthy controls, I assessed serum 
concentrations of the sarcomeric protein cardiac myosin binding protein C (cMyC) and 
objective markers of disease progression and mortality. cMyC concentrations were 
independently associated with imaging evidence of left ventricular mass, fibrosis volume and 
extracellular volume. These relationships were not observed in healthy controls. cMyC 
concentrations were also associated with all-cause mortality over 11 years of follow-up. This 
suggests a role for cMyC as a novel objective biomarker of aortic stenosis disease severity.  
 
Other blood biomarkers including cardiac troponin, brain-type natriuretic peptide (BNP) and 
galectin-3 have been suggested as disease biomarkers in aortic stenosis. However, 
performance and precision of these assays has not been described in older patients. In a study 
of analytical and biological variability, I undertook repeated hourly and weekly blood 
sampling for cardiac troponin, BNP and galectin-3 in 14 subjects with severe asymptomatic 
aortic stenosis. These biomarkers demonstrated low indices of individuality, implying that 
interpretation requires serial testing for change rather than isolated elevated blood 
concentrations. The reference change values for weekly fresh sampling were 42% for cardiac 
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troponin, 55% for BNP and 14% for galectin. These values for cardiac troponin and BNP 
were lower than equivalent studies in healthy controls and in stable heart failure. 
 
To assess the role of frailty in the assessment of patients for aortic valve replacement, I first 
performed a systematic review and meta-analysis of studies including frailty assessment 
before Transcatheter Aortic Valve Implantation (TAVI). This procedure is reserved for 
patients considered at prohibitive risk of complication from conventional open-heart surgery. 
Ten cohort studies with 4,592 TAVI patients were included. Frailty was associated with 
increased risk of early and late mortality, and use of an objective frailty tool rather than 
subjective assessment identified those at highest risk; these patients experienced greater than 
double the mortality risk of non-frail individuals. 
 
In 185 patients with severe aortic stenosis, I prospectively assessed frailty using four tools: 
the Fried phenotype, Edmonton Frail Scale, Short Physical Performance Battery and Clinical 
Frailty Scale. These measures were compared to surgical risk assessment scores from the 
Society of Thoracic Surgeons (STS) and EuroSCORE II. Agreement between frailty 
measures was moderate and unrelated to patient age or the degree of aortic valve severity. 
Frail patients had poorer physical and mental wellbeing. Frailty increased at higher STS and 
EuroSCORE estimates, but using principal components analysis I demonstrated divergence 
between frailty measures and surgical risk estimates. Outcomes after aortic valve 
replacement are now required to establish if this observation is meaningful for the improved 
prediction of outcomes after surgery. 
 
My findings suggest that serial testing of blood biomarkers of myocardial injury in patients 
with aortic stenosis may detect meaningful disease progression prior to decompensation. In 
patients considered for valve replacement, measurement of frailty differs from existing 
surgical risk tools and may add to the holistic assessment of older patients.   
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LAY SUMMARY 
 
Aortic stenosis describes the degeneration of the main valve that controls blood flow out of 
heart. This more frequently occurs in older people. Without a surgical procedure to replace 
the valve, aortic stenosis results in thickening and scarring of heart muscle and eventual 
heart failure. There are no proven alternative treatments to slow or stop progression of 
disease, and timing valve replacement is challenging. The rate of aortic stenosis progression 
varies unpredictably between individuals and assessing symptoms of early heart failure can 
be difficult in older people with other health problems. Further, in older patients undergoing 
valve replacement, the risks of complications may outweigh potential benefits of surgery. 
Increasingly, such risk is measured in terms of frailty, which describes individuals at 
increased risk of dependency or death due to a lack of health reserves. However, frailty is not 
currently included in the surgical risk calculations that are used to help inform decisions for 
valve intervention in older patients.   
 
The first aim of this thesis was to test the role and reliability of blood tests of heart damage 
to identify progression of aortic stenosis. Second, in older patients considered for aortic 
valve replacement, my aim was to compare measures of frailty with existing surgical risk 
scores. 
 
In 265 patients with aortic stenosis and 46 healthy controls with normal heart valves, blood 
levels of a heart muscle protein called cardiac myosin binding protein C (cMyC) were 
measured. Higher levels of this blood test were independently associated with thickening of 
heart muscle and scarring on cardiac magnetic resonance imaging in aortic stenosis patients. 
These relationships were not seen in healthy controls. Patients with higher levels of cMyC 
were also more likely to die of any cause over 11 years of follow-up. This suggests a 
possible role for cMyC as a measure to track progression of aortic stenosis using a simple 
blood test. 
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Other blood tests may also be useful markers of heart damage in aortic stenosis and in a 
second experiment I tested the reliability of three different tests in 14 older patients with 
aortic stenosis. Blood tests for heart muscle damage (cardiac troponin), scarring (galectin-3) 
and heart failure (BNP) were measured repeatedly at hourly and weekly intervals in the same 
patients to investigate the stability of these measures. I calculated the percentage change in 
each blood marker that would signify a meaningful change between tests taken weeks apart, 
such as between clinic appointments. This was a 42% change for cardiac troponin, 55% for 
BNP and 14% for galectin-3. 
 
To investigate the role of frailty testing in older patients under consideration for aortic valve 
replacement, I first systematically looked at previous studies in patients undergoing 
Transcatheter Aortic Valve Implantation (TAVI). This procedure is reserved for patients 
considered at prohibitive risk of complication from conventional open-heart surgery. Ten 
studies with 4,592 TAVI patients were included in this assessment. Frailty was associated 
with increased risk of early and late death after TAVI, and use of a specific frailty tool rather 
than end-of-the-bed assessment identified those at highest risk; these patients experienced 
double the risk of dying early after TAVI when compared to non-frail individuals. 
 
To compare frailty measures with existing surgical risk scores, I assessed 185 patients with 
severe aortic stenosis using 4 different tools. These measures were compared to surgical risk 
assessment scores from the Society of Thoracic Surgeons (STS) and EuroSCORE II. 
Agreement between the frailty measures was moderate, but was unrelated to the age of 
patients or the severity of their aortic stenosis. Frail patients by all measures had poorer 
physical and mental wellbeing and generally had higher surgical risk scores. However, using 
a technique called principal component analysis, which compares the patterns in data 
between patients, the frailty scores appeared to show consistent differences from the two 
surgical risk scores. This suggests that frailty adds additional information to what is currently 
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captured by the STS and EuroSCORE, but collecting outcomes of these patients in the future 
will help understanding of the value of these extra measures in helping to predict outcomes 
after surgery. 
 
My findings suggest that blood testing for markers of heart damage in patients with aortic 
stenosis may be a simple method to detect meaningful progression of disease and identify 
patients at risk of heart failure without valve replacement. In patients considered for valve 
replacement, measurement of frailty differs from existing surgical risk tools and may add to 
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Aortic stenosis is the most common valvular heart disease in the Western World, affecting 1 
in every 8 older adults over 75 years old.1 Ageing population demographics continue to 
increase the incidence of severe stenosis, at which point the risk of progression to 
decompensated heart failure or death without replacement surgery rises to 40% at one year.2 
Current guidelines advocate valve replacement in the event of symptomatic severe aortic 
stenosis, but the effects of comorbidity in an older population may obscure this assessment.3 
Decision-making is therefore complex, with exposure to the risks of major cardiac surgery in 
the absence of meaningful benefit if symptoms are mistakenly attributed to aortic stenosis.  
 
Clinical biomarkers offer the potential for objective patient assessment. Circulating blood 
markers of myocardial injury may identify the advanced hypertrophic and fibrotic response 
of the myocardium to aortic stenosis. However, the degree of change in these markers that 
would be indicative of significant change is currently unclear in an older population. 
Similarly, patient assessment including biomarkers of frailty may be an additive marker of 
risk to improve current surgical assessment tools in older populations. Such clinical 
biomarkers may help make individualised assessments and reduce the risk of harm, but their 
potential role in the care of older patients with aortic stenosis requires further evaluation.  
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1.2 AORTIC STENOSIS IN OLDER ADULTS 
Below the age of 60, aortic stenosis necessitating valve replacement is almost exclusively 
associated with congenitally bicuspid valves.4 However, as the population ages, degenerative 
calcification is the predominant driver of stenosis and is being identified in greater numbers 
of older individuals.5,6 Meta-analysis of seven large population prevalence studies suggests 
that 3.4% of all individuals over 75 years old have severe aortic stenosis. This equates to 
approximately 1 million older individuals in Europe alone.1 Population prevalence appears to 
increase rapidly after the age of 65.7 Systematic community screening in this demographic as 
part of the OxVALVE study identified 1.3% of the population with aortic stenosis. 
Projections from this dataset suggest that that the burden of valvular disease will double over 
the next twenty years.8 
 
Importantly, outcomes have not significantly improved in this growing population with 
aortic stenosis. In a large American series of valvular heart disease over the last three 
decades, mortality from aortic valve disease has risen by an average of 1.56% per year, 
undoubtedly partly driven by reduced competing mortality risks. However, in contrast to 
progress in the management of coronary disease over this period, there has been virtually no 
improvement in the age- and sex-adjusted mortality rates from valvular heart disease 
between 1979 and 2009.9,10 In the developing world, rheumatic heart disease remains an 
important precipitant of aortic valve disease, where stenosis often occurs concurrently 
alongside regurgitation and mitral valve dysfunction.11 Within Europe, only one in five cases 
of valvular disease can still be attributed to rheumatic heart disease, as the burden of age-
related degenerative disease increases.7 
 
1.2.1 PROGRESSION OF DISEASE 
Progression of aortic stenosis is unpredictable. A preclinical phase of aortic sclerosis, namely 
thickened aortic valve cusps without significant blood flow limitation, occurs prior to the 
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development of calcific aortic stenosis, but many individuals will never progress. Indeed, 
population studies have suggested that by the age of 85 years old, half of the population will 
have developed aortic sclerosis. The conversion from sclerosis to stenosis affects 
approximately 1.8-1.9% of patients per year, but there are no clear methods for identifying 
who will progress, nor for predicting the rate of disease advancement in an individual.12,13 
However, observational data has suggested that individuals with the greatest valve 
calcification are at higher risk of rapid progression of aortic stenosis. Other suggested factors 
identified for rapid progression are older age (over 50 years old), coexisting coronary artery 
disease and diabetes mellitus, although in multivariate modelling including these 
characteristics, only valve calcification remained an independent predictor of death or 
requirement of valve replacement.2,14 
 
Once aortic stenosis has developed, the response of the myocardium is critical to 
determining progression and development of symptomatic disease. Left ventricular 
hypertrophy develops as a result of increased afterload, which is necessary to preserve 
ejection fraction and normalise left ventricular wall stress.15 Hypertrophy is associated with 
reactive interstitial fibrosis as a result of collagen production from myofibroblasts.16 This 
process exhibits wide individual heterogeneity, which may explain the variability in 
progression to symptomatic decline. Those with maladaptive hypertrophy and 
inappropriately high left ventricular mass appear at highest risk of poor outcomes.17 
Furthermore, the severity of stenosis across the valve is not well related to the degree of 
hypertrophy.18 However, it is clear that development of myocardial fibrosis in response to 
aortic stenosis is a poor prognostic sign, with an up to 8-fold increased mortality risk 
compared to those without fibrosis, despite similar degrees of aortic stenosis severity and 
coronary disease.18,19 
 
In the natural history of untreated aortic stenosis, compensation through hypertrophy and 
fibrosis is eventually exhausted and heart failure ensues. This transition is characterised by 
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progressive cardiomyocyte death and replacement fibrosis.20 Reductions in left ventricular 
ejection fraction or cardiac output are end-stage features of aortic stenosis, usually after 
symptoms have developed. These include exertional dyspnoea as a result of pulmonary 
hypertension from raised left ventricular pressures, and anginal chest pain from reduced 
coronary perfusion secondary to greater vascular resistance and increased demand from 
hypertrophied left ventricular tissue.21,22 Exertional pre-syncope or syncope may occur when 
peripheral vasodilation cannot be matched by increased stroke volume. These symptoms 
become more pronounced when overt left ventricular failure and fluid overload develop. 
Sudden cardiac death is also associated with untreated aortic stenosis, although this is a rare 
occurrence in the absence warning symptomology. 
 
1.2.2 TREATMENT OPTIONS 
There are currently no pharmacological therapies for aortic stenosis. Similarities in the 
processes of atherosclerosis and valve calcification previously generated interest in statin 
therapy. However, these drugs have now been proven to not influence disease 
progression.23,24 Purely medical management may be offered to patients who do not wish to 
undergo a surgical procedure, or in whom the risk of surgery is considered excessive. The 
mainstay of such an approach is blood pressure control and symptom management, using 
standard therapies for heart failure when this develops.3  
 
In those suitable for intervention, there are three broad approaches to management which 
may be considered when symptoms develop or in an asymptomatic patient with evidence of 
left ventricular impairment.  
 
1.2.2.1 SURGICAL AORTIC VALVE REPLACEMENT (SAVR) 
Cardiac surgery via a median sternotomy approach to directly replace the aortic valve 
remains the mainstay of treatment in the majority of patients considered fit enough for 
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surgery. In older patients, bioprosthetic valves obviate the need for anticoagulation when 
compared to mechanical valves, but at the cost of reduced longevity of the prosthesis.25 
SAVR typically carries a 4-8% risk of in-hospital mortality in older patients (over 70 years), 
which may rise with comorbidity.3 A meta-analysis of 8,975 over 80 year olds undergoing 
combined valve replacement and bypass grafting reported a 30 day mortality rate of 10%.26 
 
1.2.2.2 TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) 
TAVI has become a widespread and viable alternative for patients considered high-risk for 
conventional surgery. This is a less invasive approach, usually performed via femoral arterial 
access. The PARTNER trial randomised patients considered at excessively high-risk from 
SAVR to either medical management or TAVI. After one year, mortality and hospitalisation 
was significantly lower in the TAVI group (composite 42.5% vs 71.6% in medically treated 
group). This was despite higher rates of stroke and bleeding in those undergoing the 
procedure.27  
 
The subsequent PARTNER II trial assessed those with intermediate surgical risk and 
suggested that TAVI in this group has similar outcomes to conventional surgery.28 However, 
meta-analysis of all such studies highlighted potentially poorer outcomes with trans-apical 
TAVI compared to conventional SAVR, although the inherent perioperative risk of those 
selected for trans-apical TAVI over SAVR in observational cohorts is likely to be higher.29 
In Germany, adoption of TAVI has been rapid, with the number of procedures performed 
now outstripping surgical valve replacements. However, questions remain over the longevity 
of the implanted valve and persisting high rates of post-procedure permanent pacemaker 
implantations (required in 1 in 8 cases in the German TAVI registry).30 Furthermore, patient 
selection over conventional surgery remains challenging, when the benefits of intervention in 
the oldest and frailest patients are not always clear.31 
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1.2.2.3 BALLOON AORTIC VALVULOPLASTY (BAV) 
This procedure uses the inflation pressure of a balloon across the stenotic aortic valve to 
temporarily reduce the transvalvular gradient. Effects typically last for weeks to months and 
must be balanced with risks of periprocedural complications such as bleeding and stroke. In 
one series of 301 BAV procedures for severe aortic stenosis that was deemed inoperable, 
serious adverse events occurred in 16% of patients, the most common of which were 
significant vascular complications (7%).32 Long-term survival after BAV was also noted to 
be poor, with half of patients dead within 6 months. There are two areas where BAV is 
advocated. Firstly, as a bridge to definitive therapy in patients suitable for TAVI or SAVR 
but in whom acutely florid symptoms limit immediate treatment or there is a requirement for 
urgent major non-cardiac surgery.3 Secondly, where the origin of symptoms cannot be 
conclusively determined, such as with progressive dyspnoea with evidence of intrinsic lung 
disease, BAV may offer a therapeutic trial whereby relief of symptoms indicates the 
presence of truly symptomatic aortic stenosis.31 
 
1.2.3 CURRENT GUIDELINES 
Current clinical guidance from the European Society of Cardiology (ESC) provide clear 
advice (class I recommendation) favouring SAVR in patients with severe aortic stenosis who 
are symptomatic or have provoked symptoms on exercise testing. Severe aortic stenosis 
should be defined using a combination of measures from doppler echocardiography 
assessment rather than a single parameter. ESC guidelines recommend severe status is 
applied where the transvalvular peak jet velocity exceeds 4 metres per second and where 
valve area is less than 1.0cm2. It is also noted that severe aortic stenosis usually occurs with a 
mean transvalvular pressure gradient greater than 40mmHg.3  
 
ESC guidelines recommend that asymptomatic severe aortic stenosis patients should be 
considered for SAVR where there is evidence of left ventricular impairment (ejection 
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fraction <50%), or where the patient is undergoing other major cardiac surgery.3 However, 
these recommendations are largely based on observational studies of patients with 
asymptomatic severe aortic stenosis such as that performed by Rosenhek et al. in 1994, 
where the mean age of included participants was just 60 years old.2 The ESC 
recommendations are consistent with those made by the American Heart Association and 
American College of Cardiology (AHA/ACC).33 
 
There is lower quality evidence to recommend SAVR in so-called ‘low-flow, low-gradient’ 
aortic stenosis with preserved ejection fraction, which is more common in older patients. 
This occurs where valve parameters suggest severe stenosis, but the transvalvular gradient 
does not meet the criteria for severe disease (i.e. AVmax velocity <4m/s and/or mean pressure 
gradient <40mmHg). However, observational cohort data suggests that these patients have a 
similar risk of poor outcomes as those with mild-to-moderate aortic stenosis.34 
 
The ESC also provide guidance on patient selection for TAVI. It is recommended that 
patients are assessed by a “heart team” including cardiologists, cardiac surgeons, imaging 
specialists and with the potential to include general practitioners, geriatricians and intensive 
care doctors.35 TAVI may be considered where this team deems conventional SAVR 
unsuitable due to “severe comorbidities”. Patients selected for TAVI should have a life-
expectancy of at least one year and be expected to gain improvement in quality of life after 
the procedure.3 Interestingly, the one year mortality rate in the PARTNER trial TAVI arm 
was 30.7%, suggesting that clinician estimation of this outcome is challenging.27 In both 
European and American guidelines, there is little clarity on assessment of older patients and 
interpretation of the significance of comorbidity on surgical outcomes. It may be argued that 
current guideline pathways have failed to keep pace with a fundamental shift in the aortic 
valve surgical population, from younger patients with failing bicuspid valves, to the elderly 
with calcific degenerative valve disease and multimorbidity. 
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1.2.4 NATURAL HISTORY WITHOUT INTERVENTION 
When considering complex aortic valve interventions it is important to understand the 
natural history of medically managed severe aortic stenosis. As previously described, 
progression of stenosis in an individual patient is unpredictable. Taken in aggregate, valve 
area decreases on average by 0.1cm2 per year, while mean transvalvular gradient increases 
by 7mmHg.36,37 Recent studies allocating patients with severe aortic stenosis to either TAVI 
or medical management have provided relevant data on outcomes for those managed 
conservatively. In two such series, one-year all-cause mortality rates varied between 40-
51%.27,38 Rosenhek et al. reported event rates in a severely stenotic cohort for a composite 
endpoint of death or aortic valve replacement necessitated by symptoms as 33% at one year, 
44% at two years and 67% by four years.2 The hard outcomes for medically managed 
patients are therefore poor, but this must be balanced against the risks of intervention and 
quality of life in elderly individuals. It is however possible that clinician perceived risk of 
cardiac surgery prevents referral of patients who may benefit from valve replacement; a 
multicentre study has suggested that up to one third of patients with severe aortic stenosis are 
not considered suitable for assessment referral for valve replacement. In the majority of these 
cases, conventional risk scores were not significantly higher than in those who received 
surgery, suggesting either variability of referral or assessment of these patients.39 
 
1.2.5 COMPLICATIONS OF AORTIC VALVE REPLACEMENT 
Complication rates from SAVR have been progressively falling with time. Across all age 
groups, estimates suggest a short-term mortality rate of less than 3% for isolated SAVR 
procedures, although this increases with age and concomitant cardiac procedures such as 
coronary bypass grafting.40-42 Between 1995 and 2003, outcomes from 32,839 cardiac 
operative procedures were recorded by the Society of Cardiothoracic Surgeons of Great 
Britain and Ireland (SCTS). This revealed an in-hospital mortality rate of 3.3% in those 
under 50 years old, but a comparable rate of 10.3% in those over 79 years old. In risk 
Clinical biomarkers in older patients with aortic stenosis 10 
modelling based on large consecutive series of SAVRs, age was a key determinant of short-
term mortality risk, surpassed only by a procedure being performed as an emergency.43,44  
 
Patients undergoing TAVI are generally older, but only experienced a 5% mortality rate at 
30 days after TAVI in the PARTNER trial cohort.27 However, the intermediate death rates 
are striking, with 54% and 72% of TAVI patients dead by 3 and 5 years respectively.45,46 
This compares to a 28% 5-year mortality rate amongst high-risk isolated AVR cases.47 Non-
mortality complication event rates are also more significant in older populations.  
 
1.2.5.1 STROKE 
Calcification of the stenotic aortic valve and associated atherosclerotic changes in the aorta 
are significant potential foci for embolisation and stroke at the time of aortic valve 
replacement. This may be a devastating consequence of an elective surgical procedure. 
During SAVR, immediate stroke events appear related to cannulation of a calcified aorta to 
initiate cardiopulmonary bypass.48 However, late strokes may continue to occur as a result of 
microembolisation following valve replacement.49 Intracardiac surgery such as valve 
replacement has long been observed to carry a higher stroke risk than extracardiac 
procedures such as coronary artery bypass grafting.50 Overall post-SAVR stroke rates are 
estimated at 1.5%, but rising to between 2% and 4% in older cohorts.47,48  
 
Periprocedural stroke was initially reported as a more common outcome amongst TAVI 
patients complicating up to 6% of procedures. Transcranial doppler studies suggest that 
embolisation occurs during the balloon valvulopasty and valve deployment phases of the 
procedure.51  Stroke event rates are likely to have fallen with technological improvements 
and increased procedural experience. However, predisposition to delayed strokes remain a 
significant concern; long-term follow-up of the PARTNER trial TAVI cohort revealed that 
15.7% had experienced a major stroke by three years after the procedure, compared to 5.5% 
in those receiving medical therapy.45 
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1.2.5.2 DELIRIUM AND COGNITIVE DECLINE 
Delirium is a common but severe post-operative complication. It is characterised by 
inattention, altered arousal and disorganised thinking. In some studies, this has been 
described in up to half of all older cardiac surgery patients, with greater risk in those 
procedures including valve replacement.52-55 Across all ages, delirium acts as an independent 
risk factor for death, even ten years after surgery.56 It is also associated with severe patient 
and carer distress, increased length of hospital stay and loss of functional independence.57,58 
Saczynski et al. assessed cognitive trajectories for one year after cardiac surgery in those 
who did and did not develop post-operative delirium. Using the mini-mental state 
examination as a test of global cognitive function, the 46% of all patients who developed 
delirium had persisting cognitive deficits for at least one month after surgery and a trend 
towards persisting effects up to one year.59 This adds to other research that has established a 
link between delirium and future cognitive decline, or acceleration of pre-existing 
dementia.60,61 Traditional views of a harmless and transient post-operative confusional state 
are therefore outdated; delirium represents acute brain dysfunction with poor clinical, 
functional and pathological outcomes. 
 
It has been postulated that post-operative delirium may be related to cerebral 
microembolism. However, rates appear lower after TAVI despite microembolic events being 
a near universal phenomenon.54,62-64 The long-term consequences of these microemboli are 
unclear, but are associated with an increasing burden of cerebral small vessel disease. White 
matter hyperintensities (WMH) are one form of these lesions and have been strongly related 
to cognitive decline in longitudinal studies.65 Preoperative high WMH burden has been 
associated with delirium after cardiac surgery, supporting a theory of measurable cerebral 
vulnerability.66 As with delirium in other circumstances, the pathogenesis of post-operative 
delirium is unclear and is likely to reflect multiple putative causative derangements rather 
than a final common pathway. This may include dysregulated neuroinflammation, altered 
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neuroendocrine responses, oxidative stress and disturbed circadian rhythms in response to 
physiological stressors experienced during surgery and recovery.67 
 
1.2.5.3 FUNCTIONAL DECLINE AND QUALITY OF LIFE 
A limitation of aortic valve replacement studies has been a focus on mortality, rather than 
functional and quality of life outcomes, which may be of particular importance in older 
patients. A systematic review of such outcomes after TAVI by Kim et al. concluded that: 
 
“more comparative studies on functional status and quality of life  
are needed for informed treatment decision making”68 
 
In one single-centre study of cardiac surgery including SAVR, 10% of patients required 
‘institutional’ care in place of discharge home after surgery, defined as rehabilitation or 
ongoing nursing level care.69 Abah et al. systematically reviewed the evidence for quality of 
life changes amongst those over 80 years old undergoing cardiac surgery. The majority 
appeared to experience improvements, but a significant minority of between 8-19% of all 
patients experienced declines in quality of life after surgery.70  
 
Amongst the PARTNER randomised controlled trial cohort of TAVI patients, function was 
measured using the New York Heart Association symptom scale. This appeared to improve 
in the majority of patients with effects sustained for at least three years.45 However, 
assessing quality of life components of the Kansas City Cardiomyopathy Questionnaire 
performed in the study and subsequent registry revealed that up to 33% of the 2,137 
participants undergoing TAVI had a ‘poor’ 6-month outcome.71 Others have reported smaller 
proportions of TAVI patients with functional decline, but these individuals remain an 
important and significant minority.72  
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Despite the uncertainty of evidence in this area, ESC guidelines do prioritise expected 
functional outcomes over survival, stating that TAVI is ‘absolutely contraindicated’ in those 
without an expected improvement in quality of life.3 The optimum method of identifying 
these vulnerable individuals is unclear, but is of paramount importance to the management of 
older patients with aortic stenosis. 
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1.3 CURRENT ASSESSMENT OF OLDER AORTIC STENOSIS PATIENTS 
Given the variation in outcomes after aortic valve replacement, objective assessment of 
procedural risk is essential to guide choice of management. Current assessment is largely 
based on models constructed from large datasets of observed procedural outcomes, with a 
focus on early mortality and morbidity.  
 
1.3.1 CARDIAC SURGERY RISK ASSESSMENT TOOLS 
The most widely used risk tool is from the Society of Thoracic Surgeons (STS), where the 
SAVR model is based upon outcomes from 67,292 procedures performed between 2002 and 
2006.73 The covariates include age, gender, ethnicity, body mass index, comorbidities and 
preoperative cardiac status. There is however no inclusion of functional status or dependency 
in the model. The most commonly cited output is the STS operative mortality, which 
predicts the percentage risk of death during the initial surgical admission or within 30 days if 
discharged. In the PARTNER trial of TAVI or medical management for high-risk surgical 
candidates, a threshold STS score of 10% was chosen to define the group for 
randomisation.27 Further output scores include estimated risk of stroke, acute renal failure, 
prolonged ventilation, deep sternal wound infection and the requirement for reoperation.73 
 
Similarly, the EuroSCORE II risk assessment tool was initially based on 6,753 consecutive 
SAVR procedures across 154 surgical units over 12 weeks in 2010. The model includes 
similar covariates to the STS score, but does additionally prescribe risk to patients with 
‘severe mobility impairment secondary to musculoskeletal or neurological dysfunction’.74 
Due to the challenges of collecting data from disparate centres, the outcome measure is 
defined as mortality during the initial surgical admission rather than by a fixed follow-up 
period. The included derivation dataset is also much smaller than for the STS score, which is 
particularly noteworthy for the estimation of risk in older patients. The calculator carries a 
warning stating that: 
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“Of over 20,000 patients in the EuroSCORE database, only 21 patients  
were aged over 90 - therefore the risk model may not be accurate in these  
patients. Please exercise clinical discretion in interpreting the score.” 
 
Even without considering holistic markers of risk in older populations such as function and 
frailty, both scores do not include important conditions such as a history of stroke, liver 
disease, ‘porcelain’ aorta and prior chest irradiation which may increase surgical risk.75 It is 
also worth acknowledging that these risk scores derived in cardiac surgery populations are 
not validated for prediction of outcomes after TAVI. Indeed the ESC guidelines 
acknowledge the deficiencies in this area, stating that: 
 
“In the absence of a perfect quantitative score, the risk assessment should mostly  
rely on the clinical judgement of the ‘heart team’, in addition to the 
 combination of scores”3 
 
Ongoing registries of TAVI procedures will eventually have sufficient power to model risk 
in a similar manner to the STS and EuroSCORE tools.  
 
1.3.2 DISCRIMINATION AND CALIBRATION OF EXISTING RISK SCORES 
Model accuracy is defined by two complementary measures: discrimination and calibration. 
Discrimination describes how successfully a model separates cases into groups; in the 
example of the STS and EuroSCORE tools discrimination for operative risk is generally 
good. The c-statistic for the discrimination of operative mortality in valve replacement 
surgery using the STS score is 0.7876 and by EuroSCORE II is 0.69.77 However, these data 
are provided as measures of discrimination across the whole adult surgical population; it is 
unclear if performance is maintained amongst the oldest patients. Calibration is also 
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important, assessing how well predicted probabilities agree with observed risk.78,79 On this 
measure, both STS and EuroSCORE perform relatively poorly, particularly in older 
populations. In a study of valvular heart surgery patients, the STS score predicted 40% less 
mortality than was observed, whilst the logistic EuroSCORE (a predecessor of the 
EuroSCORE II) expected mortality rate was greater than three-fold higher than actual 
levels.80 The lack of calibration therefore limits the ability of these models to accurately 
estimate operative risk in an individual rather than as part of a cohort of patients with similar 
characteristics.81 This strongly suggests that existing tools fail to capture critical components 
of the risks of cardiac surgery in older patients. Calibration of models also vary between 
populations, reflecting differences in baseline risk including age demographics; models 
therefore frequently require recalibration when applied to disparate populations. 
 
1.3.3 CHALLENGES OF ASSESSMENT IN OLDER PATIENTS 
Guidelines for aortic valve replacement necessitate the presence of symptoms or left 
ventricular impairment in all but the lowest risk patients. However, in an elderly population 
with multiple comorbidity, discriminating symptoms from aortic stenosis is challenging. A 
Scottish population-level epidemiological study of trends in aortic valve disease 
retrospectively assessed 13,220 individuals with aortic stenosis. Across all ages, 17% of 
patients had co-existing significant respiratory disease, a further 11% diabetes mellitus, 9% 
cancer and 8% renal disease.82 These figures are likely to be even higher in older 
populations, where respiratory comorbidity has been noted in between 18%-24% of 
cases.27,47  
 
It has been suggested that exercise stress testing may unmask true symptoms where there is 
doubt due to comorbidity.83 However, many older patients are unlikely to tolerate such 
investigations or gain meaningful results due to the limitations of poor mobility. Similar 
challenges exist in determining myocardial fibrosis by cardiac magnetic resonance imaging. 
Many older patients are unable to tolerate prolonged scanning lying flat or the intermittent 
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breath-holding required for such diagnostic imaging. Others would advocate a trial of 
therapy for aortic stenosis by means of balloon valvuloplasty, but this exposes the patient to 
important risks from valve manipulation such as stroke in order to reach a firm diagnosis. In 
the event of short-lived symptomatic benefit indicating a culprit aortic valve, these risks are 
effectively duplicated by undertaking definitive valve replacement.  
  
Clinical biomarkers in older patients with aortic stenosis 18 
1.4 NOVEL ASSESSMENT TOOLS   
The evidence presented shows that objective, non-invasive biomarkers of functionally 
relevant aortic stenosis are currently lacking. Furthermore in the assessment of patients for 
valve replacement, existing surgical risk scores lack the calibration to provide reliable 
individual measures of risk, particularly in an older patient. Assessment and decision-making 
in this population would be greatly enhanced by objective markers of aortic stenosis 
progression and surgical risk, acknowledging that outcomes after surgery include quality as 
well as quantity of life. These may be considered as biomarkers, defined by the Oxford 
English Dictionary as: 
 
“a diagnostic indicator of (predisposition to) a medical condition”84 
 
This thesis will consider two broad groups of biomarkers. First, putative biomarkers of the 
consequences of aortic stenosis, including markers of ventricular wall stress, fibrosis and 
myocardial injury. These may be considered as candidates for tracking disease progression 
that could provide early identification of a declining patient in whom aortic valve 
replacement should be considered. Second, physical performance and frailty measures may 
act as biomarkers of perioperative risk and long-term mortality. Such measures could be 
used to inform and modify a decision for aortic valve replacement, potentially by enhancing 
the prediction of existing surgical risk scores. These measures may not necessarily just 
influence the binary decision to proceed to valve replacement; increased awareness of 
perioperative risk may identify a population for enhanced early post-operative care (e.g. a 
longer monitoring period in an intensive care setting) and rehabilitation programmes after a 
valve procedure.  
 
These two groups of biomarkers will now be considered in more detail. 
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1.4.1 BLOOD BIOMARKERS OF MYOCARDIAL INJURY 
An objective assessment of the myocardial response to aortic stenosis to detect early 
decompensation may identify a window of opportunity for effective intervention. 
Progression of aortic stenosis is characterised by cardiomyocyte death and replacement 
fibrosis.20 Circulating biomarkers of myocardial injury and cell death are therefore attractive 
potential markers of advancing disease.  
 
1.4.1.1 CARDIAC TROPONIN 
Cardiac troponin is a structural sarcomeric protein present in cardiac muscle (Figure 1.1), 
with plasma concentration acting as a highly specific marker for myocardial injury.85 It may 
now be quantified with high precision at extremely low circulating blood concentrations.86,87 
Chin et al. investigated whether plasma cardiac troponin concentration was associated with 
long-term prognosis in patients with asymptomatic aortic stenosis of moderate severity. 
Cardiac troponin was quantifiable using a high-sensitivity assay in all cases of aortic 
stenosis. One in ten patients had concentrations above the upper reference limit that is 
recommended as the diagnostic threshold for myocardial infarction. Cardiac troponin 
concentration was an independent predictor of outcomes (valve replacement or 
cardiovascular death) at 10 years after adjustment for age, sex, symptoms, coronary artery 
calcium and severity of valvular disease (HR 2.10 per 2-fold increase in cardiac troponin, 
95% confidence intervals [CI] 1.22–3.61, p=0.007). Interestingly, levels of this biomarker 
correlated with left ventricular hypertrophy and replacement fibrosis rather than the severity 
of stenosis.88,89  
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Figure 1.1 – Simplified schematic representation of a cardiac sarcomere. This demonstrates 
that cardiac troponin I binds to actin in thin myofilaments which hold the troponin-
tropomyosin complex in place. Troponin I exists within a troponin complex including 
troponin T and troponin C (not shown). Cardiac myosin binding protein C is a larger structure 
that binds along the myosin thick filament. 
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In a separate analysis cardiac troponin concentrations were 4-fold higher in patients with 
aortic stenosis and left ventricular strain than in those without hypertrophy or strain 
(18.6ng/L (IQR 9.0–45.2) with strain vs 4.3ng/L (IQR 2.5–7.3) without, p<0.001), and this 
relationship persisted after adjustment for age, sex and systolic blood pressure.90 This 
suggests the response to pressure overload may be as important as pressure overload itself, 
with cardiac troponin proving a candidate biomarker of functionally significant aortic 
stenosis.  
 
These associations were however based on a single assessment of troponin at baseline in 
patients with moderate aortic stenosis. The performance of this assay in older patients with 
severe disease is uncertain. Individual variation of a biomarker around a homeostatic set-
point defines the biological variation of a test.91 Without formal investigation using serial 
sampling in a controlled experiment, caution must be taken when interpreting single blood 
results or changes in such markers over time. 
 
1.4.1.2 CARDIAC MYOSIN BINDING PROTEIN C (CMYC) 
Like cardiac troponin, cMyC is a sarcomeric protein (Figure 1.1) with a release profile that is 
exquisitely specific for cardiac tissue. It has an essential role in the structural integrity and 
function of the sarcomere and is more abundant than troponin.92 Studies using models of 
ischaemic cardiac injury reveal earlier release and decay kinetics compared to troponin, 
suggesting a possible role as a more dynamic marker of myocardial injury.93 Additionally, 
cMyC is present in the circulation as two distinct measurable forms: a full-length 149-kDa 
protein and a cleaved 40-kDa fragment released in times of cardiac stress. This fragment 
may have a pathogenic role in cardiac tissue by competing for actin and myosin binding 
sites. Overexpression of this ‘poison peptide’ in mouse models rapidly produces 
hypertrophic cardiomyopathy and heart failure.94 
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cMyC has never been studied in patients with aortic stenosis, primarily due to insufficient 
sensitivity of the assay to detect low level release. However, recent technological advances 
open new avenues to explore the potential of this biomarker of myocardial injury to identify 
patients with early progressive aortic stenosis.95 
 
1.4.2 BLOOD BIOMARKERS OF MYOCARDIAL FIBROSIS AND HEART FAILURE 
As cardiomyocyte death progresses, fibrosis and heart failure become predominant features 
in patients with progressive aortic stenosis. Circulating biomarkers may provide early 
warning of patients at risk of decompensation. 
 
1.4.2.1 B-TYPE NATRIURETIC PEPTIDE (BNP) 
BNP is a well-established marker of heart failure that is widely used in clinical practice. It is 
a natriuretic and vasodilating hormone, released predominantly by ventricular 
cardiomyocytes in response to volume overload and stretch.96 The inactive N-terminal of the 
prohormone (termed NT-proBNP) is also quantifiable and may be more stable for delayed 
laboratory measurement. BNP may have a role in identifying patients with aortic stenosis 
who are at risk of decompensation. In a study of 126 patients with asymptomatic disease, a 
BNP value of >61pg/ml successfully predicted the likelihood of symptom development or 
the requirement for valve replacement.97 However, Lim et al. reported a different series of 
aortic stenosis patients where similar BNP concentrations of >66pg/ml identified already 
symptomatic patients with a sensitivity and specificity of 84 and 82% respectively.98 This 
questions the generalisability of single-measure BNP approach. Serial testing in an 
individual patient may be more informative for detecting disease progression, although as 
with cardiac troponin, concerns about biological variability in aortic stenosis patients require 
further evaluation.99 
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1.4.2.2 GALECTIN-3   
Galectin-3 is a beta-galactoside-binding lectin protein expressed by activated macrophages. 
Particularly high concentrations are observed in the lung, spleen, adrenal gland, 
gastrointestinal tract, ovary and uterus. Cardiac expression is relatively low, but importantly 
may be upregulated in disease states.100 Higher circulating concentrations of galectin-3 are 
noted in heart failure, with a postulated role for the protein in the development of the 
disease.101 Increased expression of galectin-3 promotes proliferation of cardiac fibroblasts 
and deposition of type I collagen, which are critical steps in the development of myocardial 
fibrosis and subsequent failure.102  
 
In a study of ventricular remodelling by serial echocardiograms in 240 heart failure patients, 
rising galectin-3 levels were observed in a group of patients with remodelling compared to 
static or falling concentrations in the non-remodelled cases.103 Interestingly, there were no 
significant differences in NT-proBNP levels, suggesting a potential additive role for 
galectin-3 in the identification of early changes on the pathway to decompensated heart 
failure. In a small study of patients undergoing aortic valve replacement, circulating galectin-
3 concentrations correlated with interstitial levels from explanted valve tissue. Preliminary in 
vitro work demonstrated activation of both fibrotic and osteogenic pathways, perhaps 
suggesting a direct role for galectin-3 in valve calcification.104     
 
1.4.3 FRAILTY 
Frailty is a multimodal concept describing loss of strength, endurance and physiological 
reserve across multiple systems that increases vulnerability for developing dependency or 
death when exposed to a stressor.105 Common physiological stressors in older adults include 
infection, trauma and poor control of multiple comorbid diseases. Frailty becomes more 
common with age, but is a very distinct concept encapsulating biological rather than 
chronological years; indeed the majority of individuals over 85 years old are not frail. It also 
captures more than just recognised illness; a quarter of those affected by physical frailty may 
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have no notable comorbidity or disability.106 Common frailty models focus on the 
development of a physical phenotype or the gradual accumulation of deficits over time.107,108  
 
1.4.3.1 FRIED PHENOTYPE 
The Fried phenotype considers frailty to be the development of at least three out of five 
possible traits: weakness, slowness, reduced physical activity, exhaustion and unintentional 
shrinking (weight loss). It is easy to see how these components may be interlinked in a 
‘cycle of frailty’; weakness developing through loss of muscle mass may precipitate slow 
gait speed and reduced activity. Individuals with one or two traits are said to be ‘pre-frail’ or 
vulnerable. The phenotype was developed in 5,317 community dwelling participants of the 
Cardiovascular Health Study aged over 65 years old. Frailty was independently predictive of 
future hospitalisation, loss of independence with activities of daily living, falls and death.107 
 
1.4.3.2 ROCKWOOD FRAILTY INDEX 
While the frailty phenotype uses physical attributes as a surrogate for loss of physiological 
reserve, Rockwood’s frailty index takes a different approach by attempting to specifically 
define the loss of reserve. Frailty is described as part of continuous spectrum of up to 80 
accumulated deficits, which may be comorbidities, symptoms, signs or disabilities that do 
not saturate in the population as part of normal ageing.109 Each deficit is given equal 
weighting, with the index simply being the proportion of total possible deficits affecting an 
individual. Frailty indices have shown excellent discrimination for poor health outcomes in 
older individuals.108,110-112 Such an approach models the compensation law of mortality 
observed in all complex systems; as it ages, the hazard rate of a system changes in relation to 
its redundancy. This redundancy may be considered in humans as the degree of 
physiological reserve possessed by an individual. As health deficits accumulate, redundancy 
becomes exhausted and the system as a whole becomes unreliable and prone to failure (or 
death).113,114 This process is observed across frailty indices, where individuals appear unable 
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to develop an index value greater than approximately 0.7 – developing any combination of 
70% of possible deficits appears to exhaust redundancy and results in death. It is plausible 
that such a biomarker of robustness and reserve of an individual may improve assessment of 
older patients under consideration for major surgical procedures. 
 
1.4.3.3 OTHER FRAILTY MEASURES 
Despite these two core theories of frailty, there remains a lack of consensus on the optimum 
assessment method, resulting in a vast array of tools. Many of the instruments described as 
measuring frailty do not directly relate to the consensus definition described. As this 
definition includes the risk estimation for future dependency or death, multiple correlates of 
frailty may demonstrate predictive power for these outcomes while being conceptually very 
distinct from frailty. This lack of specificity and true consensus around a limited number of 
frailty measures frequently impairs direct comparison between studies and meta-analysis of 
results. 
 
It is also recognised that cognitive impairment frequently coexists with physical frailty but is 
not reflected in the frailty phenotype criteria and has minimal weighting in most frailty 
indices. International consensus has been reached on the concept of ‘cognitive frailty’115 and 
more recent frailty tools do incorporate cognitive testing.116  
 
Some frailty measures have been formally examined in cardiac surgical populations. The 
Comprehensive Assessment of Frailty (CAF) incorporates additional physical and laboratory 
tests with the frailty phenotype. Individuals are scored between 0–35 points, with higher 
values representing greater impairments and those with scores ≥10 described as frail. 
Discrimination for 12-month mortality was good for an older cardiac surgical population ≥74 
years old (area under the curve [AUC] 0.70, 95% CI 0.60–0.80). Age alone was not 
predictive of death and the relationship between the CAF and one-year mortality remained 
significant after adjustment for preoperative EuroSCORE (OR 1.09 per point increase in 
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CAF, 95% CI 1.05–1.14, p<0.001).117,118 In another study by Afilalo et al. of 152 patients 
≥70 years old undergoing cardiac surgery, slow gait speed (≥6 seconds to walk 5 metres) as 
a measure of frailty was associated with increased risk of postoperative mortality or major 
morbidity (OR 2.63, 95% CI 1.17–5.90, p<0.05). When combined with measures of 
disability, slow gait speed improved the discrimination of the STS score for a combined 
mortality and major morbidity outcome (AUC 0.73 vs 0.68 with STS score alone).119 This 
suggests frailty measures incorporate important risk factors for surgery in elderly cohorts 
that are not identified by conventional assessment. Similar relationships between frailty and 
mortality have been observed in TAVI populations, but once more there is a lack of evidence 
to suggest one tool over another.120-122  
 
A further limitation of studies in this area has been a focus on mortality, rather than the 
effect of pre-intervention frailty on subsequent functional and quality of life outcomes, 
which may be of particular importance in older patients. In an elderly patient with severe 
aortic stenosis, it is unclear how much frailty is ‘reversible’ by SAVR or TAVI.123 It is 
plausible that a proportion of patients will have irreversible frailty and will be liable to the 
complications of cardiac intervention without scope to improve their wellbeing due to 
overwhelming intrinsic non-cardiac disease driving the frail state. However, even where 
frailty is a direct consequence of cardiac disease, it does not have to be reversible to be 
useful as a risk marker to guide decisions for intervention and the intensity of post-operative 
care. Valve replacement alone may not be sufficient to reverse frailty, particularly if the loss 
of physical function accrued during progression of disease cannot be recovered through 
exercise training after intervention. Using objective measures to identify a target population 
with reversible frailty for valve replacement has potential to improve outcomes for elderly 
populations with aortic stenosis. 
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1.5 AIMS AND HYPOTHESES 
There are two core aims to this thesis. Firstly, it will seek to address the assessment of older 
patients with aortic stenosis, by investigating the validity of novel biomarkers of disease 
progression in situations where traditional symptom-based assessment is challenging. 
Secondly, in those considered for aortic valve replacement, this thesis will explore clinical 
biomarkers of surgical risk and how these compare to existing tools.   
 
The following hypotheses will be addressed: 
i) cMyC as a novel biomarker of myocardial injury will predict progression of 
aortic stenosis and outcomes (Chapter 3). 
ii) Cardiac troponin, BNP and galectin-3 as markers of myocardial injury, fibrosis 
and heart failure will demonstrate satisfactory variability in older patients with 
aortic stenosis to make clinical monitoring by serial sampling feasible (Chapter 
4). 
iii) Pre-operative frailty will predict important patient outcomes including mortality 
after TAVI in an older population with severe aortic stenosis (Chapter 5). 
iv) Measures of frailty will identify patient factors currently not captured by 
conventional surgical risk scores in an older population with severe aortic 



















CHAPTER 2: METHODOLOGY 
 
2.1 OVERVIEW 
Data for Chapter 3 of this thesis was collected from two aortic stenosis patient studies 
previously recruited in Edinburgh: the Scottish Aortic Stenosis and Lipid Lowering Trial 
(SALTIRE) led by Dr Joanna Cowell and an observational cohort study of myocardial 
fibrosis in aortic stenosis led by Dr Calvin Chin. Additional sample analysis for cardiac 
myosin-binding protein C (cMyC) was undertaken for this thesis. Data for Chapters 4 and 6 
were prospectively collected as part of observational cohort and quality improvement studies 
of older patients with aortic stenosis including blood biomarker and frailty assessment. 
Chapter 5 is a systematic review and meta-analysis of previously published literature in the 
field of frailty assessment and TAVI. 
 
General methodological processes are presented in this chapter with additional study-specific 
methodology detailed in each of the chapters that follow. 
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2.2 COHORTS 
Recruitment for the SALTIRE23 and myocardial fibrosis in aortic stenosis89 studies has been 
previously described in detail. Briefly, the SALTIRE randomised controlled trial recruited 
adults (≥18 years old) between March 2001 and April 2002 with calcific aortic stenosis who 
were demonstrated by echocardiography to have a minimum peak velocity across the aortic 
valve of 2.5m/s. The major exclusion criteria included active or chronic liver disease, severe 
coexisting non-aortic valvular heart disease, intolerance of statin therapy or total cholesterol 
<4.0 mmol/L, left ventricular dysfunction (ejection fraction <35% on echocardiography), 
permanent pacemaker or implantable cardiodefibrillator device. Of 455 eligible individuals 
screened for the study, 155 (34%) were randomised to receive either 80mg atorvastatin or 
placebo once daily in a double-blind manner. Echocardiography and computed tomography 
(CT) assessment of aortic valve calcium were performed annually for up to three years of 
study participation (median follow-up 25 months). While atorvastatin reduced serum 
cholesterol, no difference was observed in the progression of aortic stenosis when compared 
to those in the placebo arm (adjusted mean difference in annual change in mean aortic valve 
velocity 0.002m/s, 95% confidence intervals -0.066 to 0.070).23  
 
Of the 155 participants in SALTIRE, 104 had viable serum samples remaining for analysis 
of cMyC. These samples had been stored at -80oC. The post-hoc analysis presented in 
Chapter 3 utilises novel cMyC measurement and additional follow-up data collected from 
hospital patient records and Scottish national death records for a median of 11.3 years after 
study recruitment. For the purposes of the analysis the group was considered as a single 
observational cohort without distinction of the original study arm (atorvastatin or placebo) 
given the neutral findings of the randomised trial. 
 
The myocardial fibrosis in aortic stenosis observational cohort study recruited patients with 
all degrees of aortic stenosis from mild to severe determined by routine outpatient clinical 
care echocardiography. These participants were deemed to be clinically stable by their 
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reviewing cardiologist. The major exclusion criteria included significant coexisting non-
aortic valvular disease (more than moderate severity), contraindication to magnetic 
resonance imaging, and the presence of acquired or inherited cardiomyopathies. A further 
group of healthy controls without evidence of significant valve or coronary disease were also 
recruited. All participants underwent cardiac magnetic resonance (CMR) for markers of 
disease severity at the time of baseline blood sampling. Of the 161 patients with aortic 
stenosis included in this study, ten underwent tru-cut myocardial biopsy at the time of 
subsequent aortic valve replacement.88 These samples were used for histological analysis 
(performed by Dr Jacek Kwieciński) for autophagy and oncosis with detail provided in 
Chapter 3. Autophagy describes the regulated mechanism of disassembly of unnecessary or 
dysfunctional components, while oncosis refers to unprogrammed ischaemic cell death.124 In 
contrast, apoptosis is used to describe programmed cell death. 
 
Chapters 4 and 6 include participants with moderate-severe aortic stenosis specifically 
studied for these analyses of blood biomarkers and frailty. This comprises 80 individuals 
recruited into an ongoing observational cohort study of older patients with moderate-severe 
aortic stenosis determined by echocardiography with a minimum peak velocity across the 
aortic valve of 3.5m/s. All patients underwent comprehensive frailty assessment. Within this 
group, 14 participants undertook additional blood sampling at hourly and weekly intervals to 
assess the biological variability of biomarkers of interest in aortic stenosis (Chapter 4). The 
same frailty assessments were also performed in 105 patients with severe aortic stenosis who 
were referred to the Transcatheter Aortic Valve Implantation (TAVI) assessment clinic at the 
Scottish TAVI centre, Royal Infirmary of Edinburgh. These assessments were performed as 
part of a quality improvement project in this clinic to aid the multidisciplinary team 
assessment of candidate patients for this procedure. Therefore in total 185 patients with 
aortic stenosis were assessed for frailty measures across these two cohorts (Chapter 6). 
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2.3 BLOOD BIOMARKER ASSAYS 
Four candidates blood biomarkers of disease progression in aortic stenosis are presented in 
this thesis. With the exception of cardiac myosin binding protein C (cMyC), these 
biomarkers are available as part of a high-throughput laboratory platform and are therefore 
available for clinical use. The cMyC assay was undertaken using a research platform and is 
currently unavailable for clinical reporting. Precision of each assay is represented by 
standard performance measures: the Limit of Detection (LoD) which is the lowest 
concentration of an analyte that can be distinguished from the absence of that substance, and 
the lower Limit of Quantification (LoQ) which for the purpose of these assays additionally 
requires the coefficient of variation (CV) to be ≤20%.125 The CV of an assay is a 
standardised method for expressing the relative variability and is determined by the ratio of 
the standard deviation to the mean (i.e. CV = standard deviation/mean). 
 
2.3.1 CARDIAC MYOSIN BINDING PROTEIN C (CMYC) 
cMyC was measured in stored serum aliquots that were maintained at -80oC after 
centrifugation and separation from whole blood samples. Samples were analysed by trained 
technicians blinded to any participant information. This immunoassay utilises mouse 
monoclonal antibodies to two cardiac restricted epitopes within the N-terminus of cMyC: 
IA4 and 3H8. Antibodies to IA4 (the ‘capture antibody’) were combined with magnetic 
microparticles (Millipore Sigma, California, USA) before agitating for 2 hours at 25oC with 
the serum for analysis. The magnetic microparticles were then extracted via a magnetic bed, 
with any unbound material removed by washing. Fluorescently labelled mouse antibody to 
3H8 (the ‘detection antibody’) was added and then agitated at 25oC for a further 1 hour. The 
process of separation by magnetic bed and removal of unbound material by washing was 
repeated. The remaining magnetic microparticles were transferred to a new 384 well plate 
and exposed to proprietary buffers and fluorescent labelling solution for the Erenna single-
molecule counting system (Millipore Sigma, California, USA).  
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Using this technique, Marjot et al. defined this assay LoD at 0.4ng/L and LoQ at 1.2ng/L. 
The 99th percentile value in healthy individuals without obstructive coronary artery disease 
was determined at 87ng/L.95 As part of the assessment of assay precision and calibration 
prior to sample analysis for the studies presented in Chapter 3, known concentrations of 
control cMyC material were tested across a range of 8 concentrations to generate a standard 
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Figure 2.1 – Standard Curve for cMyC. This demonstrates high precision of the assay across 
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2.3.2 CARDIAC TROPONIN 
Cardiac troponin was measured using the ARCHITECT STAT high-sensitive troponin I 
assay (Abbott Diagnostics, Illinois, USA). This two-step immunoassay is widely used in 
clinical laboratories and has been well established for quantification of low circulating 
troponin concentrations. It is a rapid test, allowing reporting of results within 30 minutes of 
sample collection. The manufacturer reported LoD ranges between 1.1–1.9ng/L and based 
on prior work the LoQ is 1.5g/L to satisfy a ≤20% CV criterion.88,126 The 99th centile in 
healthy reference populations has been demonstrated to be sex-dependent at 34ng/L for men 
and 16ng/L for women.87 Blood samples were drawn into ethylenediaminetetraacetic acid 
(EDTA) tubes, held on ice and centrifuged within 30 minutes to derive a fresh plasma 
sample for analysis within 60 minutes of blood collection. Remaining plasma was frozen in 
aliquots for later retesting to allow fresh-frozen comparisons. 
 
2.3.3 B-TYPE NATRIURETIC PEPTIDE (BNP) 
Whole BNP was measured using the ARCHITECT STAT two-step sandwich immunoassay 
(Abbott Diagnostics, Illinois, USA). This required a plasma sample, obtained from the 
centrifugation of EDTA whole blood. As previous work using alternative but similar assays 
had demonstrated non-linear degradation of BNP after freezing, analysis was performed on 
fresh samples within 60 minutes of sampling as described for cardiac troponin above.127 The 
ARCHITECT STAT assay uses monoclonal antibodies specific for human BNP, with 
detection by chemiluminescence. The manufacturer stated LoD is 10pg/mL.  
 
2.3.4 GALECTIN-3 
Galectin-3 was measured using the ARCHITECT STAT two-step sandwich immunoassay 
(Abbott Diagnostics, Illinois, USA) with labelling by M3/M28 anti-galectin-3 coated 
microparticles and detection by chemiluminescence. Analysis was performed on EDTA-
derived plasma samples within 60 minutes of sampling and later repeated on samples frozen 
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at -80oC for fresh-frozen comparison. Existing performance data for this assay suggests a 
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2.4 FRAILTY AND QUALITY OF LIFE MEASURES 
Frailty assessments were performed in an identical manner in 186 participants across the two 
cohorts described above. Physical measurements required for the Fried phenotype, 
Edmonton Frail Scale (EFS) and Short Physical Performance Battery (SPPB) were assessed 
concurrently to minimise burden to the participant. Similarly, components of the Fried 
phenotype, EFS and the 12-item Short Form Survey (SF-12) assessed by participant 
response were combined into a single questionnaire (see Appendix I). The frailty 
measurements were deliberately chosen for their speed of completion, to be feasible 
candidates for inclusion into a busy clinic environment. In the current TAVI assessment 
clinic, patients are allocated approximately 30 minutes for full surgical and nursing 
assessment for aortic valve replacement suitability. The complete frailty assessment required 
approximately 15 minutes to complete. 
 
2.4.1 FRIED FRAILTY PHENOTYPE 
The Fried phenotype was obtained using two physical measures and three questionnaire 
responses to ascertain five components.  
 
Grip strength was assessed by three trials (two dominant hand, one non-dominant hand) of 
maximal unsupported hand grip strength assessed using a Jamar digital dynamometer. This 
machine provides a maximal strength measure obtained on each trial to the nearest 0.1kg. 
The associated phenotypic trait of weakness was allocated if participants achieved lower 
than the 20th percentile derived from population data adjusted for gender and body mass 
index (see Table 2.1).107 If a participant was unable to complete the grip strength assessment 
they were allocated a mark for weakness. 
 
Gait speed was assessed using an unobstructed 5 metre track marked by cones, with a clear 
1 metre runoff at each end. Participants started in the runoff area and were asked to walk at 
their normal pace past the farthest away cone using their own walking aids if required. 
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Timing was taken by stopwatch for the period the participant was travelling between the two 
cone markers. Three trials were undertaken with each participant, with the mean of these 
three recordings used to calculate a gait speed in metres per second. The associated 
phenotypic trait of slowness was allocated if participants achieved lower than the 20th 
percentile gait speed derived from population data adjusted for gender and height (see Table 
2.1).107 If a participant was unable to complete all three trials they were allocated the 
slowness marker. 
 
Shrinking was assessed by a positive questionnaire response for self-reported weight loss:  
 “Have you unintentionally lost more than 10lbs (4.5kg) in weight in the last year?” 
 
Exhaustion was assessed using responses to two statements from the Centre for 
Epidemiology Studies Depression (CES-D) scale129: 
 “I felt that everything I did was an effort in the last week” and 
“I could not get going in the last week” 
 
Participants were provided with four options for each statement and asked to pick the single 
response that best fitted their experience. A response of “moderate amount of the time (3-4 
days per week)” or more frequent for either question resulted in allocation of an exhaustion 
trait. 
 
For determining low physical activity, participants were asked if, in the last 3 months, they 
either (a) did not perform any weight bearing physical activity, (b) spent more than 4 hours 
continuously sitting per day, or (c) went for a short walk once per month or less. The 
presence of any of these markers were used to allocate the low physical activity trait to a 
participant. This is a modification of definition used by Fried et al. in the original description 
of the phenotype, but is consistent with use in large frailty studies such as the Invecchiare in 
Chianti study130 and the Frailty Intervention Trial.131 The original Fried phenotype used the 
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Minnesota leisure time physical activity questionnaire.132 This content was considered less 
relevant for non-American respondents and the length of the questionnaire was also 
prohibitive. 
 
A final Fried phenotype frailty status was then determined by the presence of any three or 
more of these five traits in an individual participant. The pre-frail phenotype was considered 
in those with one or two traits.107 
 
2.4.2 EDMONTON FRAIL SCALE (EFS) 
The EFS in a multidimensional assessment across the domains of prior hospitalisations, self-
reported health, functional dependence, social support, polypharmacy, nutrition, mood, 
continence and cognitive function.116 It is frequently considered as a frailty tool although it 
does include some measures of disability in keeping with many similar measures. These 
assessments are largely completed by questionnaire (see Appendix I), but include a simple 
clock-drawing test for cognition and Timed Up and Go (TUG) as a measure of mobility and 
balance. In the clock-drawing test, the participant was asked to draw a standard clock-face, 
to write on all the numbers and place the hands to show the time of ten-past-eleven. The 
TUG was measured by stopwatch as the time taken to rise from an armchair independently, 
walk 3 metres to a marker (using any aids required), turn around and then return back to a 
seated position in the chair. For consistency, the same style of armchair was used for all 
participants. 
 
Participants were scored using criteria shown in Table 2.2. The total scale score reflects 
increasing frailty from 0 points up to a maximum of 17 points. The original authors of the 
EFS did not set cut-offs with which to dichotomise a population by frailty, although others 
have proposed this at a scale score ≥8, with pre-frailty or vulnerability at 6–7 points.133  
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Table 2.1 – Scoring thresholds for grip strength and gait speed used to derive weakness and 
slowness criteria of the Fried phenotype. Thresholds are determined from Fried et al.107 with 
conversion of walk times over 15 feet into gait speed cutoffs suitable for a 5 metre timed 
walk. 
 
Domain Gender BMI (kg/m2) Height (cm) Threshold 
Grip Strength  Male ≤24  ≤29kg 
  24.1–26  ≤30kg 
  26.1–28  ≤31kg 
  >28  ≤32kg 
 Female ≤23  ≤17kg 
  23.1–26  ≤17.3kg 
  26.1–29  ≤18kg 
  >29  ≤21kg 
     
Gait Speed Male  ≤173 ≥0.65m/s 
   >173 ≥0.76m/s 
 Female  ≤159 ≥0.65m/s 
   >159 ≥0.76m/s 
  
Clinical biomarkers in older patients with aortic stenosis 41 
Table 2.2 – Scoring of the Edmonton Frail Scale. The questionnaire used to collect patient 
reported components is shown in Appendix I. 
 
Domain 0 Points 1 Point 2 Points 
Number of hospital admissions 
in the last year 
No admissions 1-2 ≥3 
Self-rated health Excellent/Very 
Good/Good 
Fair Poor 
Number of activities of daily 
living requiring assistance 
0-1 2-4 5-8 
Availability of social support 
when needed 
Always Sometimes Never 
Use of ≥5 regular prescribed 
medications 
No Yes  
Forgetting to take medications No Yes  
Recent loss of weight such that 
clothing is looser 
No Yes  
Often feeling sad or depressed No Yes  
Urinary incontinence No Yes  
Clock-drawing task No errors Minor spacing 
error 
Any other error 
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2.4.3 SHORT PHYSICAL PERFORMANCE BATTERY (SPPB) 
The SPPB comprises three tests of lower extremity function: gait speed, standing balance 
and chair rises. Although frequently described as a frailty measure, the SPPB is best 
described as a measure of physical performance, although the components are clearly related 
to the frailty construct. Each element scores a maximum of 4 points, with a lower score 
indicating greater impairment and 0 points an inability to complete the task. The gait speed 
scoring allocation in the original description of the SPPB was based on the time taken to 
walk an 8 foot track.134,135 To reduce repetitive testing, these cut-off times were converted 
into a speed in metres per second and points were allocated using the mean measure of gait 
speed obtained from the Fried phenotype testing across three trials of a 5 metre walk. 
Although the distance covered by this gait assessment varies from the original description of 
the SPPB across a 4 metre track, multiple walking tests across marginally different lengths 
could introduce a bias from participant fatigue, and so a pragmatic decision was made to 
perform a single walking test and convert thresholds into true gait speeds (in metres per 
second). 
 
For standing balance, participants were sequentially asked to maintain their feet in side-by-
side, semi-tandem and tandem positions for 10 seconds each without the use of external 
balancing aids. The balance positions and allocation of points are shown in Figure 2.2. 
Assessment was stopped at the point at which a participant was unable to complete a full 10 
second balance. Participant safety was a priority and testing was performed with staff in 
close proximity to the participant for support in case of imbalance. As with all elements of 
assessment, the activity was demonstrated to participants, who only undertook the balance 
testing if they were agreeable. Testing was also rarely terminated where research staff, on 
observing an individual during the research visit, felt they were at excessive risk of falling by 
attempting a balance posture. 
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For the final component of the SPPB, participants were asked to rise from a chair with their 
arms folded across their chest, so as not to use their upper limbs or chair arms for propulsion. 
If a participant was able to complete this task, they were timed standing up and sitting down 
in this manner 5 times as quickly as possible. Scores between 1–4 were allocated according 
to cut-offs defined by the study authors135, with 0 points for those unable to complete all 5 
chair rises. 
 
The sum total of these three components was used to produce a SPPB score between 0 and 
12 points. To dichotomise the population for frailty, a cut-off of ≤5 points was used in 
keeping with the work of others, although there is a lack of consensus in this area and 
different thresholds have been suggested.123 
  














Figure 2.2 – Feet position and scoring for standing 
balance component of the SPPB. The test is completed from left to right and terminated 
when a participant is unable to complete 10 seconds at any level. Scoring for this component 
is between 0 points (unable to start or manage 10 seconds side-by-side) and 4 points 






(10 seconds = 1 point) 
Semi-Tandem 
(10 seconds = 1 point) 
 
Tandem 
(3–9 seconds = 1 point; 
10 seconds = 2 points) 
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2.4.4 CLINICAL FRAILTY SCALE (CFS) 
The CFS is a structured scale of descriptors to guide selection between nine levels ranging 
from “very fit: 1” to “terminally ill: 9”. It requires no physical measures or formal 
questionnaire responses, but knowledge of the participant is required. Assessment criteria 
include activity, symptoms and assistance usually required with personal activities of daily 
living (e.g. washing and toileting), and instrumental tasks necessary for independent 
community living (e.g. managing finances and medications). Frailty may be assessed as a 
continuum, but is considered present at a score ≥5, with vulnerability or pre-frailty at 4 
points (see Figure 2.3).110 Clinic nursing staff or research nurses completed the CFS based on 
their professional assessment, discussion with the participant or family and any 
documentation of premorbid functional status.  
  
As frailty measures were designed to score participants as having a frailty marker when 
unable to complete an assessment (e.g. gait speed), complete frailty data was available in all 
participants included in the study. 
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Figure 2.3 – The Clinical Frailty Scale. This is reproduced from the Geriatric Medicine 
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2.4.5 SHORT FORM SURVEY (SF-12) 
This 12-item questionnaire tests self-rated health, physical function, health expectations and 
emotional wellbeing. The output provides separate physical and mental component summary 
scores, which are standardised on a scale from 0 to 100, where increasing values represent 
higher levels of health. The calculation of these summary scores is independent of age. The 
SF-12 was developed as a short-form of a longer and more intensive 36-item questionnaire 
(SF-36) that was derived from the Medical Outcomes Study.136 Interpretation of question 
responses in psychometric testing may be subject to geographical and cultural variation. 
Using data from over 8,000 participants in the Oxford Health and Lifestyle Survey, the 
median physical component score (PCS) and mental component score (MCS) in a United 
Kingdom population was shown to be 53.2.137 The SF-12 summary scores were calculated 
under license (Optum SF, Minnesota, USA) in all participants. 
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2.5 ETHICAL CONSIDERATIONS 
Written informed consent was obtained from all participants recruited across the studies 
included in Chapters 3, 4 and 6. All studies were reviewed by the South East Scotland 
Research Ethics Committee and procedures were conducted in accordance with the 
Declaration of Helsinki.  
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2.6 DATA ANALYSIS AND STATISTICS 
Detailed descriptions of statistical methods are presented in each of the following Chapters. 
Wherever possible, analysis was performed on continuous data without dichotomisation, 
except where it was considered relevant for clinical interpretation (e.g. defining frailty). 
Parametric data are summarised using mean ± standard deviation and non-parametric data by 
median ± interquartile range. Blood biomarker concentrations are frequently positively 
skewed and where this was observed log-transformation was undertaken prior to further 
testing. All analyses were performed using R (versions 3.1.3 to 3.4.1; http://www.r-
project.org). Two-sided tests were performed throughout, with statistical significance 
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CHAPTER 3: CARDIAC MYOSIN-BINDING PROTEIN C AS A NOVEL MARKER OF 
MYOCARDIAL INJURY AND FIBROSIS IN AORTIC STENOSIS 
 
3.1 OVERVIEW 
Cardiac myosin binding protein C (cMyC) is an abundant sarcomeric protein and novel 
highly specific marker of myocardial injury. Myocyte death characterises the transition from 
hypertrophy to replacement myocardial fibrosis in advanced aortic stenosis. We 
hypothesised that serum cMyC concentrations would be associated with cardiac structure 
and outcomes in patients with aortic stenosis. 
 
cMyC was measured in two cohorts in which serum had previously been prospectively 
collected: a mechanism cohort of patients with aortic stenosis (n=161) and healthy controls 
(n=46) who underwent cardiac magnetic resonance imaging, and an outcomes cohort with 
aortic stenosis (n=104) followed for a median of 11.3 years. 
 
In the mechanism cohort, cMyC concentration correlated with left ventricular mass (adjusted 
ß=11.0g/m2 per log unit increase in cMyC, p<0.001), fibrosis volume (adjusted ß=8.0g, 
p<0.001) and extracellular volume (adjusted ß=1.3%, p=0.01) in patients with aortic stenosis 
but not in controls. In those with late gadolinium enhancement (LGE) indicative of 
myocardial fibrosis, cMyC concentrations were higher (32 [21–56] ng/L vs 17 [12–24] ng/L 
without LGE, p<0.001). cMyC was unrelated to coronary calcium scores. Unadjusted Cox 
proportional hazards analysis in the outcomes cohort showed greater all-cause mortality (HR 
1.49 per unit increase in log cMyC, 95% CI 1.11–2.01, p=0.009). 
 
Serum cMyC concentration is associated with myocardial hypertrophy, fibrosis and an 
increased risk of mortality in aortic stenosis. The quantification of serum sarcomeric protein 
concentrations provide objective measures of disease severity and their clinical utility to 
monitor the progression of aortic stenosis merits further study.  
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3.2 INTRODUCTION 
Aortic stenosis is the most common valvular disease in the Western World and the incidence 
is rising in keeping with an ageing population.138 The response of the myocardium to aortic 
stenosis is variable, with heterogeneity in the development of ventricular hypertrophy and in 
how this process ultimately decompensates.17-19 This results in a poor correlation between the 
severity of stenosis and the development of symptoms. Decompensation of the hypertrophic 
response in aortic stenosis is driven by two processes: progressive myocyte cell death and 
myocardial fibrosis.20 Biomarkers of myocardial injury are therefore an attractive addition to 
current imaging markers of disease progression, perhaps providing critical evidence of early 
decompensation that may identify patients who would benefit from early valve replacement. 
We have previously demonstrated that cardiac troponin I concentration is associated with 
advanced hypertrophy, replacement fibrosis and poor long-term outcomes in aortic stenosis 
patients,88 suggesting that myocardial injury in advanced aortic stenosis is common, 
detectable and of prognostic importance. 
 
Cardiac myosin binding protein C (cMyC) is a cardiac-restricted sarcomeric protein located 
on the thick filament.93,139 Recent advances in assay technology have allowed measurement 
of cMyC with high precision at extremely low concentrations.95 It is more abundant in 
myocardial tissue and the circulation than cardiac troponins and has an important role in the 
assembly and function of the cardiac sarcomere.92,140,141 Indeed, mutations in the MYBPC3 
gene encoding cMyC are the most common known genetic cause of hypertrophic 
cardiomyopathy.142 Furthermore, the proteolytic cleavage of cMyC is highly regulated by a 
variety of myocardial kinases143 and the resultant peptide is cardiotoxic.94 Hence, there is 
growing interest in the protein as both a biomarker and a determinant of myocardial 
injury.144 Given myocyte death characterises the transition from hypertrophy to replacement 
myocardial fibrosis in advanced aortic stenosis, we hypothesise that serum cMyC 
concentrations would be associated with cardiac structure and outcomes in patients with 
aortic stenosis.  
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3.3 METHODS 
We evaluated cMyC in two cohorts: a mechanism cohort of aortic stenosis patients and 
healthy controls with cardiac magnetic resonance (CMR) imaging, and an outcomes cohort 
of aortic stenosis patients with greater than ten years of clinical follow-up. These groups 
were derived from existing studies in patients with stable aortic stenosis recruited from 
cardiology clinics across the South East of Scotland, where serum had been prospectively 
collected and frozen at the time of study inclusion. Additionally a sub-group of patients from 
the mechanism cohort underwent myocardial biopsy at the time of subsequent aortic valve 
replacement (AVR), providing exploratory histological correlation with cMyC 
concentrations. The studies were conducted in accordance with the Declaration of Helsinki 
and approved by the local research ethics committee. Written informed consent was obtained 
from all participants. 
 
3.3.1 MECHANISM COHORT 
The mechanism cohort consisted of 161 patients with mild to severe aortic stenosis and 46 
healthy volunteers without evidence of significant valvular heart disease enrolled in an 
observational study assessing the role of myocardial fibrosis in aortic stenosis 
(NCT:01755936). Exclusion criteria comprised significant (moderate or severe) non-aortic 
valvular disease or any cardiomyopathy (acquired or inherited). The imaging protocol 
undertaken in all participants has been described in detail previously.88-90,145 Briefly, CMR 
was performed using a 3T scanner (MAGNETOM Verio, Siemens AG, Healthcare Sector, 
Erlangen, Germany). Dedicated software was used to assess left ventricular (LV) volume 
and mass indexed to body surface area and to calculate ejection fraction. Diffuse myocardial 
fibrosis was determined by fibrosis volume and the extracellular volume (ECV) fraction in 
keeping with current evidence of reproducibility from T1 mapping.145,146 Focal myocardial 
replacement fibrosis was determined by the late gadolinium enhancement (LGE) technique, 
with its presence determined visually and independently by two experienced assessors. 
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Comprehensive echocardiography was performed on all subjects to classify markers of aortic 
stenosis severity according to European Association of Echocardiography/American Society 
of Echocardiography guidelines.147  
 
3.3.2 OUTCOMES COHORT 
This cohort was derived from the Scottish Aortic stenosis and Lipid lowering Trial, Impact 
of REgression (SALTIRE) study. The study design, recruitment and findings have been 
reported previously.23,148 Briefly, between March 2001 and April 2002 a total of 155 patients 
with asymptomatic moderate to severe aortic stenosis were randomised to receive either 
atorvastatin or placebo. Sufficient stored sample remained for cMyC analysis in 104 patients. 
In addition to comprehensive echocardiography, computed tomography (CT) calcium 
scoring of the coronary arteries was performed (Twin II Flash, Philips Medical Systems). 
 
Outcomes data was obtained by two independent investigators who were blinded to cMyC 
results. The General Register of Scotland was searched for all deaths. The cause of death 
was adjudicated for a cardiac cause from the issued death certification, using additional 
information from electronic health records if necessary. This included summaries of a 
patient’s final hospital admission resulting in death, where the cause was uncertain from the 
death certificate. Disagreements were resolved by consensus. Electronic health records were 
also reviewed in all cases for evidence of surgical AVR.  
 
3.3.3 BLOOD SAMPLING AND ANALYSIS 
Serum cMyC concentrations were measured in duplicate on the single molecule counting 
Erenna platform (Singulex/Merck Millipore, CA, USA). The assay has a lower limit of 
detection (LoD) of 0.4 ng/L, a lower limit of quantification (LoQ) of 1.2 ng/L (at 20% 
coeeficient of variation, CV) and reasonable recovery (107.1 ± 3.7%; mean+/-SD), dilutional 
linearity (101.0 ± 7.7%) and intra- (CV 11 ± 3%) and inter- (CV 13 ± 3%) series precision. 
Cardiac troponin was determined using a high-sensitivity assay (Abbott ARCHITECT 
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STAT, Abbott Diagnostics, IL, USA) as previously described. This assay has a LoD of 1.2 
ng/L and based on our previous work a LoQ of 1.5 ng/L (at 20% CV).88 
 
3.3.4 MYOCARDIAL BIOPSY AND HISTOLOGICAL ANALYSIS 
Tru cut myocardial biopsies were obtained from the left ventricles of 10 patients in the 
mechanism cohort who underwent AVR and also had cMyC measured. For autophagy and 
oncosis assessment formalin-fixed, paraffin-embedded 4µm thick tissue sections were cut 
and dehydrated. Further details of the histological analysis are provided in Appendix II. 
 
3.3.5 STATISTICAL ANALYSIS 
Statistical analysis was performed using the statistical software R version 3.3.2 
(http://www.r-project.org). Continuous variables are presented as mean (standard deviation) 
or median [interquartile range] for non-parametric data. We used analysis-of-variance 
(ANOVA) to compare continuous parametric data and the Kruskall–Wallis test for non-
parametric data across tertiles of cMyC. Categorical variables are presented as absolute 
numbers (percentage) and were compared using a Chi-squared test. Due to the positive 
skewing in the sample, cMyC concentrations were log transformed prior to inclusion in 
modelling, with the normality of the distribution tested by the Shapiro Wilk test (p=0.22 
across the population). Multivariate linear regression modelling was used to assess the 
change in markers of aortic stenosis disease progression with serum cMyC concentration. 
Receiver operating characteristics (ROC) curve analysis and multivariate logistic regression 
modelling were used to assess the relationship between cMyC concentrations and late 
gadolinium enhancement. Survival analysis was performed with a Kaplan-Meier analysis 
using time to any cause of death, with significance calculated by log-rank test. This 
relationship was also assessed using Cox proportional hazard modelling. AVR was included 
as a time-varying covariate as survival could be expected to improve in those who received 
surgery during the follow-up period. A value of p<0.05 was considered statistically 
significant.   
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3.4 RESULTS 
The mechanism cohort consisted of 161 individuals with aortic stenosis (mean age 69 years, 
AVmax 3.8 ± 0.9 m/s, 70% male) and 46 healthy control participants (mean age 58 years, 
AVmax 1.4 ± 0.2 m/s, 63% male). The outcomes cohort consisted of 104 patients (mean age 
68 years, AVmax 3.4 ± 0.7 m/s, 68% male) with a median follow-up period of just greater 
than 11 years (4,067 [3,882–4,161] days). 
 
Baseline characteristics by tertile of cMyC are presented in Tables 3.1 and 3.2 for the 
mechanism and outcome cohorts respectively. cMyC was measurable above the lower limit 
of quantification (LoQ 1.2 ng/L) in all but one subject, giving an overall detection rate of 
99.7%, including all healthy controls (Figure 3.1). Similar to observations with cardiac 
troponin, cMyC concentrations were positively skewed across all cohorts (Figure 3.2) and 
weakly correlated with renal function (Figure 3.3). The median cMyC concentration was 
similar amongst aortic stenosis patients in the mechanism (20.5 [13.7–33.2] ng/L) and 
outcome (18.2 [12.2–30.1] ng/L) cohorts (p=0.21), with both being higher than in controls 
(9.5 [7.6–15.1] ng/L, p<0.001 for both). Samples were tested in duplicate, with a CV 
between repeated measurements of 5.9 ± 5.1% in the mechanism cohort, 6.1 ± 4.9% across 
the outcome cohort and 8.5 ± 4.5 % in controls. 
 
Cardiac troponin concentrations were above the LoQ in 92.3% of subjects, but in only 65.2% 
of healthy controls. A strong correlation was observed between cMyC and cardiac troponin 
across all samples tested (r=0.74, 95% CI 0.69–0.79, p<0.0001, Figure 3.1). 
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Age, years 68.5 (11.4) 64.3 (13.0) 69.4 (9.3) 71.8 (10.5) 0.002 57.9 (20.5) 
Sex (male), n (%)  112 (69.6) 29 (53.7) 42 (76.4) 41 (78.8) 0.008 29 (63.0) 
BMI, kg/m2 28.9 (4.8) 29.1 (5.2) 28.7 (4.0) 29.0 (5.1) 0.88 26.8 (3.8) 
BSA, m2 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 0.71 1.9 (0.2) 
       
Comorbidity       
Diabetes mellitus, n (%) 24 (14.9) 9 (16.7) 6 (10.9) 9 (17.3) 0.59 0 (0.0) 
Hypertension,  n (%) 109 (67.7) 30 (55.6) 42 (76.4) 37 (71.2) 0.06 12 (26.1) 
Hyperlipidemia, n (%) 72 (44.7) 20 (37.0) 22 (40.0) 30 (57.7) 0.07 8 (17.4) 
IHD, n (%) 61 (37.9) 12 (22.2) 23 (41.8) 26 (50.0) 0.01 2 (4.3) 
Previous PCI, n (%) 25 (15.5) 6 (11.1) 8 (14.5) 11 (21.2) 0.35 2 (4.3) 
Previous CABG, n (%) 7 (4.4) 2 (3.7) 1 (1.9) 4 (7.7) 0.33 0 (0.0) 
s 
 
     Medications       
Antiplatelet,  n (%) 79 (49.1) 17 (31.5) 29 (52.7) 33 (63.5) 0.004 7 (15.2) 
ACE-I/ARB, n (%) 67 (41.6) 16 (29.6) 28 (50.9) 23 (44.2) 0.07 9 (19.6) 
Beta-blocker, n (%) 55 (34.2) 16 (29.6) 17 (30.9) 22 (42.3) 0.32 5 (10.9) 
Diuretic, n (%) 52 (32.3) 16 (29.6) 21 (38.2) 15 (28.8) 0.51 4 (8.7)  
Blood Tests       
Creatinine, µmol/L 79.1 (17.1) 73.5 (11.1) 78.6 (15.5) 85.2 (21.5) 0.002 72.5 (15.3) 
eGFR, mL/min/1.73m2 86.3 (18.5) 89.0 (15.9) 88.0 (18.8) 81.7 (20.1) 0.09 97.7 (19.8) 
Troponin I, ng/L 6.6 [3.8-12.3] 3.3 [2.3-4.5] 6.7 [4.8-9.5] 15.5 [10-30.2] <0.001 2.7 [1.1-5.4] 
       
Echo Parameters       
AVmax, m/s 3.8 (0.9) 3.4 (0.8) 3.9 (0.8) 4.3 (0.9) <0.001 1.4 (0.2) 
AV area, cm2 1.0 (0.4) 1.1 (0.4) 0.9 (0.3) 0.9 (0.4) 0.006 2.4 (0.6) 
AV MPG, mmHg 34.4 (18.6) 25.9 (13.5) 34.5 (16.6) 43.2 (21.3) <0.001 4.2 (1.4) 
Indexed LV mass, g/m2 122.7 (32.0) 102.3 (22.8) 127.6 (27.3) 139.4 (33.7) <0.001 93.2 (24.4) 
E/e’ 14.6 (7.6) 12.4 (4.8) 13.1 (5.0) 18.3 (10.4) <0.001 8.6 (2.5) 
       
MRI Parameters       
Indexed LV mass, g/m2 88.8 (21.5) 74.2 (15.2) 90.1 (16.6) 102.5 (22.1) <0.001 65.8 (13.7) 
Ejection fraction, % 66.8 (7.3) 67.5 (5.6) 65.8 (8.3) 67.2 (7.8) 0.44 64.4 (4.4) 
Indexed SV, ml/m2 47.6 (10.2) 44.3 (8.4) 47.1 (9.6) 51.4 (11.2) 0.001 46.1 (8.2) 
Indexed ESV, ml/m2 24.2 (9.8) 21.6 (6.6) 25.5 (11.5) 25.6 (10.2) 0.055 26.0 (7.4) 
Indexed EDV, ml/m2 71.8 (16.9) 65.9 (13.3) 72.6 (17.8) 77.0 (17.8) 0.003 72.1 (14.6) 
ECV, % 27.8 (2.6) 27.1 (2.2) 27.4 (2.1) 28.9 (3.2) 0.001 26.6 (1.7) 
Fibrosis volume, g 44.6 (15.3) 36.0 (8.9) 44.2 (11.1) 54.5 (18.5) <0.001 31.0 (7.6) 
       
Outcomes       
AVR, n (%) 41 (25.5) 8 (14.8) 20 (36.4) 13 (25.0) 0.04 0 (0.0) 
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Cardiac death,  n (%) 1 (0.6) 0 (0.0) 0 (0.0) 1 (1.9) 0.35 0 (0.0) 
All cause death, n (%) 6 (3.7) 1 (1.9) 1 (1.8) 4 (7.7) 0.19 0 (0.0) 
Values are number (%), mean (SD) or median [interquartile range]. P-value represents the difference between 
tertiles of cMyC by ANOVA. 
Abbreviations: BMI = body mass index; BSA = body surface area; IHD = ischemic heart disease; ACE-I = 
angiotensin converting enzyme- inhibitor; ARB = angiotensin receptor blockers; eGFR = estimated glomerular 
filtration rate; AV = aortic valve; MPG = mean pressure gradient; LV = left ventricle; SV = stroke volume; ESV 
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Age, years 68.2 (9.8) 64.4 (10.5) 70.1 (9.0) 70.0 (9.1) 0.02 
Sex (male), n (%) 71 (68.3) 21 (60.0) 19 (54.3) 31 (91.2) 0.002 
BMI, kg/m2 27.9 (4.5) 27.6 (4.1) 28.1 (4.9) 27.8 (4.7) 0.91 
BSA, m2 1.9 (0.2) 1.9 (0.2) 1.9 (0.2) 2.0 (0.2) 0.19 
      
Comorbidity      
Diabetes mellitus, n (%) 2 (1.9) 1 (2.9) 0 (0.0) 1 (2.9) 0.60 
Hypertension, n (%) 57 (54.8) 16 (45.7) 24 (68.6) 17 (50.0) 0.13 
Hyperlipidaemia, n (%) 7 (6.7) 0 (0.0) 5 (14.3) 2 (5.9) 0.06 
IHD, n (%) 17 (16.3) 2 (5.7) 10 (28.6) 5 (14.7) 0.03 
      
Medications      
Aspirin, n (%) 42 (40.4) 13 (37.1) 16 (45.7) 13 (38.2) 0.74 
Anticoagulant, n (%) 10 (9.6) 1 (2.9) 4 (11.4) 5 (14.7) 0.23 
ACE-I /ARB, n (%) 20 (19.2) 5 (14.3) 7 (20) 8 (23.5) 0.63 
Beta-blocker, n (%) 23 (22.1) 8 (22.9) 11 (31.4) 4 (11.8) 0.14 
      
Blood Tests      
Creatinine, µmol/L 91.3 (21.3) 85.3 (18.1) 89.3 (17.9) 100.1 (25.6) 0.01 
eGFR, mL/min/1.73m2 73.5 (17.4) 77.2 (13.9) 71.7 (16.4) 71.6 (21.3) 0.31 
Troponin I, ng/L 7.2 [5.4-12.6] 4.9 [3.9-6.0] 8.3 [6.7-10.6] 14.3 [12.1-17.9] <0.001 
      
Echo Parameters      
AVmax, m/s 3.4 (0.7) 3.4 (0.7) 3.4 (0.8) 3.5 (0.6) 0.90 
AV area, cm2 1.0 (0.4) 1.0 (0.4) 1.0 (0.4) 1.0 (0.4) 0.89 
AV PG, mmHg  48.8 (19.2) 47.6 (18.7) 49.7 (21.8) 49.2 (17.1) 0.89 
Indexed LV mass, g/m2 184.4 (52.2) 170.0 (56.8) 175.7 (38.8) 208.7 (52.0) 0.004 
Ejection fraction, % 66 (31) 69 (22) 66 (25) 61 (44) 0.64 
      
CT coronary  
calcium score 
382.6 (611.1) 370.3 (608.3) 491.0 (783.2) 283.6 (360.2) 0.37 
      
Outcomes      
AVR, n (%) 48 (46.2) 19 (54.3) 15 (42.9) 14 (41.2) 0.49 
Cardiac death, n (%) 16 (15.4) 4 (11.4) 7 (20.0) 5 (14.7) 0.61 
All cause death, n (%) 36 (34.6) 7 (20.0) 14 (40.0) 15 (44.1) 0.08 
Values are number (%), mean (SD) or median [interquartile range]. P-value represents the difference between 
tertiles of cMyC by ANOVA. 
Abbreviations: BMI = body mass index; BSA = body surface area; IHD = ischemic heart disease; ACE-I = 
angiotensin converting enzyme- inhibitor; ARB = angiotensin receptor blockers; eGFR = estimated glomerular 
filtration rate; AV = aortic valve; MPG = mean pressure gradient; LV = left ventricle; AVR = aortic valve 
replacement.  
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Figure 3.1 – Assay performance of the cMyC assay against high-sensitivity cardiac troponin I. 
(A) Proportion of patients with aortic stenosis (mechanism and outcome cohorts) and (B) 
controls (mechanism cohort) in whom cardiac troponin and cMyC concentrations were 
above the lower limit of quantification (20% CV) of 1.5 ng/L and 1.2 ng/L respectively. (C) 
Correlation between cardiac troponin I and cMyC concentrations across all cohorts (aortic 
stenosis and control patients). 
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Figure 3.2 – Frequency histograms of cMyC concentrations measured in each cohort and all 
samples tested. This demonstrated similarly positively skewed distributions in each case. 
cMyC was detectable above the lower limit of quantification in 99.7% of samples tested. 
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Figure 3.3 – Relationship between renal function and sarcomeric proteins. The correlation 
between cMyC (left) and cTnI (right) with estimated glomerular filtration rate across all 
patients with aortic stenosis and controls. Pearson correlation coefficient (r) presented with 
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3.4.1 CMYC AND MECHANISTIC IMAGING MARKERS 
In adjusted multiple regression analyses, cMyC concentration was associated with indexed 
LV mass in those with aortic stenosis who underwent CMR imaging (ß=11.0g/m2 per log 
unit increase in cMyC after adjustment for age, sex, renal function, AVmax, cardiac troponin 
and comorbidity; 95% CI 4.7–17.3, p<0.001, Figure 3.4a). This relationship was numerically 
positive, but did not approach statistical significance amongst healthy controls (ß=2.7g/m2, 
95% CI -4.8–10.1, p=0.47, Figure 3.5a). Similarly, fibrosis volume was related to cMyC in 
those with aortic stenosis (adjusted ß=8.0g per log unit increase in cMyC; 95% CI 3.5–12.6, 
p<0.001, Figure 3.4b) but not in controls (ß=1.8g, 95% CI -1.6–5.2, p=0.28, Figure 3.5b). 
ECV as a marker of diffuse myocardial fibrosis was associated with cMyC in aortic stenosis 
patients (adjusted ß=1.3%, 95% CI 0.3–2.3%, p=0.01), but not in healthy controls (adjusted 
ß=0.5%, 95% CI -0.5–1.5%, p=0.32). Detailed modelling is shown in Tables 3.3 (LV mass), 
3.4 (fibrosis volume) and 3.5 (ECV %).  
 
To ensure collinearity between cMyC and cardiac troponin was not affecting these results, 
the final fully adjusted models were repeated without inclusion of cardiac troponin in those 
with aortic stenosis. The relationship between cMyC and LV mass remained (ß=14.1g/m2 
per log unit increase in cMyC after adjustment; 95% CI 9.8–18.5, p<0.001), and this was 
also seen with fibrosis volume (adjusted ß=9.8g; 95% CI 6.7–12.9, p<0.001) and ECV 
(adjusted ß=1.5%, 95% CI 0.8–2.2%, p<0.001).  
 
cMyC concentrations were related to severity of aortic stenosis across the range of AVmax 
measures in the mechanism cohort (adjusted ß=0.80m/s, 95% CI 0.50–1.10, p<0.001, Figure 
3.4c), although this was not observed in the narrower range included in the outcome cohort 
(Figure 3.5c). An association was further noted between cMyC and diastolic function, 
measured by echocardiography E/e’ in the mechanism cohort (adjusted ß=3.76, 95% CI 
1.21–6.32, p=0.004, Figure 3.4d). There was no relationship between cMyC and objective 
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measures of coronary disease by CT calcium scoring (adjusted ß=0.03, 95% CI -0.17-0.23, 
p=0.76, Figure 3.5d).  
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Figure 3.4 – Relationships between cMyC and markers of disease severity in the mechanism 
cohort. ß values [95% confidence interval] represent change in the progression variable for 
each log unit change in cMyC concentration after adjustment in multivariate modelling. 
Markers of disease severity are: (A) Indexed LV mass (grams/m2) determined by MRI; (B) 
Fibrosis volume (grams) by MRI; (C) AVmax (metres/second) determined by 
echocardiography;  (D) Diastolic function from echocardiographic measures of E/e’ ratio. 
*Adjusted for age, sex, glomerular filtration rate, AVmax, cardiac troponin, history of 
ischaemic heart disease, diabetes and hypertension; +As above plus body surface area; ‡As 








Figure 3.5 – Relationships between cMyC and markers of disease progression in control 
patients and the outcome cohort. Linear regression correlations cMyC concentration with 
(A) Indexed LV mass (grams/m2) in control patients determined by MRI (mechanism cohort); 
(B) Fibrosis volume (g) in control patients by MRI (mechanism cohort); (C) AV Max 
(metres/second) determined by echocardiography (outcome cohort); (D) CT coronary 
calcium score (outcome cohort). ß values [95% confidence interval] represent change in the 
progression variable for each log unit change in cMyC concentration after adjustment in 
multivariate modelling (see Supplementary Tables S1-S3). *Adjusted for age, sex, glomerular 
filtration rate, AVmax, cardiac troponin, history of ischaemic heart disease, diabetes and 
hypertension; +As above plus body surface area. ‡As above excluding AVmax.  
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Table 3.3 – Linear regression modelling for predictors of change in LV mass in (A) aortic 
stenosis patients and (B) controls. Model 1 unadjusted; Model 2 adjusted for age and sex; 
Model 3 additionally adjusted for glomerular filtration rate and AVmax; Model 4 additionally 
adjusted for cardiac troponin; Model 5 additionally adjusted for comorbidity (ischaemic 
heart disease, diabetes mellitus and hypertension). ß values represent change in LV mass in 
univariate and multivariate analyses.  ***p<0.001, **p<0.01, *p<0.05. 
 
(A) Aortic Stenosis Patients 
Variable Model 1 ß Model 2 ß Model 3 ß Model 4 ß Model 5 ß 
Log cMyC 16.8*** 
(13.0 – 20.7) 
17.4*** 
(13.5 – 21.3) 
14.0*** 
(9.7 – 18.3) 
10.9*** 
(4.7 – 17.1) 
11.0*** 
(4.7 – 17.3) 
Age, per 10 years  -4.3*** 
(-1.9 – -6.7) 
-3.3** 
(-0.8 – -5.7) 
-3.3** 
(-0.9 – -5.7) 
-3.0* 
(-0.3 – -5.6) 
Male sex  10.4*** 
(4.6 – 16.2) 
10.2*** 
(4.6 – 15.9) 
10.6*** 
(5.0 – 16.2) 
11.4*** 
(5.4 – 17.4) 
eGFR, per fall of 
10mL/min/1.73m2 
  -1.4 
(-2.9 – 0.1) 
-1.3 
(-2.8 – 0.1) 
-1.3 
(-2.8 – 0.2) 
AVmax, per 1m2   6.4*** 
(3.3 – 9.5) 
6.6*** 
(3.5 – 9.7) 
6.6*** 
(3.5 – 9.8)  
Log cTnI    2.5 
(-1.1 – 6.1) 
2.5 
(-1.2 – 6.2) 
Ischaemic heart 
disease 
    -2.3 
(-8.1 – 3.4) 
Diabetes mellitus     -1.1 
(-8.3 – 6.1) 
Hypertension     0.0 
(-6.2 – 6.2) 
Adjusted r2  0.32 0.42 0.48 0.49 0.48 
eGFR – estimated glomerular filtration rate. ***p<0.001, **p<0.01, *p<0.05. 
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(B) Controls 
Variable Model 1 ß Model 2 ß Model 3 ß Model 4 ß Model 5 ß 
Log cMyC 5.3 
(-0.9 – 11.5) 
4.2 
(-1.9 – 10.2) 
6.8* 
(0.3 – 13.4) 
3.1 
(-4.4 – 10.6) 
2.7 
(-4.8 –10.1) 
Age, per 10 years  -2.0* 
(-0.2 – -3.9) 
-0.5 
(-2.6 – 1.7) 
-1.1 
(-3.3 – 1.1) 
-1.8 
(-4.1 – 0.6) 
Male sex  12.3** 
(4.5 – 20.1) 
9.5* 
(1.7 – 17.2) 
9.5* 
(2.0 – 17.0) 
8.9* 
(1.4 – 16.4) 
eGFR, per fall of 
10mL/min/1.73m2 
  -3.1** 
(-0.8 – -5.4) 
-3.0* 
(-0.8 - -5.3) 
-2.4* 
(-0.1 - -4.8) 
AVmax, per 1m2   1.9 
(-12.6 – 16.4) 
-0.1 
(-14.3 – 14.2) 
-7.8 
(-24.7 – 9.1) 
Log cTnI    3.9 
(-0.2 – 8.1) 
4.6* 
(0.4 – 8.8) 
Ischaemic heart 
disease 
    12.3 
(-7.2 – 31.7) 
Hypertension     4.0 
(-5.1 – 13.1) 
Adjusted r2  0.04 0.25 0.33 0.37 0.39 
eGFR – estimated glomerular filtration rate. ***p<0.001, **p<0.01, *p<0.05. Diabetes excluded from 
modelling as there were no positive cases within the control group. 
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Table 3.4 – Linear regression modelling for predictors of change in fibrosis volume in (A) 
aortic stenosis patients and (B) controls. Model 1 unadjusted; Model 2 adjusted for age and 
sex; Model 3 additionally adjusted for glomerular filtration rate and AVmax; Model 4 
additionally adjusted for body surface area; Model 5 additionally adjusted for cardiac 
troponin; Model 6 additionally adjusted for comorbidity (ischaemic heart disease, diabetes 
mellitus and hypertension). ß values represent change in fibrosis volume in univariate and 
multivariate analyses.  ***p<0.001, **p<0.01, *p<0.05. 
 
(A) Aortic Stenosis Patients 
Variable Model 1 ß Model 2 ß Model 3 ß Model 4 ß Model 5 ß Model 6 ß 
Log cMyC 11.2*** 
(8.4 – 14.0) 
11.7*** 
(8.9 – 14.6) 
9.7*** 
(6.4 – 13.0) 
9.7*** 
(6.6 – 12.7) 
7.9*** 
(3.5 – 12.3) 
8.0*** 
(3.5 – 12.6) 
Age, per 10 years  -3.5*** 
(-1.7 – -5.2) 
-3.0** 
(-1.1 – -4.8) 
-1.7 
(-3.5 – 0.1) 
-1.7 
(-3.6 – 0.1) 
-1.4 
(-3.4 – 0.7) 
Male sex  7.2** 
(2.9 – 11.4) 
7.5*** 
(3.2 – 11.8) 
2.3 
(-2.3 – 6.9) 
2.6 
(-2.0 – 7.2) 
3.0 
(-1.8 – 7.8) 
eGFR, per fall of 
10mL/min/1.73m2 
  -0.5 
(-1.6 - 0.6) 
-0.8* 
(-1.9 - 0.2) 
-0.8 
(-1.8 - 0.3) 
-0.7 
(-1.8 - 0.3) 
AVmax, per 1m2   3.9** 
(1.6 – 6.3) 
3.8*** 
(1.6 – 6.0) 
3.9*** 
(1.7 – 6.1) 
3.9*** 
(1.7 – 6.2) 
Body surface 
area, per m2 
   26.4*** 
(15.3 – 37.5) 
26.0*** 
(14.9 – 37.1) 
26.7*** 
(15.2 – 38.2) 
Log cTnI     1.4 
(-1.2 – 4.0) 
1.4 
(-1.2 – 4.0) 
Ischaemic heart 
disease 
     -1.6 
(-5.7 – 2.6) 
Diabetes 
mellitus 
     0.6 
(-4.8 - 6.0) 
Hypertension      -1.0 
(-4.8– 6.0) 
Adjusted r2  0.28 0.39 0.43 0.50 0.50 0.50 
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(B) Controls 
Variable Model 1 ß Model 2 ß Model 3 ß Model 4 ß Model 5 ß Model 6 ß 
Log cMyC 2.8 
(-1.0 – 6.5) 
1.7 
(-1.9 – 5.4) 
4.1* 
(0.7 – 7.5) 
3.8* 
(0.7 – 6.8) 
2.1 
(-1.4 – 5.6) 
1.8 
(-1.6 – 5.2) 
Age, per 10 years  -0.9 
(-1.9 – 0.1) 
0.1 
(-0.9 – 1.0) 
0.4 
(-0.6 – 1.4) 
0.2 
(-0.8 – 1.2) 
-0.2 
(-1.3 – 0.8) 
Male sex  7.4** 
(3.1 – 11.7) 
4.7* 
(0.7 – 8.7) 
1.2 
(-3.0 – 5.3) 
1.0 
(-3.1 – 5.0) 
0.5 
(-3.4 - 4.5) 
eGFR, per fall of 
10mL/min/1.73m2 
  -2.3*** 
(-1.1 – -3.6) 
-2.1*** 
(-1.0 – -3.2) 
-2.0*** 
(-0.9 – -3.1) 
-1.7** 
(-0.6 - -2.8) 
AVmax, per 1m2   4.4 
(-3.0 – 11.8) 
2.0 
(-4.7 – 8.7) 
0.9 
(-5.7 – 7.6) 
-3.6 
(-11.2 – 4.0) 
Body surface 
area, per m2 
   18.5** 
(7.3 – 29.7) 
20.0*** 
(9.0 – 31.0) 
20.6*** 
(9.9 - 31.3) 
Log cTnI     1.7 
(-0.1 – 3.6) 
2.1* 
(0.2 - 3.9) 
Ischaemic heart 
disease 
     6.5 
(-2.0 – 15.0) 
Hypertension      2.6 
(-1.4 – 6.6) 
Adjusted r2 0.03 0.25 0.44 0.56 0.59 0.62 
eGFR – estimated glomerular filtration rate. ***p<0.001, **p<0.01, *p<0.05. Diabetes excluded from 
modelling as there were no positive cases within the control group. 
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Table 3.5 – Linear regression modelling for predictors of change in ECV % in (A) aortic 
stenosis patients and (B) controls. Model 1 unadjusted; Model 2 adjusted for age and sex; 
Model 3 additionally adjusted for glomerular filtration rate and AVmax; Model 4 additionally 
adjusted for body surface area; Model 5 additionally adjusted for cardiac troponin; Model 6 
additionally adjusted for comorbidity (ischaemic heart disease, diabetes mellitus and 
hypertension). ß values represent change in extracellular volume  in univariate and 
multivariate analyses.  ***p<0.001, **p<0.01, *p<0.05. 
 
(A) Aortic Stenosis Patients 
Variable Model 1 ß Model 2 ß Model 3 ß Model 4 ß Model 5 ß Model 6 ß 
Log cMyC 1.2*** 
(0.7 – 1.7) 
1.3*** 
(0.8 – 1.9) 
1.5*** 
(0.8 – 2.1) 
1.5*** 
(0.8 – 2.1) 
1.3* 
(0.2 – 2.3) 
1.3* 
(0.3 – 2.3) 
Age, per 10 years  0.2 
(-0.2 – 0.5) 
0.2 
(-0.2 – 0.6) 
0.2 
(-0.2 – 0.6) 
0.2 
(-0.2 – 0.6) 
0.3 
(-0.1 – 0.7) 
Male sex  -1.4** 
(-0.6 – -2.3) 
-1.4** 
(-0.5 – -2.3) 
-1.3* 
(-0.3 – -2.4) 
-1.3* 
(-0.3 – -2.4) 
-1.3* 
(-0.2 – -2.4) 
eGFR, per fall of 
10mL/min/1.73m2 
  -0.1 
(-0.3 – 0.2) 
-0.1 
(-0.3 – 0.2) 
-0.1 
(-0.2 – 0.3) 
-0.0 
(-0.3 – 0.2) 
AVmax, per 1m2   0.0 
(-0.5 – 0.5) 
0.0 
(-0.5 – 0.5) 
0.0 
(-0.5 – 0.5) 
0.0 
(-0.5 – 0.5) 
Body surface 
area, per m2 
   -0.3 
(-2.8 – 2.2) 
-0.4 
(-2.9 – 2.1) 
-0.4 
(-3.0 - 2.2) 
Log cTnI     0.2 
(-0.4 – 0.7) 
0.2  
(-0.4 – 0.8) 
Ischaemic heart 
disease 
     -0.2 
(-1.2 – 0.7) 
Diabetes mellitus      1.2* 
(0.0 – 2.4) 
Hypertension      -0.7 
(-1.7 – 0.3) 
Adjusted r2  0.10 0.16 0.16 0.15 0.15 0.17 
eGFR – estimated glomerular filtration rate. ***p<0.001, **p<0.01, *p<0.05. 
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(B) Controls 
Variable Model 1 ß Model 2 ß Model 3 ß Model 4 ß Model 5 ß Model 6 ß 
Log cMyC -0.4 
(-1.2 – 0.5) 
-0.2 
(-1.1 – 0.6) 
0.1 
(-0.8 – 1.0) 
0.2 
(-0.7 – 1.0) 
0.5 
(-0.5 – 1.5) 
0.5 
(-0.5 –1.5) 
Age, per 10 years  0.2 
(0.0 – 0.5) 
0.4** 
(0.1 – 0.7) 
0.4** 
(0.1 – 0.6) 
0.4** 
(0.1 – 0.7) 
0.4* 
(0.1 – 0.7) 
Male sex  -1.5** 
(-0.5 – -2.5) 
-1.9*** 
(-0.9 – -2.9) 
-1.3* 
(-0.2 – -2.5) 
-1.3* 
(-0.2 – -2.4) 
-1.4* 
(-0.2 – -2.5) 
eGFR, per fall of 
10mL/min/1.73m2 
  -0.4* 
(-0.7 – 0.0) 
-0.4* 
(-0.1 – -0.7) 
-0.4** 
(-0.1 – -0.7) 
-0.4* 
(-0.1 – -0.7) 
AVmax, per 1m2   0.1 
(-1.8 – 2.0) 
0.5 
(-1.4 – 2.3) 
0.7 
(-1.2 - 2.6) 
0.2 
(-2.1 – 2.5) 
Body surface 
area, per m2 
   -2.9 
(-6.0 – 0.2) 
-3.2* 
(-6.3 – -0.2) 
-3.1 
(-6.3 – 0.1) 
Log cTnI     -0.4 
(-0.9 – 0.2) 
-0.3 
(-0.9 – 0.2) 
Ischaemic heart 
disease 
     0.5 
(-2.0 – 3.0) 
Hypertension      0.4 
(-0.8 – 1.6) 
Adjusted r2  0.00 0.21 0.27 0.32 0.34 0.31 
eGFR – estimated glomerular filtration rate. ***p<0.001, **p<0.01, *p<0.05. Diabetes excluded from 




Clinical biomarkers in older patients with aortic stenosis 73 
LGE was present in 57 (35.4%) of the aortic stenosis patients in the mechanism cohort. 
cMyC concentrations were almost double in those with evidence of LGE compared to those 
without (32.3 [21.3 – 56.3] ng/L vs 17.2 [11.5 – 24.2] ng/L, p<0.001). By ROC analysis, 
cMyC improved discrimination for LGE beyond age and gender (area under curve [AUC] 
0.77, 95% CI 0.70–0.85, Figure 3.6a). Similar results were obtained with AVmax included in 
the model (AUC 0.71, 95% CI 0.63–0.79 for a model including AVmax, age and sex, 
improving to 0.77, 95% CI 0.70–0.85 with addition of cMyC). A sensitivity analysis 
restricted to those with mid-wall fibrosis only (77% of those with any LGE) demonstrated 
similar discrimination (AUC 0.77, 95% CI 0.70–0.84). Using logistic regression modelling 
adjusted for age and sex, the predicted probability of LGE was seen to progressively increase 
with cMyC concentration (Figure 3.6b). Univariate correlations between cMyC and baseline 
variables used for covariate adjustment in the mechanism cohort are presented in Table 3.6. 
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Figure 3.6 – cMyC and late gadolinium enhancement. (A) ROC curve analysis for outcome of 
LGE. AUC=area under the curve. Addition of cMyC improves the prediction of age and 
gender for LGE, p=0.002 (DeLong’s method with bootstrapping). (B) Logistic regression 
modelling for the predicted probability of LGE with serum cMyC concentration (adjusted for 
age and sex). Shaded area represents 95% confidence interval.  
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Table 3.6 – Univariate correlations between log cMyC and baseline variables used for 
covariate adjustment in aortic stenosis patients (mechanism cohort). 
 
Variable b coefficient for  
log cMyC (95% CI) 
p-value 
Age, per 10 years 0.21 (0.12 – 0.30) <0.001 
Male sex 0.40 (0.16 - 0.64) 0.001 
eGFR, per fall of 
10mL/min/1.73m2 
0.07 (0.02 – 0.13) 0.01 
AVmax, per 1m2 0.36 (0.25 – 0.48) <0.001 
Body surface area,  
per m2 
0.18 (-0.43 – 0.79) 0.57 
cTnI, per log unit  
increase 
0.36 (0.32 – 0.41) <0.001 
Ischaemic heart disease 0.37 (0.14 – 0.59) 0.002 
Diabetes mellitus 0.18 (-0.14 – 0.49) 0.27 
Hypertension 0.29 (0.05 - 0.52) 0.02 
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3.4.2 CMYC AND MYOCYTE DEATH 
Clear differences were observed in staining patterns for oncosis and autophagy between 
subjects with low and high cMyC concentrations (Figure 3.7). Exploratory analysis 
suggested a relationship between cMyC and the rate of myocyte death (expressed as the sum 
of apoptosis, oncosis and autophagy counts) in 10 subjects with myocardial biopsy tissue 
taken at the time of aortic valve replacement (r=0.67, 95% CI 0.08–0.92, p=0.03).  
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Figure 3.7 – Patterns of myocyte death in aortic stenosis patients. Images showing differing 
patterns of oncosis and autophagy visualized using a 3,3’-diaminobenzidine based detection 
kit in individuals with aortic stenosis. (A) oncosis and (B) autophagy in a patient with a low 
(9.4 ng/L) cMyC concentration. (C) oncosis and (D) autophagy in a patient with a high (87.2 
ng/L) cMyC concentration. There is a marked difference in staining intensity by cMyC 
concentration for both oncosis and autophagy.  
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3.4.3 CMYC AND LONG-TERM OUTCOMES 
Subjects in the outcomes cohort were stratified by tertile of cMyC (Table 3.2). As with CMR 
in the mechanism cohort, indexed LV mass by echocardiography increased across tertiles of 
cMyC (170.0 ± 56.8g in lowest tertile vs 208.7 ± 52.0g in highest, p=0.004). There were no 
consistent differences in cardiac risk factors across the tertiles. During the follow-up period, 
36 (34.6%) subjects died, of which 16 (15.4%) were adjudicated as cardiac deaths. 48 
patients (46.2%) within the cohort underwent surgical AVR, with no cases of transcatheter 
aortic valve implantation (TAVI) undertaken. There was a trend towards poorer survival 
over the period of follow-up with increasing tertile of cMyC (Figure 3.8, log-rank test for 
difference p=0.07).  
 
In cox proportional hazards analysis, cMyC concentration was associated with an increased 
risk of all-cause mortality over the follow-up period after inclusion of AVR as a time-
varying covariate (HR 1.49 per log unit increase of cMyC, 95% CI 1.11 – 2.01, p=0.009). 
However, following adjustment for age, sex, AVmax, CT coronary calcium scores or LV 
mass, statistical significance was lost. Age was significantly associated with cMyC in all 
models (Table 3.7). 
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Figure 3.8 – Survival by tertiles of cMyC in the outcome cohort. 
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Table 3.7 – Cox proportional hazard modelling (cMyC and all-cause mortality). For the 
relationship between cMyC and all-cause mortality at a median follow-up of 11.3 years. 
Model 1 – including only aortic valve replacement as a time-varying covariate; Model 2 –
additionally adjusted for age and sex; Model 3 - as Model 2 plus adjustment for maximum 
velocity across the aortic valve (AV Max); Model 4 - as Model 2 plus adjustment for CT 
coronary calcium score; Model 5 – as Model 3 plus adjustment for LV mass. Values are 
hazard ratios (95% CI). ***p<0.001, **p<0.01, *p<0.05. 
  




(1.11 – 2.01) 
1.26 
(0.88 – 1.80) 
1.26 
(0.88 – 1.80) 
1.27 







(0.31 - 1.49) 
0.75 
(0.34 - 1.65) 
0.78 
(0.33 - 1.85) 
0.75 
(0.34 – 1.66) 
0.80 
(0.33–1.90) 
Age, per 10 years  2.14 ** 
(1.69 – 2.71) 
2.14 ** 
(1.69 – 2.71) 
2.12** 
(1.65 – 2.72) 
2.06** 
(1.63–2.60) 
Sex, male  1.64 
(0.70 – 3.81) 
1.64 
(0.71 – 3.82) 
1.61 
(0.67 – 3.89) 
1.72 
(0.72–4.13) 
AVmax, per 1m/s 
increase 
  0.94 





per 10 fold 
increase 
   1.02 
(0.75 – 1.38) 
 




Clinical biomarkers in older patients with aortic stenosis 81 
3.5 DISCUSSION 
In a comprehensive series of clinical assessments, we report the relationship between serum 
cMyC concentration, a novel marker of myocardial injury, and cardiac structure and 
outcomes in patients with aortic stenosis.  We have made several important observations. 
First, serum cMyC concentrations can be reliably quantified in the vast majority of patients 
with aortic stenosis. Second, cMyC strongly associates with markers of both diffuse 
interstitial and focal replacement fibrosis as well as indexed left ventricular mass, a marker 
of the hypertrophic response to aortic stenosis. These observations were independent of the 
severity of valve stenosis and cMyC concentrations were unrelated to coronary artery 
disease. Third, cMyC concentrations are strongly correlated with cardiac troponin, and in 
histological analyses, are associated with myocyte cell death, suggesting that sarcomeric 
protein release is a direct consequence of the maladaptive myocardial response to aortic 
stenosis. We believe these novel observations demonstrate the utility and validity of cMyC 
as a marker of sustained chronic myocardial injury.  
 
3.5.1 ASSAY PERFORMANCE 
The release profile of cMyC has been previously studied after acute injury in myocardial 
infarction, alcohol ablation for hypertrophic cardiomyopathy and coronary artery bypass 
grafting.93,144 These models have shown cMyC to be more abundant, to be released earlier 
following injury, and to decline more rapidly when compared to cardiac troponin. These 
observations suggest that cMyC has enhanced potential for dynamic monitoring of 
myocardial injury and disease. However, previous generations of the cMyC assay had 
limited sensitivity at the low levels that would be expected in the presence of chronic 
myocardial injury such as in aortic stenosis. For example, cMyC was only detectable in 2 out 
of 20 patients with hypertrophic cardiomyopathy.149 Here we report cMyC measurements 
from a high-sensitivity assay using magnetic nanoparticle and single molecule counting 
technology, and demonstrate near universal quantification in patients with aortic stenosis and 
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healthy controls. The weak correlation with renal function observed for both cMyC and 
cardiac troponin is consistent with previous work, where chronic elevations reflect 
worsening cardiovascular disease and left ventricular hypertrophy observed in patients with 
chronic kidney disease.150,151 There appears to be limited convincing evidence of impaired 
clearance of these markers even in severe renal impairment.152 
 
3.5.2 CMYC AS A BIOMARKER OF DISEASE 
Our observations suggest cMyC is a sensitive marker of the hypertrophic and subsequent 
fibrotic myocardial response to aortic stenosis. ECV fraction on CMR T1 mapping is a 
marker of diffuse interstitial fibrosis, which may precede the focal mid-wall replacement 
fibrosis detected by LGE.145,146  Histological studies have suggested that myocyte death 
drives this transition.20 Our exploratory analysis in myocardial biopsy tissue relates 
combined measures of autophagy, oncosis and apoptosis to serum cMyC concentrations, 
providing histological correlation of biomarker release as a result of myocyte death. This 
combination of autophagy and oncosis in failing myocardial tissue has been independently 
associated with mortality in larger studies.153  
 
Our observations are consistent with our previous findings using a high-sensitivity cardiac 
troponin I assay. Using two independent sarcomeric proteins, we have now demonstrated 
that serum markers of myocardial injury mirror important pathological changes in the 
myocardium in response to aortic stenosis.88,154,155 Similar to cardiac troponin, although 
cMyC was related to AVmax by echocardiography in the mechanism cohort, its association 
with markers of hypertrophy, fibrosis and diastolic function were independent of the severity 
of aortic stenosis. This suggests that these novel markers of the myocardial response to 
stenosis will add to conventional clinical assessment in aortic stenosis. Whilst CMR imaging 
provides important detail on the extent of the progression to fibrosis and heart failure, it is a 
resource-intensive investigation.19,156 As such, there is great potential for simple blood 
measures of myocardial injury to improve decision making in aortic stenosis, to better target 
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detailed imaging or even help determine the timing of surgery. Current guidelines advocate 
aortic valve replacement in the presence of left ventricular impairment or symptoms, but 
these are challenging to define objectively and may signify that irreversible myocardial 
fibrosis has already developed. A precise and early marker of myocardial injury such as 
cMyC may have great clinical utility in patients with aortic stenosis. 
 
We demonstrate an increased mortality risk with rising cMyC concentrations, but this 
association was not independent of other variables. Our outcomes cohort benefits from 
extensive follow-up over 11 years after sampling, but the cohort size was restricted by 
limited remaining stored samples. This analysis is likely to be underpowered and further 
work is required in larger studies to clarify whether cMyC will provide additional prognostic 
information in the assessment of patients with aortic stenosis. 
 
3.5.3 LIMITATIONS 
We acknowledge some limitations with the current study in addition to sample size. There is 
only limited overlap for comparison of imaging endpoints between our two cohorts, although 
the magnitude of associations between cMyC and LV mass are similar. The clinical utility of 
biomarkers such as cMyC is more likely to be of interest in severe cases of aortic stenosis 
approaching the need for valve replacement, where myocardial injury becomes more 
pronounced. Our mechanism and outcomes cohort contained only 84 and 52 patients with 
severe aortic stenosis respectively. Whilst this represents half of our study population, 
further evaluation in a larger population with severe disease would be informative. The 
histological analysis presented is exploratory and the tru cut technique used may provide 
limited volumes of myocardium compared to novel scalpel methods.157  
 
Our findings add to our previous observations with cardiac troponin.88,154,155 Compared to 
those assays, the latest generation cMyC assay is still in the early stages of development, 
with no definitive healthy population studies to derive a normal reference range. However, 
Clinical biomarkers in older patients with aortic stenosis 84 
our study suggests that the biomarker will be measurable in virtually all individuals and is 
likely to meet the criteria for a high-sensitivity assay.86 Larger cohort studies are necessary to 
assess the relationship and potential differences in cMyC and cardiac troponin release, and to 
determine whether the association of cMyC and long-term outcomes is independent of other 
patient factors and cardiac biomarkers. Further validation with prospective serial sampling of 
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3.6 CONCLUSIONS 
Serum cMyC concentration is associated with myocardial hypertrophy, fibrosis and an 
unadjusted increased risk of mortality in aortic stenosis. The quantification of serum 
sarcomeric protein concentrations provide objective measures of disease severity and their 

















VARIABILITY OF CARDIAC TROPONIN I, B-TYPE 
NATRIURETIC PEPTIDE AND GALECTIN-3 IN OLDER 
ADULTS WITH AORTIC STENOSIS
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CHAPTER 4: VARIABILITY OF CARDIAC TROPONIN I, B-TYPE NATRIURETIC 
PEPTIDE AND GALECTIN-3 IN OLDER ADULTS WITH AORTIC STENOSIS 
 
4.1 OVERVIEW 
Blood biomarkers of myocardial injury, ventricular wall stress and fibrosis are attractive 
targets for monitoring disease progression in aortic stenosis. However, the analytical and 
biological variability of these biomarkers in older multimorbid patients is uncertain. We 
assessed hourly and weekly variability of cardiac troponin I, B-type natriuretic peptide 
(BNP) and galectin-3 using fresh and frozen sampling regimes in older patients with aortic 
stenosis. 
 
The study included fourteen subjects >65 years old with moderate to severe aortic stenosis in 
the absence of clinical or echocardiographic evidence of left ventricular decompensation. 
Participants underwent hourly blood draws for four hours with further testing 7 and 14 days 
later. Plasma samples were analysed for high-sensitivity cardiac troponin I, BNP and 
galectin-3 using a high-throughput commercial analyser within a controlled laboratory 
environment. Samples were tested in the fresh state directly after processing and repeated as 
a single frozen batch at the end of the study. Analytical (CVa), biological (CVi), and inter-
individual variations were calculated alongside the index of individuality (II) for each assay. 
The reference change value (RCV) was determined for a significant change between serial 
samples.  
 
All three biomarkers were detectable above the assay-specific limits of detection in every 
sample obtained. BNP demonstrated degradation in frozen compared to fresh samples, but 
troponin and galectin-3 remained highly stable. CVa was ≤5% for all three assays in both 
fresh and frozen sample processing. CVi in fresh weekly samples was 15% for cardiac 
troponin, 20% for BNP and lowest for galectin-3 at just 5%. The II was <0.6 for all assays, 
confirming that interpretation requires a change between serial samples. The RCV for 
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weekly fresh sampling was 42% for cardiac troponin, 55% for BNP and 14% for galectin. 
These values for cardiac troponin and BNP are lower than equivalent studies in healthy 
controls and in stable heart failure. 
 
It is feasible to measure these putative biomarkers of disease progression in older aortic 
stenosis patients using a high-throughput platform with excellent analytical precision. These 
data demonstrate differences with prior studies of younger, healthier subjects, with 
significant change between serial samples indicated by smaller variations in biomarker 
concentrations amongst older patients. Further studies of analytical variability using multiple 
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4.2 INTRODUCTION 
Aortic stenosis is the most common form of valvular heart disease in the Western World, 
affecting up to 12% of those over 65 years old.138 In the absence of definitive surgical 
treatment, progressive aortic stenosis results in decompensated heart failure and death. 
However, heterogeneity in the myocardial response creates discrepancy between the degree 
of stenosis and the symptoms that guide decisions for surgical intervention. It has previously 
been demonstrated by cardiac magnetic resonance (CMR) imaging that left ventricular 
hypertrophy and myocardial fibrosis are independent early markers of adverse prognosis in 
patients with aortic stenosis, with up to 8-fold increase in mortality.17-19,158 However, CMR is 
costly and may not be tolerated by an older group of patients. It is plausible that blood 
biomarkers of myocardial injury and ventricular wall stress may provide useful prognostic 
information and objectively track this disease progression in patients with aortic stenosis.  
 
Before such markers could be considered for clinical use, there must be an understanding of 
what constitutes a significant change of each biomarker over time. Variability arises from 
two main components of measurement: test imprecision (analytical variability) and the 
natural variability of a marker in a subject over time (biological variability). Traditional 
approaches to the measurement of variability rely on repeated testing in healthy individuals 
generally of young to middle age. However, the underlying pathology of aortic stenosis may 
modify the homeostatic set-point of a given biomarker and alter the natural variation around 
this level.  
 
Differences between the variability of biomarkers in diseased and healthy states have been 
noted for a number of organ specific biomarkers including creatinine, CA125 and alpha-
fetoprotein.159 In these cases, use of reference change values derived from healthy subjects 
may under or overestimate variability and thus reduce the value of serial testing in disease 
states by increasing false positive or false negative rates.  
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In this study, we tested the variability of three putative biomarkers of disease progression in 
aortic stenosis: cardiac troponin I, brain natriuretic peptide (BNP) and galectin-3. We used a 
population of older patients with asymptomatic moderate to severe aortic stenosis, the 
clinical group where a more objective assessment using simple blood testing would be most 
attractive. Cardiac troponin is a structural sarcomeric protein, with serum concentration 
acting as a highly specific marker for myocardial injury.85 It has previously been 
demonstrated that higher cardiac troponin concentrations on a single measure in patients 
with aortic stenosis identifies those at highest risk of future decompensation and death.88  
 
BNP is released predominantly by ventricular cardiomyocytes in response to volume 
overload and stretch.96 As a well-established marker of heart failure, it is likely to have a role 
in distinguishing symptomatic aortic stenosis from related comorbidity in elderly 
individuals, such as breathlessness due to chronic lung disease. Single measures of BNP 
have been suggested as a predictor of future symptom development or the requirement for 
valve replacement in patients with stable, asymptomatic aortic stenosis.97 However, BNP 
measurement is not routinely undertaken in the evaluation of these patients and there is 
limited evidence for serial testing.  
 
Galectin-3 is a beta-galactoside-binding lectin protein expressed by activated macrophages. 
Particularly high concentrations are observed in the lung, spleen, adrenal gland, 
gastrointestinal tract, ovary and uterus. Cardiac expression is relatively low, but importantly 
may be upregulated in disease states.100 Higher circulating concentrations of galectin-3 are 
noted in heart failure, with a postulated role for the protein in the development of the disease 
through promotion of cardiac fibroblast proliferation. 97,98  
 
We hypothesised that these three candidate biomarkers of disease progression, namely 
cardiac troponin, BNP and galectin-3, would demonstrate satisfactory variability in older 
adults with aortic stenosis to make clinical monitoring by serial sampling feasible. As many 
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biomarker studies with potential to influence patient care are performed retrospectively in 
large research cohorts using stored frozen sample, we additionally analysed the validity of 
fresh-frozen comparisons of these biomarkers to better understand the translation of research 
findings to the clinical setting. 
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4.3 METHODS 
The methods and sample size are in keeping with other studies of variability of circulating 
blood biomarkers and best-practice guidance.91,160-163 
 
4.3.1 PARTICIPANT SELECTION 
Fourteen subjects (8 males, 6 females) with moderate-severe aortic stenosis were recruited 
from outpatient cardiology clinics at the Royal Infirmary of Edinburgh. Participants >65 
years old were included on the basis of a specialist cardiologist review determining stable 
moderate to severe aortic stenosis without current or prior clinical decompensation. Further, 
subjects required echocardiography within 6 months of enrolment demonstrating a peak 
velocity across the aortic valve (AVmax) greater than 3.5m/s, evidence of normal left 
ventricular function by visual assessment and without other significant valve dysfunction 
(i.e. not greater than mild severity). Potential participants were further excluded if there was 
any history of heart failure or current use of diuretic medication, current smoking habit, or if 
screening blood tests showed significant derangement of liver or renal function (calculated 
creatinine clearance <30mL/min). Finally, participants were required to have had no changes 
to any regular prescribed medication in the 4 weeks prior to the start of variability testing. 
During the testing period, subjects were excluded if they developed any new symptoms 
consistent with disease progression or intercurrent illness. Written informed consent was 
obtained from all participants. The study protocol was reviewed and approved by the local 
research ethics committee (SE/14/SS/1110). 
 
4.3.2 BLOOD SAMPLING AND PROCESSING  
Blood was drawn at six timepoints over 14 days (Figure 4.1). To assess short term variability 
(hour-to-hour), samples were taken every 60 minutes for four hours. To assess medium term 
variability (week-to-week), further samples were taken 7 and 14 days later at a similar time 
of day. All sampling occurred between 9am and 2pm. At each timepoint, blood was drawn 
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into 4.9mL EDTA plasma tubes (Sarstedt, Nümbrecht, Germany) and placed on ice. Within 
30 minutes of blood draw, these samples were spun at 2000g in a refrigerated centrifuge at 
4oC for 15 minutes to separate out the plasma layer. This was divided into four 500µl plasma 
aliquots, which were labelled as two pairs (‘A’ and ‘B’ aliquots). One pair was frozen at -
80oC, while the other pair was directly analysed within 30 minutes to replicate testing on 
demand in a clinical laboratory. At the end of the study, frozen aliquots were allowed to 
thaw at room temperature before being analysed in a single batch. 
  











Clinical biomarkers in older patients with aortic stenosis 95 
4.3.3 ASSAYS 
High-sensitivity cardiac troponin I, BNP and galectin-3 were run concurrently using the 
high-throughput ARCHITECT STAT analyser (Abbott Diagnostics, Illinois, USA) held 
within a dedicated biomarker research laboratory. The same reagent lot was used for each 
assay throughout the study. As fresh and frozen testing occurred on different days, the 
machine was calibrated prior to any sample runs according to manufacturer guidance. 
 
4.3.4 STATISTICAL ANALYSIS 
Continuous data are summarised using the sample mean ± standard deviation, while 
categorical data are presented as the total number within the sample (percentage). At 
completion of the study, results of each of the three assays were available in duplicate (‘A’ 
and ‘B’ aliquots) for each subject and at each timepoint in both fresh and frozen form. 
Variability was assessed using standard formulae described in the methods of Fraser and 
Harris.164 Hourly variability was determined using only results from the first day of 
sampling, while weekly variability included all timepoints.  
 
The variation in each biomarker within each subject was tested for normality using the 
Shapiro-Wilk test. The normality assumption for later calculations was considered true if 
>50% of subjects did not meet the criteria to reject the null hypothesis of normality at 5% 
significance. A key component of variability calculations is the coefficient of variation (CV) 
which is defined as the ratio of the standard deviation (σ) of the sample to its mean (µ): 
 
!" = $%&' × 100% 
 
4.3.4.1 ANALYTICAL VARIABILITY (CVA) 
The analytical coefficient of variation (CVa) was determined for each pair of identical 
aliquots analysed (i.e. the ‘A’ and ‘B’ sample). This was summarised as a mean CVa value 
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for each assay. Linear regression analysis was undertaken to investigate the effect of assay 
concentration on analytical variability, plotting the mean concentration of each pair of 
aliquots against its CVa. 
 
4.3.4.2 TOTAL SUBJECT VARIABILITY (CVT) 
The total variability in each individual was determined using the mean and standard 
deviation of all samples and the CV formula above. This represents the combination of 
analytical and biological variability, plus any unmeasured pre-analytical differences that 
persist despite controlled sampling methodology. 
 
4.3.4.3 BETWEEN-SUBJECT VARIABILITY (CVG) 
The between-subject coefficient of variation (CVg) was determined for each assay using the 
mean and standard deviation of biomarker concentrations across all fourteen participants. 
This represents the variability of each biomarker between individuals with aortic stenosis. 
 
4.3.4.4 BIOLOGICAL VARIABILITY (CVI) 
The biological variability is the within-subject coefficient of variation (CVi) after accounting 
for analytical variation. It was determined using the formula:  
 
!", = -(!"/0 − !"20) 
 
4.3.4.5 INDEX OF INDIVIDUALITY (II) 
The index of individuality represents the variation in the homeostatic setpoint for an assay 
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In keeping with the existing literature, an II<0.6 was considered indicative of high variation 
in the homeostatic setpoint, such that serial testing would be justified in place of a universal 
reference range. 
 
4.3.4.6 REFERENCE CHANGE VALUE (RCV) 
The RCV describes the minimum percentage change between two serial measures that 
overcomes the calculated analytical and biological variability. It may therefore be considered 
as the minimum change between serial samples in an individual that represents a statistically 
significant change in a biomarker. The symmetrical limits of a normally distributed RCV 
were determined using the formula: 
9!" = : × √2 × -5!"20 + !",07 
where Z = 1.96 corresponding to a 95% confidence level. 
 
4.3.4.7 FRESH-FROZEN COMPARISONS 
For each biomarker, correlation coefficients were determined for the comparison of fresh 
and frozen aliquot concentrations. Bland-Altman plots were used to visualise agreement and 
assess mean differences.  
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4.4 RESULTS 
The baseline characteristics of the fourteen included subjects are summarised in Table 4.1. 
Following the initial day of sampling, one participant developed a chest infection and was 
therefore withdrawn from further weekly sampling. However, data for hourly variation was 
retained. A second participant developed a syncopal episode between Day 7 and 14 sampling 
and was subsequently referred for aortic valve replacement. Once more weekly sampling 
was withdrawn from the study but hourly data was retained. All samples for all three 
biomarkers were detectable above the assay-specific limits of detection. 
 
Using all available results for each participant, the distribution of each biomarker 
concentration was assessed for normality by Shapiro-Wilk testing at the 5% significance 
level. For the fresh cardiac troponin assay, results from 12 (86%) participants did not reject 
the null hypothesis of normality. This was seen with 11 (79%) subjects on frozen sample 
testing. Similarly with  BNP and galectin-3, 12 (86%) subjects in each of the fresh and 
frozen sample sets demonstrated insufficient evidence to reject the normal distribution. 
Given these findings, data were not log-transformed. 
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Table 4.1 – Baseline characteristics. 
 
n=14 
Age, years 79.3 ± 8.3 
Females 6 (43) 
Body mass index, kg/m2 27.9 ± 3.9 
Creatinine clearance, mL/min 69.8 ± 24.0 
AVmax, m/s 4.3 ± 0.5 
  
Comorbidity  
Myocardial infarction 1 (7) 
Stroke or TIA 3 (21) 
Diabetes mellitus 1 (7) 
Hypertension 9 (64) 
Atrial fibrillation 2 (14) 
Chronic kidney disease 1 (7) 
Current smoker 0 (0) 
Ex-smoker 7 (50) 
s 
 
Biomarker concentrations  
Cardiac troponin I, ng/L 10.8 ± 7.8 
BNP, ng/L 145.2 ± 142.2 
Galectin-3, µg/mL 18.1 ± 6.4 
Values are mean ± SD or number (%) 
Creatinine clearance was determined by the Cockcroft-Gault equation 
AVmax = maximal velocity across the aortic valve determined by echocardiography 
TIA = transient ischaemic attack 
Chronic kidney disease defined by primary care or hospital coding  
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4.4.1 ANALYTICAL AND BIOLOGICAL VARIABILITY 
Key components of variability for each biomarker are summarised for hourly (Table 4.2) and 
weekly (Table 4.3) sampling regimes. The spread of data across all subjects is shown in the 
representative plots for fresh and frozen cardiac troponin concentrations in Figure 4.2. 
Overall analytical variability was ≤5% for all three biomarkers, with no discernible 
improvement in performance with single-run batch testing of frozen samples when compared 
to immediate processing of fresh plasma. Between-subject variation (CVg) was high for all 
three biomarkers which was reflected in universally low indices of individuality (all <0.6).  
 
Biological variability (CVi) was similar in all three biomarkers on hourly sampling. 
However, galectin-3 remained stable on weekly testing, while the CVi of both cardiac 
troponin and BNP increased. This is reflected in the RCVs, with galectin-3 results 
suggesting a ~15% change in concentration between serial tests at either hourly or weekly 
intervals would represent significant change in the biomarker. However, both cardiac 
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Table 4.2 – Key variability data for hourly sampling with fresh and frozen protocols. 
 
Variability component Troponin I BNP Galectin-3 
Fresh     
Mean concentration ± SD 10.4 ± 7.7ng/L 137.7 ± 129.8ng/L 18.0 ± 6.5µg/mL 
Analytical (CVa, % ) 4.1 2.8 1.7 
Between subject (CVg, %) 75.4 96.7 36.3 
Biological (CVi, %) 5.9 4.8 3.6 
Index of Individuality (II) 0.1 0.1 0.1 
Reference change value (%) 19.9 15.4 11.0 
    
Frozen    
Mean concentration ± SD 10.9 ± 9.8ng/L 82.8 ± 80.2ng/L 18.5 ± 6.8µg/mL 
Analytical (CVa, %) 5.0 3.4 1.6 
Between subject (CVg, %) 92.4 99.4 37.0 
Biological (CVi, %) 5.0 4.7 3.4 
Index of Individuality (II) 0.1 0.1 0.1 
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Table 4.3 – Key variability data for weekly sampling with fresh and frozen protocols. 
 
Variability component Troponin I BNP Galectin-3 
Fresh     
Mean concentration ± SD 11.2 ± 8.1ng/L 153.3 ± 155.8ng/L 18.1 ± 6.3µg/mL 
Analytical (CVa, %) 3.4 1.9 1.4 
Between subject (CVg, %) 71.9 105.1 34.3 
Biological (CVi, %) 14.8 19.9 4.7 
Index of Individuality (II) 0.2 0.2 0.1 
Reference change value (%) 42.2 55.3 13.7 
    
Frozen    
Mean concentration ± SD 12.4 ± 10.6ng/L 95.3 ± 99.9ng/L 18.8 ± 6.5µg/mL 
Analytical (CVa, %) 3.8 2.9 1.7 
Between subject (CVg, %) 90.3 106.9 34.4 
Biological (CVi, %) 14.2 21.4 5.0 
Index of Individuality (II) 0.2 0.2 0.2 








Figure 4.2 – Spread of troponin concentrations across all samples. Data is presented as mean 
and range for fresh (A) and frozen (B) sampling regimes. 
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4.4.2 VARIABILITY BY BIOMARKER CONCENTRATION 
Linear regression was used to assess the relationship between CVa in fresh samples and 
mean concentration at each timepoint (Figure 4.3). Concentrations from fresh samples were 
analysed as these demonstrated the lowest CVa across all three biomarkers. The analytical 
variability was observed to decrease as each biomarker concentration increased. This was 
most notable for cardiac troponin (correlation coefficient, r=-0.30, 95% confidence intervals 
[CI] -0.08 to -0.49, p=0.008) and galectin-3 (r=-0.29, 95% CI -0.07 to -0.48, p=0.01). A 
similar pattern was observed for BNP, although this did not reach statistical significance (r=-
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Figure 4.3 – Relationship between mean concentration and analytical variability. Linear 
regression line shown with shaded area representing 95% confidence intervals for cardiac 
troponin (A), BNP (B) and galectin-3 (C) fresh sampling.  
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4.4.3 FRESH-FROZEN COMPARISONS 
Fresh and frozen sample runs were compared by correlation and Bland-Altman plots for 
mean difference. For cardiac troponin (Figure 4.4) correlation between fresh and frozen 
concentrations was strong (r=0.97, 95% CI 0.95 to 0.97, p<0.001), although results at the 
higher end of the spectrum in one subject appeared greater on frozen than fresh testing. The 
results for this individual subject lay outside of the limits of agreement (one standard 
deviation away from the mean difference) by Bland-Altman, although the overall mean 
difference across all samples was negligible. 
 
When BNP was analysed in an identical manner, a clear trend for lower values in frozen 
samples was observed (Figure 4.5). Although simple correlation demonstrated excellent 
agreement (r=0.99, 95% CI 0.99 to 1.00, p<0.001), the mean difference between fresh and 
frozen samples was greater than 50ng/L. The Bland-Altman plot suggested a linear trend 
with the difference between fresh and frozen results rising with increasing BNP 
concentration. Owing to the large mean difference, only those samples tested at the highest 
concentrations lay outside of the limits of agreement. 
 
Agreement between fresh and frozen galectin-3 samples was excellent (r=0.99, 95% CI 0.98 
to 0.99, p<0.001), with a negligible mean difference (Figure 4.6). A small number of 
samples lay outside the limits of agreement by Bland-Altman, but these were symmetrical 
and appeared unrelated to galectin-3 concentration. 
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Figure 4.4 – Relationship between fresh and frozen cardiac troponin concentrations. In the 
correlation between fresh and frozen samples (A), the dashed line represents complete 
agreement and the red line is the best fit linear regression line through the results, with 
shaded 95% confidence intervals. A Bland-Alman plot (B) shows the mean difference (central 
line) with upper and lower lines of limits of agreement, defined as 1 standard deviation each 
side of the mean difference.  
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Figure 4.5 – Relationship between fresh and frozen BNP concentrations. In the correlation 
between fresh and frozen samples (A), the dashed line represents complete agreement and 
the red line is the best fit linear regression line through the results, with shaded 95% 
confidence intervals. A Bland-Alman plot (B) shows the mean difference (central line) with 
upper and lower lines of limits of agreement, defined as 1 standard deviation each side of 
the mean difference.  
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Figure 4.6 – Relationship between fresh and frozen galectin-3 concentrations. In the 
correlation between fresh and frozen samples (A), the dashed line represents complete 
agreement and the red line is the best fit linear regression line through the results, with 
shaded 95% confidence intervals. A Bland-Alman plot (B) shows the mean difference (central 
line) with upper and lower lines of limits of agreement, defined as 1 standard deviation each 
side of the mean difference.  
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4.5 DISCUSSION 
In this analysis we have reported the performance of three putative blood biomarkers of 
disease progression in older subjects with aortic stenosis. We have made a number of 
important observations. Firstly, cardiac troponin I, BNP and galectin-3 demonstrated low 
analytical variability on a high-throughput platform, even using a fresh sampling protocol 
simulating clinical laboratory practices. Second, all three biomarkers were detectable in all 
subjects above assay limits of detection. Third, degradation of BNP on frozen sampling 
indicates that batch testing in this manner would not be valid for clinical use. Finally, the 
index of individuality across all three biomarkers was low, mandating serial testing to 
determine a clinically significant change in an individual subject. Reference change values to 
overcome inherent biological and analytical variability between samples taken weeks apart 
were 14% for galectin-3, 42% for cardiac troponin I and 55% for BNP. Taken together, these 
findings may inform the appropriate use of these blood biomarkers for monitoring disease 
progression in the clinical setting of older patients with moderate to severe aortic stenosis.   
 
The use of blood biomarkers to monitor progression of aortic stenosis is currently not 
widespread, but the evidence base is growing.165 Serial testing of stable, asymptomatic aortic 
stenosis patients could be an attractive enhancement to clinical assessment and routine 
echocardiography, and may help to stratify patients for more invasive or costly 
investigations. However, this approach could only be considered with sufficient 
understanding of the analytical and biological variability of these biomarkers. In contrast to 
other groups who have focused on young and healthy volunteers, we have assessed these 
biomarkers in the population with the most potential for clinical application, namely older, 
comorbid individuals with moderate to severe aortic stenosis. 
 
Differences are observed with the variability of the same cardiac troponin I assay in a study 
of 12 healthy volunteers aged 19–58 years old by Wu et al.162 Analytical variability on 
weekly frozen sampling in this study was 15%, compared to just 3.8% in our study. This 
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may be explained by frequency of low concentrations of cardiac troponin near to the limit of 
detection of the assay amongst the healthy volunteers, with virtually no results above 5ng/L. 
In a different study of older patients with stable coronary disease (median age 68 years), the 
CVa was also lower than healthy volunteers at 8% with a mean troponin concentration of 
7.8ng/L.160 In our older aortic stenosis population, the mean cardiac troponin was higher at 
12.4ng/L, a level where analytical imprecision is even lower, as we have demonstrated by 
our comparison of CVa across concentrations within our cohort. Interestingly, biological 
variability in the healthy volunteers cohort was 14%, which matches that seen in our 
subjects.162  
 
Therefore largely as a result of smaller analytical imprecision, our study generated a lower 
RCV for cardiac troponin between weekly serial samples. This is important if such testing 
were to enter clinical practice. Application of a higher RCV threshold derived from younger 
cohorts to define a clinically meaningful change in cardiac troponin may reduce test 
sensitivity in older patients, by increased false-negative rates in those with potentially 
progressive aortic stenosis. 
 
Although our data suggest a decay of BNP on frozen sample analysis, this did not 
significantly alter analytical or biological variability resulting in a similar RCV to fresh 
sampling. However, this finding clearly adds uncertain pre-analytical variability to the 
interpretation of any BNP concentrations derived from frozen samples, limiting the 
translation of findings from such stored samples into clinical laboratory testing. The 
deterioration of endogenous BNP has been acknowledged before and may be overcome on 
frozen sampling by testing for the amino-terminal NT-proBNP, which appears more stable in 
this setting.166 However, NT-proBNP and BNP concentrations are not directly comparable.99 
The RCV for BNP observed in our study at 55% was smaller than in cohorts of stable heart 
failure patients on frozen sampling, where threshold changes of 95–113% between weekly 
serial samples were indicated.99,167 This is likely to reflect the deliberate exclusion of 
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subjects with signs of heart failure within our sample, resulting in biological variability 
values that were approximately half that of the heart failure cohorts.  
 
Galectin-3 proved the most stable of the three biomarkers, with little variation on hourly or 
weekly testing. The observed RCV of 14% is comparable to healthy cohorts, and slightly 
lower than the ~25% change observed in heart failure patients.167,168 It is interesting to note 
that the mean concentration of galectin-3 in aortic stenosis subjects included in our study 
was comparable to that in the CORONA trial of older patients with ischaemic heart failure, 
where the biomarker was predictive of cardiovascular and all-cause mortality.169 However, in 




Unfortunately, two subjects had samples excluded from weekly sampling due to unforeseen 
intercurrent illness and the development of symptoms that could be consistent with disease 
progression. This limits the numbers included in this analysis, although at 12 subjects 
remains similar in size to other such studies.162 Although the findings for fresh sample 
analysis are reassuring for the translation of these findings to on-demand clinical laboratory 
settings, the pre-analytical phase was tightly controlled within this experiment. For true 
testing of analytical variability in ‘real-world’ laboratory settings, test samples of known 
concentration could be randomly included within routine clinical samples. It is likely that 
different operators obtaining and processing blood samples, as well as multiple analysers, 
reagent lots and calibration regimes would increase analytical variability and thereby the true 
RCV threshold. Application of the tighter RCVs obtained from controlled experiments may 
therefore reduce test specificity by increasing false positive triggering, whereby individuals 
may be incorrectly identified with an apparent significant change in their biomarker 
concentration, which is driven by higher analytical variation. It is important to acknowledge 
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that RCV calculations determine the threshold for significant statistical change in a 
biomarker between serial measures, but further clinical correlation studies are required to 
interpret the implications for disease progression. Testing for variability is performed in 
stable patients and so interpretation of these thresholds in an individual must occur in the 
context of stability of non-cardiac disease, particularly with biomarkers that are not organ-
specific. Clinical instability is more likely in older patients due to greater comorbidity, which 
may make interpretation of many biomarkers challenging. 
 
As a small variability study of 14 subjects, the spread of possible biomarker concentrations 
was limited, which may impair interpretation of these findings at the extremes of 
concentration. It is also clear that one subject had BNP levels that would be expected with 
significant wall stress (repeated testing >500ng/L) and heart failure. However, this did not 
correlate with their clinical presentation, raising the possibility of an idiosyncratic 
heterophilic antibody reaction falsely elevating the plasma concentration.170 These data were 
retained in the analysis as the results were internally consistent for the subject and therefore 
did not meet criteria for outlier exclusion. Furthermore, the high BNP concentration was not 
matched by extreme cardiac troponin or galectin-3 results. However, this inclusion of an 
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4.6 CONCLUSIONS 
In a population of older patients with asymptomatic moderate to severe aortic stenosis, 
cardiac troponin I, BNP and galectin-3 were all detectable on a high-throughput platform 
above the limit of detection on multiple repeated hourly and weekly blood draws. Galectin-3 
proved the most stable biomarker tested, with variability similar to other reported cohorts. 
However, reference change values for cardiac troponin I and BNP were lower than that 
reported in healthy volunteer and stable heart failure cohorts. This suggests added value from 
studying variability in subjects drawn from the clinical group to which testing is likely to be 
applied. These findings may inform the appropriate use of these blood biomarkers with serial 
testing for differences greater than the newly defined reference change values for older 
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CHAPTER 5: THE RELATIONSHIP BETWEEN PREOPERATIVE FRAILTY AND 
OUTCOMES FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION: A 
SYSTEMATIC REVIEW AND META-ANALYSIS 
 
5.1 OVERVIEW 
Transcatheter aortic valve implantation (TAVI) is an increasingly common intervention for 
patients with aortic stenosis deemed high-risk for major cardiac surgery, but identifying 
those who will benefit can be challenging. Frailty reflects physiological reserve and may be 
a useful prognostic marker in this population. We performed a systematic review and meta-
analysis of the association between frailty and outcomes after TAVI. 
 
Five databases were searched between January 2000 and May 2015. From 2,623 articles 
screened, 54 were assessed for eligibility. Ten cohort studies (n=4,592) met the inclusion 
criteria of reporting a measure of frailty with early (≤30 days) or late (>30 days) mortality 
and procedural complications following TAVI as defined by the Vascular Academic 
Research Consortium (VARC).  
 
Frailty was associated with increased early mortality in four studies (n=1,900) (HR 2.35, 
95% CI 1.78-3.09, p<0.001), and increased late mortality in seven studies (n=3159) (HR 
1.63, 95% CI 1.34-1.97, p<0.001). Objective frailty tools identified an even higher risk 
group for late mortality (HR 2.63, 95% CI 1.87-3.70, p<0.001). Frail individuals undergoing 
TAVI have a mortality rate of 34 deaths per 100 patient years, compared to 19 deaths per 
100 patient years in non-frail patients. There was limited reporting of VARC procedural 
outcomes in relation to frailty, preventing meta-analysis. 
 
Frailty assessment in an already vulnerable TAVI population identifies individuals at even 
greater risk of poor outcomes. Use of objective frailty tools may inform patient selection, but 
this requires further assessment in large prospective registries.   
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5.2 INTRODUCTION 
Aortic stenosis is the most common valvular disease in the Western World, affecting 1 in 8 
individuals over the age of 75 years. The incidence of functionally important disease is rising 
in line with the ageing population, providing challenges for conventional valve replacement 
surgery.138 Patients over 80 years old undergoing elective cardiac surgery have more 
operative complications and a 10 percent mortality rate at 30 days; therefore decisions 
around intervention in older patients are complex.26 Transcatheter Aortic Valve Implantation 
(TAVI) has become a widespread and viable alternative for patients considered high-risk for 
conventional surgery. Population modelling suggests in excess of 91,000 people fall into this 
category across North America each year.138 The Society of Thoracic Surgeons (STS)73 and 
EuroSCORE171 tools are often used to guide treatment based on the predicted risk of poor 
outcomes, but these scoring systems have not been designed or formally tested in TAVI 
populations.  The application of such scores in elderly patients suitable for conventional 
surgery has also been questioned.80,172 Many believe that a holistic approach through frailty 
assessment may improve the decision making process.  
 
Frailty is a multimodal concept describing loss of strength, endurance and physiological 
reserve across multiple systems that increases vulnerability for developing dependency or 
death.105 It becomes more common with age, but is a very distinct concept of biological 
rather than chronological years; indeed the majority of individuals over 85 years old are not 
frail. Common models focus on the development of a phenotype or the gradual accumulation 
of deficits over time, but there is no clear consensus on the best form of 
measurement.105,107,108 Within non-cardiac surgical cohorts, frailty is predictive of mortality, 
post-operative complications and institutionalisation.173-176 It is plausible that such measures 
applied to high-risk patients undergoing TAVI may improve the discrimination of current 
risk assessment tools for important patient outcomes. In this systematic review, we evaluate 
the effect of pre-operative frailty on important patient outcomes after TAVI.  
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5.3 METHODS 
5.3.1 SEARCH STRATEGY 
We conducted a systematic literature review of Medline, EMBASE and CINAHL databases 
between 1st January 2000 and 1st June 2015 using the key search terms of frailty (and its 
synonyms) and TAVI (and its synonyms) (Table 5.1). Earlier dates were not searched as 
TAVI procedures were not performed routinely until 2001. Reference and forward citation 
searching via the Web of Science (Thomson Reuters) was performed on papers meeting the 
criteria for inclusion. Hand-searching using the primary search terms was performed within 
the three most commonly identified journals from the initial search. This was repeated using 




5.3.2 ELIGIBILITY CRITERIA 
We included any primary peer-reviewed paper where a measure of frailty was defined by the 
authors prior to TAVI, and where this was related to at least one of the predefined post-
TAVI outcomes. No other assessments were adjudicated to represent frailty unless stipulated 
as a determinant of frailty by the authors of a study. No restrictions were placed on the age 
of study participants, specific vascular route or operator technique by which TAVI was 
performed. Results in all languages were considered, using translation services where 
required to adjudicate eligibility.  
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Table 5.1 – Example search string (shown for Medline). 
 
Search number Search term 
1. TAVI.ti,ab. 
2. "transcatheter aortic valve implant*".ti,ab. 
3. "transcatheter aortic valve replac*".ti,ab. 
4. Aortic Valve Stenosis/ 
5. Heart Valve Prosthesis/ 
6. exp Cardiac Surgical Procedures/ 
7. Heart Valve Prosthesis Implantation/ 
8. TAVR.ti,ab. 
9. Cardiac Catheterization/ 
10. or/1-9 
11. Frail Elderly/ 
12. frail*.ti,ab. 
13. exp Geriatric Assessment/ 
14. (frail adj2 elderly).ti,ab. 
15. 




(Fried adj5 (frail* or index* or 
phenotype)).ti,ab. 
18. (frail* adj2 scor*).ti,ab. 
19. "Activities of Daily Living"/ 
20. Geriatrics/rh, su [Rehabilitation, Surgery] 
21. 
11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 or 20 
22. 10 and 21 
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The primary outcome was all-cause mortality after TAVI, either reported in the short (≤30 
days) or long term (>30 days). Secondary outcomes comprised procedural complications as 
defined by the Valve Academic Research Consortium (VARC) standardized endpoint 
definitions. These include cardiovascular mortality, myocardial infarction, major stroke, 
bleeding, acute kidney injury requiring dialysis and numerous other vascular 
complications.177 Any measures of functional capacity or patient independence after TAVI 
were sought as secondary outcomes where the relationship to a pre-TAVI frailty measure 
was presented. Review articles and non-peer reviewed material (such as conference 
proceedings and poster abstracts) were excluded.  
 
5.3.3 DATA EXTRACTION 
All extracted abstracts and full-text articles meeting the inclusion criteria were assessed 
between three researchers (AA, AV and CH), such that two people independently reviewed 
each submission. Disagreements were resolved by consensus including the third reviewer. 
For each study meeting the inclusion criteria, a standardised data extraction form was 
developed to record study design, TAVI population demographics, assessed risk of the 
population (STS and EuroSCORE), specific frailty measure, length to follow-up and any 
data related to the primary and/or secondary outcomes. Where the relationship between 
frailty and outcome was qualitatively but not quantitatively expressed, primary authors were 
contacted in an attempt to gain additional primary data. Where the same study appeared to be 
reported across more than one article, only the most complete submission was included, with 
the aim of maximising the volume of frailty data included. 
 
5.3.4 QUALITY AND BIAS ASSESSMENT 
No validated quality assessment tool has been widely established to assess observational 
studies that are not designed to directly compare two groups. The Newcastle-Ottawa Scale 
was used to provide a structured assessment of sample selection (4 points), comparability (2 
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points) and outcomes (3 points).178 This tool was chosen as an objective measure with clear 
descriptors to derive a maximum score of 9 points. Studies were independently assessed by 
two reviewers and disagreement resolved by consensus: ≥7 points considered high quality 
for frailty reporting, <7 moderate or low quality. Publication bias was assessed in the 
primary endpoint with the greatest number of studies by creating a funnel plot and using 
Egger’s regression test.179 We then corrected for asymmetry using the trim and fill method to 
determine an adjusted effect size.180  
 
5.3.5 DATA SYNTHESIS AND ANALYSIS 
All included studies were observational cohorts with respect to frailty. Meta-analysis was 
performed when at least three studies reported a comparable endpoint to generate a meta-
estimate. Given the wide number of frailty tools available, significant heterogeneity was 
expected across the studies and therefore a random-effects model (maximum likelihood 
approach) was chosen to calculate summary effect estimates.181 Statistical analysis was 
performed using the metafor statistical package within R version 3.1.3 (http://www.r-
project.org) and GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA). A 
value of p<0.05 was considered statistically significant. 
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5.4 RESULTS 
5.4.1 SEARCH RESULTS AND PATIENT CHARACTERISTICS 
We identified 2,623 abstracts from our initial search, resulting in 54 articles for full-text 
review to assess eligibility. Ten studies from Europe and North America met the full 
inclusion criteria (Figure 5.1). These comprised 4,592 patients undergoing TAVI in whom a 
frailty measure was made prior to surgery. The mean age was 80 to 86 years, 34% to 53% of 
participants were men, and the STS-predicted 30-day mortality rates where available were 
between 6.3% and 16.6%. In those studies detailing the access route chosen for TAVI, the 
femoral approach was the most common, although this ranged from 47% to 100% of cases. 
The proportion of TAVI patients identified as frail varied greatly across the included studies, 
from 5% to 83% (Table 5.2). 
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Figure 5.1 – Flow diagram of reviewed studies. 
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5.4.2 DEFINITIONS OF FRAILTY 
Frailty was identified by authors as either subjective (four studies) or objective (six studies). 
Subjective frailty was based on the judgement of a clinical team without reporting use of a 
specific tool. Objective frailty was determined by use of a tool specifically with the purpose 
of defining frailty, such as activity of daily living assessments, comprehensive geriatric 
assessment and frailty indices. With the exception of one small study of 30 patients by 
Kamga et al.184, frailty data was available as a dichotomised variable when related to 
outcomes, even where it had been measured on a continuous scale. 
 
5.4.3 FRAILTY AND MORTALITY 
Four studies (n=1,900) reported frailty (using objective measures) and early (≤30 days) 
mortality after TAVI (Table 5.3 and Figure 5.2), identifying greater than doubling of the risk 
of early death amongst patients identified as frail (HR 2.35, 95% CI 1.78-3.09, p<0.001). All 
papers reported unadjusted univariate analyses for the association between frailty and 
mortality. There was no significant heterogeneity between studies (I2=0%, p=0.33). 
 
Seven studies (n=3,159) quantified the relationship between frailty and late mortality >30 
days after TAVI, with every study completing at least one year of follow-up (Table 5.4 and 
Figure 5.2). All reported an increased risk of death amongst frail patients, with an overall 
effect size of HR 1.63 (95% CI 1.34-1.97, p<0.001). This was only marginally increased by 
restricting analysis to studies undertaking adjustment for potential confounders (5 studies, 
HR 1.85, 95% CI 1.34-2.55, p<0.001) or including only studies of higher quality for frailty 
reporting (4 studies, HR 1.79, 95% CI 1.28-2.50, p<0.001). There was moderate 
heterogeneity (I2=66%, p=0.01), which was reduced by performing a sensitivity analysis by 
the type of frailty measure used (Figures 5.3 and 5.4). The mortality risk for frail patients 
was greater amongst those studies using an objective measure (HR 2.63, 95% CI 1.87-3.70, 
p<0.001) rather than subjective assessment (HR 1.42, 95% CI 1.28-1.59, p<0.001). 
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Figure 5.2 – Risk of early (≤30 days after TAVI) and late (>30 days) mortality in studies 
suitable for meta-analysis ordered by date of publication. Summary meta-estimate 
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Figure 5.3 – Risk of late (>30 days after TAVI) mortality amongst frail patients. Summary 
meta-estimates presented grouped by type of frailty assessment used (subjective vs. 
objective), adjustment for confounders (unadjusted vs. adjusted) and study quality with 
regard to frailty reporting (low vs. high). All summary meta-estimate calculations based on 
random-effects model analysis. Individual study level data are shown in Figure 5.4. 
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Figure 5.4 – Sensitivity analysis for late mortality (>30 days) after TAVI. Individual and 
summary meta-estimates presented for subjective vs. objective frailty assessment, 
unadjusted vs. adjusted analyses, and high vs. low quality for frailty reporting. All summary 
meta-estimate calculations based on random effects model analysis. 
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Five studies provided the absolute number of deaths by frailty status allowing combined 
incidence estimations. This calculation totalled 3629 TAVI patients (24.6% frail) followed 
for the equivalent of 2717 patient years. Amongst those with frailty, 34 deaths/100 patient 
years were observed, against 19 deaths/100 patient years in non-frail individuals (Table 5.5). 
Two studies could not be included in the meta-analysis due to frailty being reported as a 
continuous variable (Kamga et al.184), or because only a composite end point of MACCE 
(major adverse cardiovascular or cerebrovascular event) rather than all-cause mortality was 
reported (Ewe et al.182). However, both studies did report significant associations of frailty 
with poorer outcomes including late mortality.
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5.4.4 FRAILTY AND VARC OUTCOMES 
There was wide variation in the reporting of secondary outcomes across the included studies, 
with only three studies reporting comparable outcomes in relation to frailty. Meta-analysis of 
these endpoints was therefore not possible. VARC outcome measures ≤30 days after TAVI 
were reported in relation to frailty status in only two of the included studies, totalling 544 
patients (Table 5.3). Both used objective tools, and reported increased effect estimates for 
the risk of major bleeding and renal failure requiring dialysis in frail patients, but only the 
latter complication reached significance in the paper by Puls et al. (OR 2.23, 95% CI 1.12-
4.47, p=0.02). Both studies reported no increase in the risk of stroke amongst frail 
individuals after TAVI.  
 
5.4.5 QUALITY AND RISK OF BIAS 
Six studies met our frailty-defined criteria for high quality (Newcastle-Ottowa scale score ≥ 
7) and four were considered moderate or low in quality (Table 5.6). No study scored 
maximum points. All those considered of lower quality did not include adjustment for 
potential confounders of the relationship between frailty and outcomes. Publication bias was 
suggested amongst the seven studies reporting late mortality (Egger’s test for asymmetry 
p=0.02). Adjustment by the trim and fill method (Figure 5.5) had no effect on the size 
estimate, which remained statistically significant (HR 1.59, 95% CI 1.33-1.90, p<0.001 vs 
HR 1.63, 95% CI 1.34-1.97, p<0.001 before adjustment). 
  
Clinical biomarkers in older patients with aortic stenosis 138 
Table 5.6 – Newcastle-Ottowa Scale quality assessment of included studies. 
 










Ewe, 2010 **** ** * 7 High 
Stortecky, 
2012 
**** * * 6 Low 
Rodes-Cabau, 
2012 
*** ** ** 7 High 
Kamga, 2013 **** ** * 7 High 
Zahn, 2013 ***  * 4 Low 
Puls, 2014 **** ** ** 8 High 
Seiffert, 2014 *** ** ** 7 High 
Capodanno, 
2014 
****  ** 6 Low 
Debonnaire, 
2015 
***  ** 5 Low 
Green, 2015 **** ** * 7 High 
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Figure 5.5 – Funnel plot for publication bias assessment in seven studies reporting late 
mortality. Each point represents one study, with the model estimating two missing studies 
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5.5 DISCUSSION 
In this systematic review and meta-analysis we explored the relationship between pre-
procedure frailty and outcomes after TAVI in 10 studies from Europe and North America 
comprising 4,592 patients. We have made several important observations. First, the 
measurement of frailty detects a population at double the risk of both early and late mortality 
after TAVI. Second, using objective measures of frailty appears to identify an even more 
vulnerable group than ‘end-of-the-bed’ subjective assessment. However, it is worth 
acknowledging that such subjective frailty assessment still provides important discrimination 
of risk within a population already considered at ‘high-risk’ for conventional surgery. Third, 
VARC complication rates in relation to frailty status are not well reported, with only very 
limited data to suggest increased risk of dialysis requirement and bleeding risk in frail 
patients. However, these observations were not suitable for meta-analysis and are subject to 
competing risk bias from the increased early mortality observed amongst those with frailty. 
 
A recent review by Puri et al has emphasised the potential value of frailty assessment in 
TAVI candidates.191 Through the process of systematic review and meta-analysis, we have 
further clarified the growing body of research in this area and have numerically quantified 
the mortality risk of frailty identified by both objective and subjective measures. Established 
methods for determining those most likely to benefit from TAVI over medical management 
or conventional surgical aortic valve replacement are lacking. The PARTNER randomised 
controlled trial of high-risk severe aortic stenosis patients, demonstrated improved survival 
with TAVI, but 43% of patients had still died within 2 years of intervention compared to 
68% with standard medical care. The stroke rate of 13.8% in the TAVI cohort was also more 
than double that of medically managed patients,27,192-194 although rates are falling as 
procedural techniques improve.195 TAVI as an intervention may therefore have population 
level survival benefits over medical management, but the severe aortic stenosis population is 
heterogeneous and individual risk is likely to vary greatly.  
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Mortality prediction using traditional risk assessment tools such as the STS mortality score 
and logistic EuroSCORE was commonly reported amongst the reviewed papers. It is 
possible to directly compare these figures to observed early (≤30 days) mortality in six of the 
included studies (Table 5.7). This comparison highlights the poor correlation of predictive 
scores with actual outcomes in this population, which is perhaps unsurprising given these 
tools were developed in younger cohorts excluding TAVI. Others have also identified the 
weakness of existing risk scores.80,172 It is noteworthy that these predictive algorithms only 
provide prognostic estimates for early surgical outcomes, which may not be the most 
important endpoint after TAVI. In such complex older patients approaching the end of life, 
quality of life after intervention may be more important than survival or avoidance of 
procedural complications. A systematic review by Kim et al of function and quality of life 
after TAVI reported mixed patient outcomes, with improvements in physical function 
amongst survivors not matched by changes in psychological and general health measures.68 
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Table 5.7 – Surgical risk prediction and observed mortality in included studies. 









Ewe, 2010182 NR 21.8 6.8 
Stortecky, 2012120 6.3 25.8 8.0 
Rodes-Cabau, 2012183 9.8 NR 10.6 
Puls, 2014186 7.3 26.0 11.3 
Debonnaire, 2015189 16.6 18.3 5.7 
Green, 2015†190 11.3 NR 10.0 
*STS operative mortality refers to the predicted risk of death within 30 days of a procedure or index 
hospitalisation episode (where death may occur after 30 days). 
†Matched predicted and observed data only available for frail individuals within this study. 
NR= not reported   
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Frailty has gained traction within surgical and cardiovascular literature as a potential metric 
for the currently unmeasured risk of older patients undergoing complex interventions.173-176 
Whilst this may be seen as positive for the holistic care of older patients, there is wide 
variation in definitions and measurement. In this review, the six studies that sought to 
objectively measure frailty each used different tools, varying from functional scales to 
composite scores including nutrition, cognition and mobility. Many of these assessments are 
described as measures of frailty, but are distinct from the consensus definition by Morley et 
al.105 However, several of these concepts are correlated with the frailty construct and clearly 
have some predictive value. In the absence of trial data with randomisation based upon 
frailty, it is not possible to infer which elements of these measures will carry the most 
prognostic weight. However, it is notable that all the tools used included some estimation of 
participation in activities of daily living. It is possible that such measures are particularly 
sensitive to procedural risk in severe aortic stenosis populations, as impairments may reflect 
established heart failure at the time of consideration for TAVI.  
 
There remains no consensus on the optimum approach to frailty assessment. The majority of 
studies included in this review considered frailty as a dichotomised variable for the purpose 
of outcome analysis. This reflects the phenotypic model of frailty and is perhaps attractive as 
a simple clinical concept.107 However, forcing a continuous variable into a binary form limits 
the consideration of a ‘pre-frail’ status, and may be open to criticism for the potentially 
arbitrary nature of the threshold used to define frailty. Dichotomous phenotypic frailty 
assessment may also suffer from saturation amongst the highest risk populations and 
therefore provide limited discrimination compared to an index of deficits.196 A formal Frailty 
Index, such as that first described by Rockwood et al110 is an alternative frailty construct, and 
may better reflect the accumulation of markers of frailty over time, although deficits are 
rarely amenable to dynamic change or reversal. Therefore, whilst a potentially useful marker 
of risk at a single timepoint, such indices are not capable of evaluating interventions to 
improve frailty which may be of interest in TAVI populations. Three of the included studies 
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do present some outcome data per unit change in the chosen frailty index, but given the 
differences in the structure of these scales meta-estimation of a combined effect size was not 
possible or logical.  
 
Although the included studies comprise 4,592 patients undergoing TAVI, there are even 
larger published population registries in America, the United Kingdom, France, Germany, 
Italy and Belgium. Unfortunately, there is currently no systematic measurement of frailty 
within any of these cohorts of consecutive patients.42,197-200 It is likely that these registries 
will be used to produce future TAVI-specific surgical risk assessment tools similar to STS 
and EuroSCORE, and therefore inclusion of frailty measurement would provide a valuable 
opportunity to test effectiveness in large populations. It is important that future work looks 
beyond the prediction of mortality after TAVI to assess the impact of the procedure on 
symptoms and quality of life amongst frail individuals. 
 
5.5.1 LIMITATIONS 
Several limitations of our review should be considered. First, there are no studies 
randomised by frailty status, and so it is likely that patient selection in the observational 
cohort studies included in our meta-analysis was already influenced by underlying and 
unmeasured frailty. This is inevitable given the nature of TAVI as a treatment reserved for 
high-risk aortic stenosis patients requiring valve replacement. Whilst this selection bias may 
limit interpretation of frailty measurement in a broader aortic stenosis population, the results 
are representative of real-world TAVI cohorts. Studies evaluating frailty and outcomes in 
patients referred for TAVI, but in whom the procedure was felt too high risk by their 
multidisciplinary team, would be informative but to our knowledge, no such studies have 
been reported.  
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Second, we have only included studies where frailty was defined by the researchers. It is 
possible that other data exist including similar measurements without specific use of the term 
frailty. However, such studies would be less likely to report outcomes directly related to 
these measures without acknowledging the concept of frailty. Combining these disparate 
tools into meta-estimates may be challenged as the constructs described as frailty are 
heterogenous. However, subgroup analyses of similar tools demonstrated low heterogeneity 
and support a predictive effect of frailty. Third, the meta-estimate for early mortality is based 
on a small number of studies, without adjustment for potential confounders. We were limited 
by the infrequent reporting of standardised VARC complications in relation to frailty status 
and these interpretations are open to competing risk bias. Therefore, whilst the observations 
of the effect of frailty on early outcomes are important, further work is required in this area. 
It is in this light that the addition of objective frailty measures to ongoing large TAVI 
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5.6 CONCLUSIONS 
We demonstrate that frailty is associated with poorer early and late outcomes in TAVI 
patients. Objective frailty tools identify an even more vulnerable population at greater than 
double the late mortality risk of non-frail patients. There is currently a lack of consistency in 
frailty measures and clarity in reporting against standardised early VARC outcomes. Given 
the ongoing uncertainty in appropriate patient selection for TAVI, randomised controlled 
trials should consider including patients based on an objective assessment of frailty status. 
 
  












FRAILTY MEASURES AND SURGICAL RISK SCORES IN 
OLDER PATIENTS WITH AORTIC STENOSIS
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 CHAPTER 6: FRAILTY MEASURES AND SURGICAL RISK SCORES IN OLDER 
PATIENTS WITH AORTIC STENOSIS 
 
6.1 OVERVIEW 
Patient selection for aortic valve replacement is challenging in an ageing population. 
Conventional surgical risk estimates are based on important cardiac status, comorbidity and 
age, but do not include frailty. This chapter examines the relationship between measures of 
frailty, quality of life and surgical risk in older patients with moderate-severe aortic stenosis. 
 
Across two cohorts, 185 patients (mean age 80 ± 8 years, 51% female) with aortic stenosis 
were included (mean AVmax 4.2 ± 0.5m/s). Frailty was measured using the Fried 
phenotype, the Short Physical Performance Battery (SPPB), Edmonton Frail Scale (EFS) and 
Clinical Frailty Scale (CFS). Surgical risk estimates were calculated from the online Society 
of Thoracic Surgeons (STS) operative risk and EuroSCORE II algorithms using clinical, 
echocardiographic, angiographic and laboratory data. Quality of life measures were taken 
from the Short Form (SF-12) questionnaire composite physical and mental component 
scores. 
 
Frailty assessment using the four tools was feasible and rapidly performed in all patients. 
Frailty was identified in 27-53% of the study population, varying with the measure used: 70 
(38%) by Fried assessment, 98 (53%) by SPPB, 50 (27%) by EFS and 52 (28%) using the 
CFS. Agreement between these measures was moderate by Cohen’s kappa (range 0.33–0.53 
with strongest agreement between Fried and SPPB –kappa 0.53, 95% confidence interval 
[CI] 0.41–0.65). Mean STS and EuroSCORE risk estimates increased with frailty between 
not frail, pre-frail and frail subgroups (p<0.05 using all frailty tools). However, principal 
component analysis without defined frailty thresholds demonstrated a divergence between 
frailty tools and surgical risk scores. Quality of life indicators declined in patients with 
frailty and higher surgical risk.  
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In a population of older patients with moderate to severe aortic stenosis, frailty assessments 
are feasible and show moderate agreement. While frail patients have higher surgical risk 
scores, deeper analysis suggests differences in the information captured by frailty measures 
and both the STS and EuroSCORE. Evaluation including outcomes after surgical 
intervention is now needed to understand if these frailty measures hold value beyond 
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6.2 INTRODUCTION 
Aortic stenosis is a progressive degenerative condition that affects up to 12% of older 
adults.1 In the absence of disease modifying therapy, the mainstay of treatment in those who 
develop symptomatic, severe aortic stenosis remains valve replacement, either through 
conventional cardiac surgery or transcatheter approaches. These procedures carry significant 
surgical risk. In an increasingly aged and frailer population, patient selection is complex. 
Surgical risk tools may assist in this process, using large database records to derive risk 
models that predict poorer outcomes in the perioperative period. Such outputs may guide 
clinician or patient preference for intervention and support in the delivery of individualised 
management plans for patients with severe aortic stenosis.  
 
The Society of Thoracic Surgeons (STS) risk calculator is based on 67,292 procedures 
performed between 2002 and 2006.73 The covariates include age, gender, ethnicity, body 
mass index, comorbidities and preoperative cardiac status. Similarly, the EuroSCORE II tool 
is based on 6,753 consecutive procedures across 154 surgical units in 2010.74 However, these 
risk calculators do not include measures of frailty or disability, which may plausibly affect 
the risk of complications and recovery from major cardiac interventions. Furthermore, these 
models were developed using outcomes from conventional cardiac surgery, but are 
frequently applied to judge the risk of harm from Transcatheter Aortic Valve Implantation 
(TAVI).201 The population of patients undergoing TAVI is generally older and with greater 
comorbidity202, resulting in a need to update risk tools specifically for this population. In an 
older population approaching the end of life, survival metrics may be less valuable than 
quality of life, although this is challenging to objectively measure. 
 
Frailty is increasingly recognised as a marker of surgical risk203,204 and functions as a 
measure of biological rather than chronological age. In patients undergoing TAVI, frailty is 
associated with a greater than doubling of early mortality after the procedure205, but the 
interaction with conventional surgical risk estimates is not clear. Numerous frailty tools have 
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been developed206 since Fried et al. first described the physical frailty phenotype in 2001.107 
The Fried criteria describes frailty in the presence of any three of five possible traits: 
weakness, slowness, reduced physical activity, exhaustion and unintentional weight loss. 
However, other tools such as the Short Physical Performance Battery (SPPB) is a more 
specific measure of physical performance, while the Edmonton Frail Scale (EFS) and 
Clinical Frailty Scale (CFS) include disability and a recognition of cognitive impairment.  
 
The aim of this study is to evaluate the feasibility and agreement of frailty tools in older 
patients with severe aortic stenosis, and how these measures compare with quality of life 
estimates and surgical risk scores. 
  
Clinical biomarkers in older patients with aortic stenosis 152 
6.3 METHODS 
We evaluated frailty tools and surgical risk scores in two cohorts: a longitudinal 
observational cohort study of older patients with asymptomatic moderate-severe aortic 
stenosis and a quality improvement study register of patients referred to the Scottish TAVI 
assessment clinic (Royal Infirmary of Edinburgh, Edinburgh, Scotland). Four tools were 
chosen based on likely acceptability to patients, speed of measurement to be feasible within 
a busy clinic environment, and the use of minimal specialist equipment. Written informed 
consent was obtained from all participants in the observational cohort and the study protocol 
was reviewed and approved by the local research ethics committee (SE/14/SS/1110). The 
quality improvement study protocol was also reviewed by the Scientific Officer for the local 
research ethics committee who provided approval for collection and use of data. The study 
was registered on the local quality improvement register and performed with the full 
cooperation and support of clinical staff in the TAVI assessment clinic. 
 
6.3.1 PARTICIPANT SELECTION 
Participants were included if they had evidence of moderate-severe aortic stenosis, defined 
by echocardiographic evidence of a maximum velocity across the aortic valve (AVmax) of 
greater than 3.5m/s or an aortic valve area less than 1.0cm2. There were no exclusion criteria 
to ensure assessment of a broad and generalisable cohort. 
 
6.3.2 FRAILTY ASSESSMENT  
Four frailty measures were undertaken in the same manner using identical equipment in all 
study participants: the Fried frailty phenotype, SPPB, EFS and CFS. Detailed methodology 
for each measure is provided in Chapter 2. All measures were performed by AA, with the 
exception of the CFS which was rated by an independent nurse who assessed each 
participant. Fried frailty was considered present if 3 or more of the five possible phenotype 
traits was detected.107 For selected analyses a pre-frailty label was applied where 1 or 2 traits 
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were present. For the SPPB, a lower score out of a maximum of 12 indicates greater frailty; a 
frailty cutoff of ≤5 was applied in keeping with previously described use amongst cardiac 
populations.123 An intermediate pre-frail group was assigned for scores of 6-9 with scores 
≥10 indicating no frailty. The EFS is scored out of 17 points and frailty was assigned at ≥8 
points. Pre-frailty was determined as 6-7 points and lower scores indicated no frailty.133 The 
CFS uses a 9-point scale where scores ≥5 indicate frailty. Pre-frailty or vulnerability was 
indicated at 4 points with lower scores denoting no frailty.110 
 
6.3.3 QUALITY OF LIFE ASSESSMENT 
Quality of life was assessed using the Short Form (SF-12) questionnaire as detailed in 
Chapter 2.136 Summary estimates for the Physical Component Score (PCS) and Mental 
Component Score (MCS) were used in all cases, with a lower value indicating greater 
impairment.  
 
6.3.4 SURGICAL RISK CALCULATORS 
The STS operative mortality risk for isolated Aortic Valve Replacement (AVR) surgery was 
calculated in all patients using its online calculator (http://riskcalc.sts.org/stswebriskcalc/#/). 
This estimates the percentage risk of death within the episode of continuous hospital care 
including AVR surgery, or within 30 days for patients discharged from hospital earlier. The 
EuroSCORE II risk was also calculated using its online calculator 
(http://www.euroscore.org/calc.html) and similarly estimates the risk of death within the 
index hospitalisation. Data required for completion of these calculations was taken from 
electronic patient records, echocardiography, angiography and laboratory databases. 
 
6.3.5 STATISTICAL ANALYSIS 
Statistical analysis was performed using the statistical software R version 3.3.3 
(http://www.r-project.org). Continuous variables are presented as mean (standard deviation) 
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and categorical variables as absolute numbers (percentage). Agreement between frailty 
measures was assessed by Cohen’s Kappa, using the dichotomised frailty thresholds 
described above for each test. STS and EuroSCORE were compared by Bland-Altman plot. 
Baseline characteristics, mean EuroSCORE and STS risk scores were compared across 
frailty groups (not frail, pre-frail and frail) by ANOVA. In the absence of a true gold 
standard frailty measure, principal component analysis was used to reduce the 
dimensionality of frailty measures and explore the relationship with surgical risk score 
values. Principal component analysis uses orthogonal transformation to produce variables 
that account for as much of the variance in the dataset as possible; in the analysis performed 
sufficient variance was explained by two principal components, so allowing the original 
individual patient data to be plotted as points on a biplot of these transformed components. 
To allow comparison of frailty and surgical risk scores, arrows that best summarise the 
direction of these scores on the transformed scale were plotted using the ggbiplot R package.  
 
In a further analysis, a principal component biplot for the four frailty measures alone was 
created with the study sample divided at an intermediate surgical risk threshold of STS and 
EuroSCORE estimated operative mortality ≥4%. In these analyses, SPPB scores were 
reversed to ensure directionality of the frailty measures was consistent (i.e. higher scores 
indicating greater frailty). Quality of life composite measures were assessed in those with 
and without frailty by each measure, and in those above and below the median STS and 
EuroSCORE risk. Comparisons were made by unpaired two-sided t-test. Absolute p-values 
are reported at 0.001 and greater, and p<0.05 was considered statistically significant. 
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6.4 RESULTS 
A total of 185 patients with aortic stenosis were included in the study. This comprised 80 
subjects from the longitudinal cohort study and 105 from the TAVI assessment clinic. 
Baseline characteristics are summarised in Table 6.1. The study sample was representative of 
an older population (mean age 80 ± 8 years, 51% female) with moderate-severe aortic 
stenosis (mean AVmax 4.2 ± 0.5m/s). Frailty was present in 27-53% of the cohort according 
to the measure used: Fried frailty was determined in 70 (38%), SBBP in 98 (53%), EFS in 50 
(27%) and CFS in 52 (28%) participants. Pre-frailty was present in 23-47%, varying from 87 
(47%) participants by Fried, 65 (35%) by SPPB, 43 (23%) by EFS and 52 (28%) by CFS. 
Using the Fried phenotype (Table 6.1), pre-frail and frail patients were more likely to be 
female, suffer heart failure and chronic kidney disease than those without any frailty 
markers. However, no relationship was observed between frailty status and age, severity of 
aortic valve disease or other comorbidity. 
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Age, years 79.8 ± 7.5 80.5 ± 7.9 80.1 ± 7.1 76.8 ± 7.2 0.07 
Females 95 (51) 45 (64) 44 (51) 6 (21) <0.001 
AVmax, m/s 4.2 ± 0.5 4.4 ± 0.6 4.2 ± 0.4 4.3 ± 0.7 0.26 
      
Comorbidity      
Myocardial infarction 22 (12) 9 (13) 10 (11) 3 (11) 0.90 
Heart failure 21 (11) 14 (20) 7 (8) 0 (0) 0.04 
Stroke  22 (12) 8 (11) 14 (16) 0 (0) 0.13 
Diabetes mellitus 35 (19) 16 (23) 18 (21) 1 (4) 0.19 
Hypertension 115 (62) 39 (56) 57 (66) 19 (68) 0.55 
Atrial fibrillation 46 (25) 19 (27) 22 (25) 5 (18) 0.80 
CKD 37 (20) 23 (33) 14 (16) 0 (0) 0.005 
COPD 25 (14) 16 (23) 8 (9) 1 (4) 0.08 
Osteoarthritis 81 (44) 44 (47) 28 (32) 9 (32) 0.57 
Depression 15 (8) 8 (11) 6 (7) 1 (4) 0.59 
s 
 
    Frailty Scores      
Fried 2.1 ± 1.4 3.6 ± 0.7 1.5 ± 0.5 0 – 
SPPB 5.6 ± 3.2 3.1 ± 2.0 6.5 ± 2.8 9.2 ± 1.7 <0.001 
EFS 5.7 ± 3.0 7.9 ± 2.6 4.8 ± 2.3 2.9 ± 2.2 <0.001 
CFS 3.6 ± 1.4 4.6 ± 0.9 3.2 ± 1.3 2.0 ± 1.1 <0.001 
      
SF-12 Quality of Life 
Scores 
     
Physical Component 
Score 
34.2 ± 10.2 28.3 ± 8.4 36.0 ± 9.2 43.1 ± 9.2 <0.001 
Mental Component 
Score 
50.1 ± 9.9 46.7 ± 10.8 50.9 ± 9.0 56.3 ± 6.2 <0.001 
      
Surgical Risk Scores      
STS Operative Risk 
(%) 
2.9 ± 1.8 3.5 ± 2.0 2.8 ± 1.7 1.8 ± 1.3 <0.001 
EuroSCORE II (%) 4.0 ± 3.7 5.0 ± 4.3 3.5 ± 2.9 2.7 ± 3.5 0.006 
Values are mean ± SD or number (%). 
P-values presented for differences between the frail, pre-frail and not frail groups by 
ANOVA for normally distributed continuous data and chi-squared test for categorical data. 
AVmax = maximal velocity across the aortic valve determined by echocardiography; COPD = 
chronic obstructive pulmonary disease; CKD = chronic kidney disease; SPPB = Short 
Physical Performance Battery; EFS = Edmonton Frail Scale; CFS = Clinical Frailty Scale; 
STS = Society of Thoracic Surgeons. 
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6.4.1 AGREEMENT BETWEEN FRAILTY ASSESSMENTS 
Agreement between measures for the allocation of frailty reached moderate agreement 
between each tested pair, except for the relationship between the SPPB and EFS where only 
fair agreement was observed (Table 6.2). The strongest association was noted between the 
Fried and SPPB tools (Cohen’s kappa 0.53, 95% confidence interval [CI] 0.41–0.65).   
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Table 6.2 – Agreement between frailty scores by Cohen’s Kappa 
  
Fried SPPB EFS CFS 
Fried 
 
0.53 (0.41–0.65) 0.46 (0.33–0.60) 0.49 (0.36–0.63) 
SPPB 
 
 0.33 (0.19–0.46) 0.47 (0.35–0.60) 
EFS    0.43 (0.28–0.58) 
CFS     
Values are Cohen’s Kappa statistics (95% CI) for the agreement between frailty measures 
using dichotomised frailty thresholds (frail vs not frail or pre-frail). 
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6.4.2 AGREEMENT BETWEEN SURGICAL RISK SCORES 
Agreement between the estimated operative risk by STS and EuroSCORE was strong 
(r=0.66, 95% CI 0.57–0.73, p<0.001). However, at higher predicted mortality, EuroSCORE 
estimates appeared greater than for the equivalent STS calculation (Figure 6.1).   






Figure 6.1 – Relationship between EuroSCORE and STS estimated operative risk. (A) Linear 
regression line shown with the shaded area representing 95% confidence intervals. The 
dotted black line demonstrates where complete agreement between the measures would 
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6.4.3 AGREEMENT BETWEEN FRAILTY AND SURGICAL RISK SCORES 
STS and EuroSCORE estimated operative mortality risk increased significantly with 
increasing frailty status using all four tools (Table 6.3). The most marked separation of risk 
estimates was observed using the Fried phenotype (Figure 6.2). Principal component 
analysis showed the four frailty measures and two surgical risk scores could be successfully 
reduced to a two component plot which explained 78% of the variance in measurement. In 
this reduced dimensional state, all four frailty measures acted in a similar direction, but the 
two surgical risk estimates were divergent with near perpendicular separation (Figure 6.3). A 
separate biplot using only the four frailty tools explained 83% of the variance in 
measurement (Figure 6.4). Within this plot, the closest directional agreement was observed 
between the three frailty tools using physical measures (Fried, SPPB and EFS) with some 
separation from the CFS. Further division by operative risk for those with high (≥4%) and 
low (<4%) STS score (Figure 6.4a) and EuroSCORE (Figure 6.4b) demonstrated extensively 
overlapping summary estimates on the frailty biplot, and therefore no clear relationship 
between frailty and these surgical risk scores.   
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Table 6.3 – Mean STS and EuroSCORE estimated operative risks by frailty assessment and 
status 
  
Not Frail Pre-frail Frail p-value 
STS Operative Risk     
Fried 1.8 ± 1.2 2.8 ± 1.7 3.5 ± 2.0 <0.001 
SPPB 2.3 ± 1.6 2.3 ± 1.3 3.5 ± 2.0 <0.001 
EFS 2.5 ± 1.7 3.2 ± 1.6 3.4 ± 2.0 0.007 
CFS 2.3 ± 1.3 2.6 ± 1.4 4.1 ± 2.3 <0.001 
     
EuroSCORE II     
Fried 2.7 ± 3.5 3.5 ± 2.9 5.0 ± 4.3 0.006 
SPPB 3.2 ± 3.1 3.2 ± 3.4 4.6 ± 3.9 0.04 
EFS 3.2 ± 3.3 4.3 ± 3.1 5.1 ± 4.5 0.009 
CFS 2.9 ± 2.7 3.8 ± 3.4 5.7 ± 4.5 <0.001 
Values are mean ± standard deviation of STS and EuroSCORE II operative risk (%). P-value 
represents the ANOVA for difference in means across frailty groups. 
SPPB = Short Physical Performance Battery; EFS = Edmonton Frail Scale; CFS = Clinical 
Frailty Scale.  
 
  








Figure 6.2 – Box and whisker plots for the relationship between Fried frailty status and 
surgical risk scores. Box represents median and interquartile range for risk estimates using 
the STS score (A) and EuroSCORE (B). By non-parametric ANOVA testing, median STS 
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Figure 6.3 – Principal component analysis biplot for frailty and surgical risk scores. The plots 
demonstrate similarity in frailty measures (arrows showing the direction of variables are 
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Figure 6.4 – Principal component analysis plots for frailty separated by surgical risk score. 
The plots demonstrate similarity in frailty measures (arrows showing the direction of 
variables are similar), but failure of separation of those with high (≥4%) and low (<4%) 
estimated surgical risk by STS score (A) and EuroSCORE (B).   
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6.4.4 RELATIONSHIP WITH QUALITY OF LIFE 
Both frailty and surgical risk tools demonstrated lower physical component quality of life 
scores in those with greater frailty or estimated surgical risk (Table 6.4). Frailty determined 
by Fried, SPPB and EFS tools identified patients with lower mental component scores, 
where no relationship was observed using the surgical risk calculators.  
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Table 6.4 – SF-12 physical and mental component scores 
  
 PCS p-value MCS p-value 
Fried Frail 28.3 ± 8.4 <0.001 46.7 ± 10.8 <0.001 
 Not frail 37.7 ± 9.6  52.2 ± 8.7  
SPPB Frail 29.8 ± 8.6 <0.001 48.2 ± 10.2 0.004 
 Not frail 39.1 ± 9.8  52.3 ± 9.1  
EFS Frail 26.6 ± 7.1 <0.001 43.0 ± 10.4 <0.001 
 Not frail 37.0 ± 9.8  52.7 ± 8.3  
CFS Frail 28.5 ± 8.6 <0.001 48.0 ± 11.5 0.09 
 Not frail 36.4 ± 10.0  51.0 ± 9.1  
STS Score Above median 32.5 ± 9.6 0.02 50.6 ± 9.6 0.50 
 Below median 35.9 ± 10.6  49.6 ± 10.2  
EuroSCORE Above median 31.4 ± 9.3 <0.001 50.7 ± 9.8 0.42 
 Below median 37.0 ± 10.4  49.5 ± 10.0  
Values are mean ± standard deviation of Physical Component Score (PCS) and Mental 
Component Score (MCS) from the SF-12 questionnaire. P-value determined by unpaired 
two-sided T-test. The not frail group includes pre-frail patients. 
SPPB = Short Physical Performance Battery; EFS = Edmonton Frail Scale; CFS = Clinical 
Frailty Scale.  
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6.5 DISCUSSION 
This study has assessed frailty, surgical risk scores and quality of life in older patients with 
moderate-severe aortic stenosis and produced several relevant observations. First, four 
different frailty tools demonstrated moderate agreement in the determination of frailty, 
although prevalence varied from a quarter to half of the study population depending on the 
tool used. Second, frailty was unrelated to the age of patients or severity of aortic valve 
disease. Third, frailty assessment identified patients with poorer physical and mental 
wellbeing. Fourth, the group of patients identified as frail by fixed thresholds were observed 
to have higher surgical risk by STS and EuroSCORE estimates. However, considering frailty 
as a continuous variable showed separation from surgical risk estimates by principal 
component analysis. Future studies including outcomes after aortic valve replacement are 
required to establish if this observed divergence between frailty and existing surgical risk 
estimates is meaningful for the improved prediction of outcomes after surgery. 
 
The disparate number of frailty tools makes research in this area challenging. We focussed 
on four measures that could be rapidly performed with potential for inclusion in busy clinical 
environments. Indeed, evaluation of all four frailty scores was achievable within 10 minutes 
per patient. The physical frailty phenotype described by Fried et al. was included given the 
extensive validity for risk estimation in a diverse range of surgical settings.119,207,208 
However, this measurement includes use of a hand-grip dynamometer which may limit 
adoption into widespread practice. Further, the validity of the self-reported exhaustion 
component of the Fried phenotype has been questioned.209  
 
There was variation in the numbers identified as frail using each tool. The SPPB, as the most 
physically demanding test identified over half of patients as frail, which may reflect the 
degree of physical limitation incurred in patients with advanced aortic valve disease. Indeed, 
physical component scores from the SF-12 questionnaire were low across the study 
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population, with 96% of aortic stenosis patients demonstrating composite physical scores 
lower than the median value for a UK population.210 In contrast, the impairment in mental 
component scores was less marked, but still meaningfully lower in those with physical frailty 
and aortic stenosis.  
 
The variation in numbers identified as frail is likely the result of forced dichotomisation 
using thresholds that have not been validated between tools. The agreement between frailty 
measures and common variable direction observed by principal component analysis supports 
a class effect and shows the value of considering frailty as a continuous marker. This shared 
effect appears distinct from the STS and EuroSCORE prediction, even though at a 
superficial level, increasing surgical risk is observed in those with frailty across all measures. 
Dichotomisation into a frail state using potentially arbitrary thresholds is frequently desirable 
by clinicians, but may limit the value of the holistic frailty assessment undertaken. 
Systematic reviews of outcome prediction in this area have demonstrated limited 
standardisation of frailty measures, failure to test frailty inclusion within the STS or 
EuroSCORE models and a lack of calibration testing.211-213 All patients exist on a spectrum 
of frailty and meaningful outcome prediction should be undertaken through continuous 
modelling including STS and EuroSCORE estimates to test for the additive effect of frailty.  
 
The data collected also provided an opportunity to assess the agreement of STS and 
EuroSCORE risk estimates in an older population with aortic stenosis. Whilst there was 
good correlation between these scores, EuroSCORE appeared to outweigh the STS estimate 
at higher risks. This is similar to findings from Kirmani et al. who described a divergence in 
the scores at >15% EuroSCORE operative mortality risk.214 Others have noted the 
procedure-specific risk modelling on the STS platform results in a more refined prediction 
than the broader EuroSCORE model that groups all non-cardiac bypass grafting procedures 
together.215 
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The strong relationship between frailty measures and quality of life indicators highlights an 
important consequence of living with frailty for older adults. This must not be overlooked in 
the assessment of a frailer patient for whom quality of life may take precedence over 
quantity. The challenge for a multidisciplinary heart team is to determine whether any 
impairment in physical and mental wellbeing is driven by symptomatic aortic stenosis with 
potential for reversibility following valve replacement. In such patients, accepting a ‘higher 
risk, higher reward’ strategy may be appropriate, but patients should be included in shared 
decision making. The SF-12 questionnaire provides some objectivity to the challenging 
assessment of general wellbeing in the research setting. However, results must be interpreted 
with some caution; the tool assumes physical and mental health scores are independent and 
uncorrelated when in reality an impairment in one domain is likely to affect the other.216 
 
6.5.1 LIMITATIONS 
There are several limitations to this study. Without surgical outcomes, it is currently unclear 
if the observed differences between frailty measures and surgical risk estimates are 
meaningful. The cohort is also small in comparison to those that were used to derive surgical 
risk tools, but the patients included are thoroughly characterised and with multiple measures 
of frailty not usually collected in routine clinical care.  
 
Despite the high prevalence of frailty, few patients were at very high surgical risk. In the 
original PARTNER trial comparing conservative medical management to TAVI, patients 
were only considered suitable for randomisation with estimated STS operative mortality 
>10%.27 Despite including 105 patients under direct assessment for TAVI, only 2 individuals 
in our cohort met this criterion. This is likely to reflect the changing risk profile of TAVI 
patients and increasing acceptance of the procedure for patients previously considered at 
intermediate risk. Indeed in the latest ESC guidelines, a decision for TAVI over conventional 
surgery is supported in those with STS or EuroSCORE II predicted operative mortality 
≥4%.217 This is reflects randomised trial evidence suggesting non-inferiority for TAVI when 
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compared to conventional surgical AVR in lower risk groups.218 The STS calculator estimate 
is frequently updated to include the latest surgical outcomes data, which continue to improve 
with time; one study demonstrated that 58% of patients determined as high-risk in 2008 
would be reclassified as intermediate risk on the latest version of the calculator used in this 
study.219 It is therefore likely that patients included in this study and assessed against the 
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6.6 CONCLUSIONS 
In a population of older patients with moderate to severe aortic stenosis, frailty assessments 
are feasible and show moderate agreement. While frail patients have higher surgical risk 
scores, deeper analysis suggests differences in the information captured by frailty measures 
and both the STS and EuroSCORE. Increasing frailty is also associated with poorer physical 
and mental wellbeing in this patient group. Evaluation including outcomes after surgical 
intervention is now needed to understand if these frailty measures hold value beyond 
conventional risk calculators to improve prediction of outcomes for patients with aortic 
stenosis.  
  












CONCLUSIONS AND FUTURE DIRECTIONS 
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 SUMMARY OF THESIS FINDINGS 
Aortic stenosis is a condition that commonly affects older adults. In the absence of lifestyle 
or pharmacological methods of ameliorating unpredictable disease progression, complex 
cardiac intervention has remained the mainstay of treatment for over 50 years. Even in the 
age of less invasive transcatheter valve implantation, the risks of complications have steered 
guidelines against valve replacement unless necessitated by the development of symptoms of 
syncope or heart failure. This makes the accurate diagnosis of symptomatic aortic stenosis 
crucial to the management of these patients. However, in an increasingly aged population, 
the establishment of symptoms independent of the expression of multimorbidity is 
challenging. Furthermore, these comorbidities result in frailer candidates for surgery, where 
the balance between operative risks and functional benefit is less clearly discernible. 
 
The core aims of this thesis were to first investigate the validity of novel blood biomarkers as 
candidate objective markers of disease progression in older patients with aortic stenosis. 
Second, in those considered for aortic valve replacement, this thesis aimed to assess frailty as 
a predictor of outcomes after surgery, and to compare this with existing risk assessment 
tools.   
 
7.1.1 CMYC AS A NOVEL MARKER OF MYOCARDIAL INJURY AND FIBROSIS  
It was hypothesised that cMyC as a novel biomarker of myocardial injury would predict 
progression of aortic stenosis and outcomes. To test this, cMyC was measured in stored 
serum from 265 patients with aortic stenosis and 46 healthy controls, across two cohorts 
designed to test mechanistic disease progression and outcomes.220 Rising cMyC 
concentrations were independently associated with increasing left ventricular mass and 
markers of myocardial fibrosis on MRI imaging after adjustment for age, sex, renal function, 
severity of aortic stenosis, cardiac troponin and comorbidity. There was also an unadjusted 
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association with all-cause mortality over 11 years of follow-up. These results add to 
previously conducted experiments with cardiac troponin and together suggest a role for the 
measurement of cardiac sarcomeric proteins in the objective assessment of the progression of 
disease in aortic stenosis. 
 
However, it must be noted that measurement of cMyC only occurred at a single timepoint 
and therefore this study does not yet truly validate this test as a tracking biomarker of 
disease. Furthermore, the outcomes analysis was limited by sample size and was unpowered 
to demonstrate any independent effect of cMyC. These findings would be enhanced by more 
observations in patients with severe disease, in whom sufficient endpoint events would 
accumulate closer to the time of blood sampling. 
 
7.1.2 VARIABILITY OF BLOOD BIOMARKERS IN OLDER PATIENTS WITH AORTIC STENOSIS 
To use a blood biomarker monitoring strategy, clinicians would require confidence that 
changes in observed blood concentrations overcome natural biological variation in an 
individual and the limits of analytical variation of sample processing. It was hypothesised 
that three candidate biomarkers, namely cardiac troponin, BNP and galectin-3, would 
demonstrate satisfactory variability in older adults with aortic stenosis to make clinical 
monitoring by serial sampling feasible. To test this, 14 older subjects with stable moderate-
severe aortic stenosis underwent repeated blood sampling at hourly and weekly intervals, 
with assay testing occurring in both fresh and frozen samples. 
 
All biomarkers could be detected at all timepoints in every subject with a low index of 
individuality confirming the requirement for serial sampling. Fresh and frozen sampling was 
comparable for galectin-3 and cardiac troponin, providing some reassurance as to the 
validity of previous analyses of these biomarkers in stored samples from clinical trials. 
However, BNP proved unstable with significant degradation after a single freeze-thaw cycle; 
this biomarker only appears suitable for analysis in fresh blood.  
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Compared to other studies in healthy controls, analytical variation was lower for all three 
biomarkers, reflecting higher median concentrations in older patients with aortic stenosis. 
However, biological variation did not appear significantly different from findings in other 
cohorts, resulting in reference change values between serial samples for cardiac troponin and 
BNP (42% and 55% respectively) that were lower than in equivalent studies of healthy 
controls and patients with heart failure. Using these lower RCV thresholds in older patients 
with severe aortic stenosis could appropriately improve the sensitivity of testing for disease 
progression, by reducing the false negative rate for significant change between serial 
samples. However, it is important to acknowledge that these biomarkers still require 
validation as clinical tools and that the variability study only provides information on the 
statistical likelihood of serial measures being significantly different. 
 
7.1.3 FRAILTY MEASUREMENT IDENTIFIES PATIENTS AT HIGH RISK AFTER TAVI 
The hypothesis here was that pre-operative frailty would predict important patient outcomes 
including mortality after TAVI. This was investigated by systematic review and meta-
analysis, which included ten relevant cohort studies of 4,592 patients who underwent TAVI 
with a prior formal assessment of frailty. Frailty was associated with increased early and late 
mortality after the procedure, particularly when identified using an objective measure such a 
determination of the frailty phenotype or deficit accumulation via a frailty index approach.205 
Subjective or ‘end-of-the-bed’ assessment did identify mortality risk, but to a lesser extent. 
The importance of this finding is emphasised by guidelines suggesting that candidate 
patients for TAVI should have an expected life expectancy beyond one year after the 
procedure3; the meta-analysis suggests that 1 in 4 patients included in these studies died 
within that period. The latest European guidelines acknowledge the lack of evidence in this 
area, stating that: 
 
“criteria for when TAVI should no longer be performed since it  
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would be futile need to be further defined.” 217 
 
A further finding of this systematic review was a lack of reporting of non-mortality 
outcomes in relation to frailty. This could be addressed through the inclusion of frailty 
assessment within existing TAVI registries. 
 
7.1.4 FRAILTY TOOLS AND DIVERGENCE WITH SURGICAL RISK SCORES 
It was hypothesised that frailty measures would identify markers not captured by 
conventional surgical risk scores in an older population with aortic stenosis. This was tested 
in two cohorts totalling 185 patients with moderate-severe aortic stenosis, who underwent 
frailty testing to calculate individual Fried, SPPB, EFS and CFS scores. These tools proved 
feasible and quick to perform in this population. Using accepted dichotomised thresholds for 
frailty, agreement between these scores was moderate with frailty varying between 27–53% 
of the study population according to the tool used. Frail patients also had higher STS and 
EuroSCORE estimated operative risk from conventional aortic valve replacement, and lower 
physical and mental components scores on the SF-12 quality of life questionnaire. However, 
analysis of frailty as a continuous measure suggested divergence with surgical risk scores. 
An analysis including outcomes after valve replacement is required to fully determine any 
additional value of these frailty scores beyond STS and EuroSCORE estimates in the 
prediction of harmful outcomes after surgery. 
 
Taken together these four chapters have assessed the emerging role for blood biomarkers and 
frailty assessments in older patients with aortic stenosis. Serum sarcomeric proteins offer 
potential to non-invasively track important markers of disease progression, by indirect 
measurement of myocyte necrosis and replacement fibrosis. Cardiac troponin, BNP and 
galectin-3 are quantifiable in an older aortic stenosis population and demonstrate a clear 
requirement for serial sampling to detect significant change above defined reference change 
values. Frailty is associated with early and late mortality after TAVI, particularly in those 
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who are identified using an objective tool. Some of this risk is already explained within STS 
and EuroSCORE risk estimates, but specific frailty measures may identify additional patient 
factors that merit further evaluation.   
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7.2 FUTURE DIRECTIONS 
The findings of this thesis raise important potential uses of clinical biomarkers in older 
patients with aortic stenosis that now warrant further investigation. The following sections 
describe ongoing, planned or suggested future studies to better understand the role of non-
invasive testing to improve decision-making in this patient group. 
 
7.2.1 SERIAL BIOMARKER MEASURES IN AORTIC STENOSIS 
Having observed the potential importance of serum sarcomeric proteins as markers of 
disease progression and demonstrated the need for serial testing, it is now crucial for 
prospective studies to assess this. I am leading a prospective observational cohort study 
entitled Cardiac biOMarkers in older Patients with Aortic StenosiS (COMPASS), collecting 
serial blood samples from patients with asymptomatic moderate-severe aortic stenosis before 
any clinical decompensation (Figure 7.1).  
 
A total of 80 patients are due to be recruited to this study, with the expectation that half will 
decompensate to the point of symptoms within 18 months. This is based on prior 
observational studies in this area.2 The outcome measure will be a composite of 
hospitalisation with heart failure, elective or urgent aortic valve replacement for new 
symptoms of heart failure, cardiovascular death, or echocardiographic evidence of new left 
ventricular systolic impairment. Early symptomatic decline will also be assessed in 6 
monthly measures of function using a 6 minute walk test, which is well validated as a 
measure in this patient population221,222, and the Kansas City Cardiomyopathy 
Questionnaire.223  
 
It is anticipated that increases in markers of myocardial necrosis, such as cardiac troponin or 
cMyC, will occur before left ventricular decompensation is evident clinically or detectable 
through changes in BNP. Significant change in serial testing will be determined by the 
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thresholds defined in Chapter 4 of this thesis. This study will prospectively determine 
whether biomarker assessment of the myocardial response to aortic stenosis could identify 
patients with functionally significant valve disease prior to the development of symptoms. 
The growing body of evidence relating to irreversibility of myocardial fibrosis has led to 
another ongoing trial randomising patients with asymptomatic aortic stenosis and myocardial 
fibrosis to early or late valve replacement (clinicaltrials.gov NCT03094143). Should this 
strategy prove effective in preserving post-surgery ventricular function, early blood 
biomarkers of the destructive path to fibrosis would be attractive screening tests for detailed 








Figure 7.1 – Schematic for the serial sampling protocol of the Cardiac biOMarkers in older 
Patients with Aortic StenosiS (COMPASS) study  
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7.2.2 ADDITIONAL BIOMARKER STUDIES 
This thesis has focussed on cMyC and cardiac troponin as markers of myocardial injury, 
BNP as a natriuretic peptide measure of ventricular wall stress and galectin-3 as a marker of 
fibrosis. However, there are further blood biomarkers that may be of interest in aortic 
stenosis. ST-2 is a member of the interleukin-1 receptor family and is secreted by 
mechanically overloaded cardiomyocytes into the circulation. It is therefore a marker of 
early ventricular failure but appears to provide additional risk prediction information beyond 
BNP in the setting of myocardial infarction.224,225 In a small study in aortic stenosis, soluble 
serum ST-2 concentrations were independently predictive of future cardiovascular events 
and only modestly correlated with BNP levels.226  
 
Growth differentiation factor 15 (GDF15) is involved in inflammatory and apoptotic 
pathways as part of the transforming growth factor superfamily. Circulating concentrations 
of this biomarker are increased when cardiomyocytes undergo biomechanical stress such as 
the pressure overload of decompensating aortic stenosis.227 GDF15 levels also appear 
predictive of mortality in aortic stenosis and outcomes after TAVI.228,229 
 
It would appear that both ST-2 and GDF15 are biomarkers of potential interest in aortic 
stenosis and complementary to those examined within this thesis. A logical future extension 
of the proposed COMPASS programme would include measurement of these promising 
novel biomarkers within stored sample to assess any value beyond existing clinical 
assessment and surgical risk scores. 
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7.2.3 BIOMARKER CHANGES AFTER AORTIC VALVE REPLACEMENT 
Biomarkers of myocardial injury may also hold predictive value after aortic valve 
replacement. In studies of mixed cardiac surgery including valve replacement, post-operative 
cardiac troponin is an independent predictor of mortality.230,231 I am a local co-investigator 
for the ongoing VISION Cardiac Surgery study, which will further inform the significance of 
this relationship in 15,000 patients undergoing cardiac surgery across the world 
(clincaltrials.gov NCT01842568). It is plausible that the kinetics of myocardial injury 
biomarker release and recovery following valve replacement may inform the likelihood of 
symptomatic improvement.  
 
As shown in Chapter 3, serum cMyC concentrations in aortic stenosis are related to left 
ventricular mass, a finding that has also been demonstrated using cardiac troponin.88 
Successful replacement of a stenotic aortic valve relieves afterload and should facilitate 
remodelling of the left ventricle with regression of hypertrophy. This would be expected to 
be accompanied by reductions in markers of wall stress (such as BNP) and myocardial injury 
(such as cardiac troponin and cMyC). However, adverse remodelling has been recognised in 
a subgroup of patients with poorer recovery after aortic valve replacement.232 This may be 
related to a variety of factors including post-operative blood pressure control and 
ethnicity.233,234 
 
An extension of the COMPASS study outlined above may provide further evidence in this 
area. In an exploratory pilot study in those who undergo aortic valve replacement, early 
perioperative measures of cardiac blood biomarkers including cMyC, cardiac troponin and 
BNP may help understand the significance of perioperative injury and stress on cardiac 
recovery. A further measure at 6 months combined with repeated functional testing and 
echocardiography would inform the relationship between circulating cardiac biomarkers and 
ventricular remodeling. A proposed outline of such a study is shown in Figure 7.2.   




Figure 7.2 – Schematic for a study of serial cardiac biomarker changes before and after aortic 
valve replacement (AVR)   
Clinical biomarkers in older patients with aortic stenosis 185 
7.2.4 VARIABILITY OF NOVEL BLOOD BIOMARKERS 
Chapter 4 of this thesis reported the analytical and biological variability of cardiac troponin, 
BNP and galectin-3 in older patients with aortic stenosis. Given the findings of Chapter 3 
and the potential utility of cMyC in these patients, an extension of this research would 
include assessment of the variability of cMyC. This could be completed in currently stored 
sample to define the parameters reported for the other biomarkers. Given the ten-fold greater 
abundance of cMyC compared to cardiac troponin92, it would be expected that 
concentrations in the same patient group may be further from the assay LoD and therefore 
subject to lower analytical variation. If the release and turnover of both cardiac troponin and 
cMyC are similar in aortic stenosis given their shared sarcomeric lineage, it would be 
expected that both assays would have similar biological variability. It is therefore plausible 
that cMyC may have a smaller RCV than cardiac troponin, given the expected lower 
analytical variability, and be more sensitive to meaningful change in this patient group. 
 
7.2.5 FRAILTY IN RELATION TO OUTCOMES AFTER AORTIC VALVE REPLACEMENT 
In older patients who are candidates for aortic valve replacement, frailty assessment captures 
patient factors that appear distinctive from components of existing surgical risk scores 
(Chapter 6). As identified by multiple systematic reviews211-213, there is currently a lack of 
high quality statistical modelling using the STS or EuroSCORE with addition of robust 
frailty measurement. This would truly test the potential of frailty measures and answer 
whether the additional time and effort required to collect these data add predictive value. 
Such an approach acknowledges that frailty exists on a spectrum and allows analysis free 
from forced dichotomisation into a frail state using arbitrary thresholds. The cohort 
presented in Chapter 6 have been robustly characterised for frailty and will be followed to 
collect important outcomes data for such an analysis. 
 
The study presented focussed on physical frailty and determination of the phenotype through 
measures not normally collected even within geriatric clinical environments. However, 
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similar assessment measures have been successfully included in Proactive care of Older 
People undergoing Surgery (POPS) clinics.173,235 Such an approach acknowledges that frailty 
measurement offers risk stratification as discussed within this thesis, but also an opportunity 
to proactively address modifiable risks identified by comprehensive geriatric assessment. 
This approach has been shown to reduce operative complications, delirium and length of stay 
in a randomised controlled trial in vascular surgery.236   
 
An alternative approach to frailty assessment reflects the accumulation of health deficits to 
generate a frailty index. The recent work of Clegg et al. has utilised routine healthcare data 
to generate such an electronic frailty index (eFI) from primary care read codes.112 This score 
is highly predictive of hospitalisation, loss of independence and mortality in a community 
population. Such a ‘big data’ approach allows frailty to be measured in all patients, with 
minimal additional costs and no requirement for face-to-face assessment. This may be an 
attractive approach for stretched surgical clinics, although the validity of this risk score in 
relation to postoperative outcomes has not yet been demonstrated. For example, primary care 
data may be relatively insensitive to change in the presence of rapidly progressing 
symptomatic aortic stenosis. However, the ability to generate an eFI score at scale should 
allow large cohort testing of this measure within existing registries where preoperative 
surgical risk scores and outcomes have already been collected. 
 
7.2.6 UNDERSTANDING TRAJECTORIES OF FRAILTY 
While observational studies including baseline frailty measures in surgical cohorts are 
numerous, longitudinal studies to understand the trajectory of frailty after intervention are 
uncommon. This is critical to understanding predictors of meaningful gain after surgery. It is 
plausible that in a frail patient with multisystem decline, valve surgery to reverse the 
deleterious effects of aortic stenosis will not improve underlying frailty. This may at least 
partly explain the observation of 1 in 4 patients dying within 12 months of TAVI (Chapter 5) 
and a failure to meet patient expectations for improvement amongst some survivors. To 
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understand these trajectories of frailty, detailed studies are required before and after surgery 
(Figure 7.2).  
 
As suggested in Figure 7.1, it would also be important to quantify the change in frailty 
markers over time in patients with severe aortic stenosis in the absence of surgery. If patient 
frailty is being driven by the consequences of severe aortic stenosis, for example through the 
effects of early left ventricular decompensation or development of syncopal symptoms, it is 
plausible that aspects of frailty may be reversed by aortic valve replacement. This 
phenomenon is anecdotally observed following successful cardiac surgery but has not been 
objectively demonstrated. A recent systematic review by Kim et al. identified no studies in 
cardiac surgery that measured frailty pre-operatively and again at least 6 months after 
surgery.213 There is a clear need to address this gap in knowledge to improve understanding 
and informed decision making in this potentially vulnerable patient group. 
 
Measuring frailty may therefore help guide aortic stenosis patients towards three broad 
treatment strategies. First, a group without frailty in whom surgical risk is considered low 
and the decision to intervene with surgery or TAVI is clear. Second, a group with presumed 
severe irreversible frailty and high perceived surgical risk in whom the benefits of 
intervention are likely to be outweighed by the surgical risks. Finally, a third group with 
intermediate surgical risk and/or some frailty markers who require further detailed 
assessment prior to surgery.  
 
It is possible that blood biomarkers of aortic stenosis progression hold the most value in this 
latter group. In the absence of progressive elevation of biomarkers of myocardial injury, 
ventricular wall stress or fibrosis, it could be hypothesised that any frailty and symptoms 
observed are independent of aortic stenosis and would be unlikely to improve with valve 
replacement. It is plausible that a proportion of patients will have such irreversible frailty 
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and will be liable to the complications of cardiac intervention without scope to improve their 
wellbeing due to overwhelming intrinsic non-cardiac disease driving the frail state. 
 
In contrast, in a frail patient with progressive blood biomarkers of disease, the risks of 
intervention may be worth considering to improve symptoms; this may be described as the 
‘high risk, high reward’ strategy. As such, measurement of frailty and blood biomarkers of 
disease progression hold potential for more individualised assessments of risk, providing 
objective evidence to help patients, families and clinicians make balanced judgements. In a 
‘high risk, low reward’ patient group, such measures could also strongly challenge the 
rationale for invasive interventions. The recently launched NHS Scotland ‘Realistic 
Medicine’ initiative has brought such concepts to the heart of clinical practice, with 
acceptance of the need to assess the “point of optimality” between benefits and harms of any 
healthcare intervention.237 
 
7.2.7 CLINICAL PERSPECTIVE OF FRAILTY 
For many the term ‘frailty’ carries stigma with negative connotations. In a survey of older 
adults performed by Age UK and the British Geriatric Society, the term was not well 
received with few participants self-identifying as frail. 238 This was related to a perception 
that the term implied an “irreversible state” with loss of independence, dignity and control 
over body functions. However, the challenges that frail people experience in everyday life 
were well recognised by respondents. Ultimately, direct use of the term frailty may not be 
helpful in a patient interaction, but discussion around the risks related to the expression of 
the frail state are likely to be highly relevant.  
 
It is important that any research involving frailty includes patients’ views as the aims must 
be to improve individualised or person-centred care. Qualitative research such as the survey 
described above must feed into quantitative research. For example, within this thesis, 
outcome measures for aortic valve disease have been discussed, but defining a suitable 
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endpoint for trials involving frail older adults is challenging. Does quality of life outweigh 
longevity? Does the burden of tablets and time spent in hospital outweigh small but 
statistically significant improvements in functional measures? Meaningful benefit from any 
intervention is a challenging entity and may lack the rigor of a so-called ‘hard’ endpoint such 
as all-cause mortality. Perception of benefit may vary between individuals for reasons as 
diverse as mood, cognitive function, values and prior expectations. Minimal Clinically 
Important Differences (MCID) provide some rigor to assessment of change in markers but 
are usually based on meaningful statistical change or the consensus view of an expert 
panel.239 These attributes have some value in improving endpoints for trials including older 
people, but further involvement of patients in study design is a clear future direction in this 
area.  
 
In 1999, Bowling commented on ageism in cardiac care.240 While these attitudes may have 
declined in the last two decades, some have argued that frailty is a modern equivalent to 
ration treatments. However, this characterisation neglects the potential benefits of holistic 
assessment for an older adult. Further, including frailty assessment in routine care identifies 
patients who are surprisingly robust, who may otherwise have been considered at higher risk 
of poor outcomes due to the bias of subjective assessment. For healthcare professionals, 
frailty offers a language to communicate risk that is independent of age. It is therefore 
critical that this professional assessment is based on objectivity and careful measurement. 
 
7.2.8 SARCOPENIA 
Whilst this thesis has focussed on frailty, sarcopenia is a related state that refers to the loss of 
skeletal muscle mass and function.241 The European Working Group on Sarcopenia in Older 
People (EWGSOP) definition requires objective evidence of loss of muscle mass, together 
with either reduced muscle strength or performance. Whilst physical frailty measures such as 
the Fried phenotype include grip strength and gait speed for strength and performance, these 
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do not include measures of muscle mass.107 This requires more specialist equipment such as 
dual energy X-ray absorptiometry (DEXA), computerised tomography, magnetic resonance 
imaging or bioimpedance analysis.242 This requirement has limited the adoption of 
sarcopenia measurements in clinical practice; even the EWGSOP guideline suggest case-
finding through strength and performance measures to limit diagnostic muscle mass 
measurement to a smaller numbers of older adults. Muscle mass may also not add 
significantly to prognostication beyond measures of muscle strength and performance, which 
may question the value of the additional resources required to define sarcopenia.  
 
However, while many individuals with frailty will have evidence of sarcopenia, due to 
broader and varied definitions, frailty may occur in the absence of physical deterioration 
through health deficits and cognitive decline.243 Sarcopenia is therefore a more precise term 
focusing solely on physical muscle health. For example, in a community cohort study of over 
80 year old adults in Belgium (BELFRAIL), sarcopenia was only observed in 12.5% by 
EWGSOP criteria. However, 56% of the cohort demonstrated muscle weakness by grip 
strength and 61% impaired muscle performance by low SPPB score.244 The specificity of 
sarcopenia is attractive for targeted interventions and there is some evidence of the ability to 
improve and reverse the process with resistance muscle training.245,246 There has been further 
interest in the role of nutritional supplementation and pharmacological therapy including 
angiotensin-converting enzyme (ACE) inhibitors, which are subject to ongoing randomised 
controlled trials.247,248 
 
Resistance exercise training is challenging in a patient developing heart failure secondary to 
decompensated aortic stenosis. However, should non-exercise based interventions prove 
successful in improving sarcopenia, this could open new avenues for the optimisation of the 
perioperative patient. Extending the work of the thesis to include measures of muscle mass 
before and after aortic valve replacement would inform the burden of disease-related 
sarcopenia and its response to alleviation of aortic stenosis.   
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7.3 CONCLUSIONS 
This thesis has explored the components of a future holistic approach to older patients with 
aortic stenosis– where blood biomarkers reveal functionally significant aortic valve disease, 
and frailty biomarkers refine surgical risk assessment and inform shared decision making. As 
currently described, frailty is a nebulous term with numerous measures that may lack the 
objectivity of blood biomarkers, but the variables that are included in frailty assessment are 
likely to be highly relevant to the likelihood of patient benefit from aortic valve replacement. 
Combining blood biomarkers of disease related risk, frailty biomarkers of surgical risk and 
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APPENDIX I: FRAILTY QUESTIONNAIRE 
 
Combined questionnaire for completion of patient-reported components of the Fried, EFS 






Please answer the questions by ticking the relevant boxes.  
 
1. In the past year, how many times have you been admitted to hospital? 
 
NO ADMISSIONS  1-2 TIMES  3 OR MORE TIMES 
 
 
2. In general, how would you describe your health? 
 
EXCELLENT   VERY GOOD   GOOD 
 
FAIR    POOR 
 
 
3. With which of the following activities do you require help (tick all that apply)? 
 
MEAL PREPARATION SHOPPING   TRANSPORTATION 
 
USING THE TELEPHONE HOUSEKEEPING   DOING LAUNDRY 
 
MANAGING MONEY TAKING MEDICATIONS  Total ______ 
 
 
4. When you need help, can you count on someone who is willing and able to support your 
needs? 
 
ALWAYS   SOMETIMES   NEVER 
 
 
5. Do you use 5 or more different prescription medications on a regular basis? 
 
YES    NO 
 
 
6. At times, do you forget to take your prescription medications? 
 
YES    NO 
 
 
7. Have you recently lost weight such that your clothing has become looser? 
 
YES    NO 
 
 
8. Have you unintentionally lost more than 10lbs (4.5kg) in weight in the last year? 
 
YES    NO 












9. Do you often feel sad or depressed? 
 
YES    NO 
 
 
10. Do you have a problem with losing control of urine when you don’t want to go? 
 
YES    NO 
 
 
11. a) I felt that everything I did was an effort in the last week: 
 
RARELY or NONE OF THE TIME (<1 day) 
 
SOME or A LITTLE OF THE TIME (1-2 days) 
 
MODERATE AMOUNT OF THE TIME (3-4 days) 
 
MOST OF THE TIME (>4 days) 
 
 
b) I could not get going in the last week: 
 
RARELY or NONE OF THE TIME (<1 day) 
 
SOME or A LITTLE OF THE TIME (1-2 days) 
 
MODERATE AMOUNT OF THE TIME (3-4 days) 
 
MOST OF THE TIME (>4 days) 
 
 
These next questions ask for views about your health and activities. Please answer each 
question by choosing just one answer. If you are unsure how to answer a question, please 
just give the best answer you can. 
 
1. The following questions are about activities you might do in a typical day. Does your 
health now limit you in these activities. If so, how much? 
 
Moderate activities (e.g. moving a table, pushing a vacuum cleaner, playing bowls or golf)? 
 
YES, limited a lot  YES, limited a little  NO, not limited at all 
 
Climbing several flights of stairs? 
 
YES, limited a lot  YES, limited a little  NO, not limited at all 
 






2. During the past 4 weeks, have you had any of the following problems with your regular 
daily activities as a result of your physical health?  
 
Accomplished less than you would like?   YES  NO 
 
Were limited in the kind of activities you could do?  YES  NO 
 
 
3. During the past 4 weeks, have you had any of the following problems with your regular 
daily activities as a result of any emotional problems (such as feeling anxious or 
depressed)?  
 
Accomplished less than you would like?   YES  NO 
 
Did work less carefully than usual?    YES  NO 
 
 
4. During the past 4 weeks, how much did pain interfere with your normal activities? 
 
Not at all A little bit Moderately Quite a bit Extremely  
 
 
5. These questions are about how you have been feeling during the past 4 weeks. 
For each question please give the one answer that comes closest to how you are feeling. 
 
How much of the time during the past four weeks… 
 
 All Most  A good bit Some A little None  
 
…have you felt calm  
and peaceful? 
 
…did you have a lot  
of energy?  
 




6. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives etc.)? 
 
All of the time   Most of the time  Some of the time  
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APPENDIX II: MYOCARDIAL BIOPSY AND HISTOLOGICAL ANALYSIS 
 
This analysis was undertaken by Dr Jacek Kwieciński and is detailed in the Supplementary 
Material of the published manuscript (Anand A et al. Heart. 2018;104:1101–1108).  
 
Tissue Sampling 
At the time of open heart surgery myocardial biopsies were obtained from the basal segment 
of the septum using a Tru-Cut needle biopsy gun. In order to minimise the chance of missed 
biopsies at least two samples per patient were collected. Immediately after collection, tissue 
was placed in buffered 10% formalin and subsequently embedded in paraffin. 
 
Tissue processing 
For apoptosis 7µm thick sections were deparaffinised in xylene, rehydrated through a graded 
series of alcohols and subsequently the DeadEndTM Fluorometric TUNEL System 
(Promega Co, US) was applied according to the manufacturer’s guidelines. The system 
labels fragmented DNA which is a hallmark of apoptosis. After cell membrane 
permeabilisation the 3’ OH ends of the cleaved DNA multimers were “tailed” with labelled 
fluorescin-12-dUTP by the Terminal Deoxynucleotidyl Tranferase enzyme. In addition all 
specimens were stained with 4,6-diamidino-2-phenylindole (DAPI) to adequately visualise 
nuclei which was necessary for proper image analysis.  
 
For autophagy and oncosis formalin-fixed, paraffin-embedded 4µm thick tissue sections 
were cut. Slides were dried for 24 hours in a 45oC oven, deparaffinised in xylene and 
rehydrated through a graded series of alcohols. Slides were then loaded into a Celerus 
Riptide de-cloaking chamber (Celerus Diagnostics Carpinteria, CA , United States) where 
heat-induced epitope retrieval was performed using Novocastra Epitope Retrieval solution 
Ph6 (Leica Microsystems GmbH, Ernst-Leitz-Straße, Wetzlar, Germany).  Slides were then 
loaded onto Leica Bond-Max automated immunostainer (Leica Microsystems GmbH, Ernst-
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Leitz-Straße, Wetzlar, Germany). For autophagy and oncosis ubiquitin and C9 mouse 
monoclonal antibodies at 1:3000 and 1:2000 dilution (Life Technologies, Carlsbad, CA, 
United States and AbD Serotec, Kidlington, Oxford, UK respectively) were applied to 
sections at room temperature for 2 hours. The specificity of these antibodies was verified by 
omission. The presence of antigen was visualized using a 3,3’-diaminobenzidine (DAB) 
based Bond Polymer refine detection kit (Leica Microsystems GmbH, Ernst-Leitz-Straße, 
Wetzlar, Germany). Slides were counterstained using haematoxylin (in order to enable 
nuclei identification), removed from bond max, dehydrated, cleared and mounted with 
permanent mounting media (Pertex). 
 
Histological image analysis 
The TUNEL stained tissue samples were analysed using confocal microscopy with FITC and 
UV filter cubes. All measurements have been performed using 40x objectives. Apoptotic 
cells (co-positive for both DAPI and TUNEL) were counted manually on entire tissue 
sections.  The total cell number present on each slide was derived from two sets of data: the 
total sample area and the number of cells positively stained with DAPI which was evaluated 
manually in three random areas of interest. Eventually the number of apoptotic cells was 
expressed as a percentage of the total cell number. 
 
All C9 and ubiquitin stained slides images were acquired on the AxioScan Z1 (Carl Zeiss, 
Oberkochen, Germany) and analysed using Image-Pro Premiere 9.1 (MediaCybernetics, 
Rockville, MD, USA). In the first step the number of oncotic/autophagic cells was calculated 
using the counting toll after manual protocol adjustment. Cut off values of signal intensity, 
object size (area) and a roundness criterion was used to distinguish myocytes positively 
stained with DAB from artefacts. For Oncosis a pixel intensity of 0-163 on the Mono scale 
together with an object area range of 400-3000 square pixels and roundness criterion of 1-1.7 
was applied. For autophagy the settings were as follows: a pixel intensity of 0-60 and an 
object area range of 200-7000 square pixels. In the second step the average cell area and the 
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total tissue area was measured using a threshold of 0-238 on the Mono pixel intensity scale. 




The median number of cells examined per patient was 115,161 [IQR 78,427 - 193,585] for 
oncosis, 109,355 [IQR 90,821 - 169,453] for autophagy and 216,320 [IQR 196,640 - 
284,500] for apoptosis. 
 
Example apoptotic cell  
As demonstrated by confocal microscopy and immunofluorescence. A: DAPI; B: TUNEL; 
C: fused image demonstrating co-staining. 
 
 
 
 
 
